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Summary	  
 
Tumor heterogeneity is a term that refers to differences between tumors of the same type in 
distinct patients as well as to differences observed between cells within a tumor. The later is 
known as intratumoral heterogeneity (ITH) and is of high clinical relevance, since it directly 
affects the robustness of prognostic, diagnostics and prediction of biomarkers. Up to date ITH 
has been mainly investigated at the genomic level. Sequencing of multiple regions from the same 
cancer specimen have revealed that within a single tumor several clones of cells with distinct 
mutational landscapes exist, likely as a consequence of clonal evolution. However, ITH can also 
be driven by differences in the microenvironment that may rather be reflected in differential gene 
expression or protein turnover than in genomic changes. Nevertheless, to what extent the ITH is 
manifested on a proteome-wide scale remains largely unknown, mainly due to technical 
limitations. To overcome these limitations an efficient protocol that allows for proteomic 
analysis of limited amounts of formalin-fixed and paraffin-embedded (FFPE) material was 
developed and employed to characterize the proteomic changes in hepatocellular carcinoma 
(HCC). First, by comparing neoplastic to the adjacent, non-neoplastic tissues, I defined 
proteomic features that distinguish tumor from peritumoral tissues. The analysis revealed a 
decrease in abundances of various mitochondrial proteins including components of the NADH 
dehydrogenase complex I, possibly indicating the metabolic rearrangement in HCC. 
Subsequently, by analyzing different regions of HCC, I demonstrated the existence of a 
proteomic heterogeneity, beyond genetic variations, even in morphologically homogenous 
specimens, which affects various biological processes. Several clinically relevant proteins were 
identified as differentially expressed across the analyzed tumors or subject to ITH, thus 
underlying the importance of ITH studies for biomarker discovery and diagnostic applications.  
 
In the second part of my thesis, I focused on the functional characterization of gp210 – a 
transmembrane component of the nuclear pore complex (NPC). In eukaryotic cells the nuclear 
envelope constitutes a barrier separating the nucleoplasm and cytoplasm. The transport of 
macromolecules between these compartments occurs through NPCs which form channels across 
the inner and outer membrane of the nuclear envelope. Apart from regulating the 
nucleocytoplasmic transport, NPCs are also involved in the other cellular processes such as 
chromatin organization, regulation of gene expression or differentiation. The NPC is comprised 
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of multiple copies of around 30 proteins called nucleoporins (~1000 protein in total). While the 
stoichiometry of scaffold components is constant across cell lines, differences in the composition 
of peripheral sites have been observed. One example of a nucleoporin with a cell-type specific 
expression is gp210. It is a transmembrane nucleoporin that associates with the NPC via its short 
C-terminal domain. The remaining larger part of the protein is localized within the perinuclear 
space and it is not required for the interaction with the NPC. The luminal function of gp210 so 
far has been linked to muscle cell differentiation but apart from this, its role remains largely 
unknown. In order to investigate the luminal function of gp210, I attempted to draft a map of 
potential interacting proteins. This was achieved by in-situ proximity labeling combined with 
mass spectrometry-based proteomics using the so-called BioID approach. Data obtained in 
BioID experiments indicate a functional link between gp210 and endoplasmic reticulum (ER) 
related biological functions. I have identified multiple factors involved in the regulation of ER 
stress and several proteins involved in glycophosphatidylinositol anchor attachment. 
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Zusammenfassung	  
 
Tumorheterogenität ist ein Begriff, der sich auf Unterschiede zwischen Tumoren des gleichen 
Typs bei verschiedenen Patienten sowie auf Unterschiede zwischen Zellen innerhalb eines 
Tumors bezieht. Intratumorale Heterogenität (ITH) beeinflusst die Verlässlichkeit der Prognose, 
Diagnose und Vorhersage von Biomarkern und deshalb klinisch relevant. Bislang wurde die ITH 
hauptsächlich auf der genomischer Ebene untersucht. Die Sequenzierung mehrerer Regionen aus 
der gleichen Patientenprobe hat ergeben, dass innerhalb eines einzelnen Tumors mehrere Klone 
von Zellen mit unterschiedlichen Mutationslandschaften existieren, vermutlich als Folge einer 
klonalen Evolution. ITH kann jedoch auch durch Unterschiede in der Mikroumgebung des 
Tumors beeinflusst werden, die sich eher in der differenziellen Genexpression oder im 
Proteinumsatz als in genomischen Veränderungen widerspiegeln. Inwieweit sich die ITH Im 
Proteom manifestiert, bleibt jedoch weitgehend unbekannt, vor allem aufgrund technischer 
Einschränkungen. Um diese Einschränkungen zu überwinden, wurde ein effizientes Protokoll 
entwickelt, das die proteomische Analyse von kleinen Mengen an formalinfixierten und in 
Paraffin eingebettetem (FFPE) Material ermöglicht. Dieses Methode ermöglichte eine 
Charakterisierung der intratumoralen, proteomischen Veränderungen im hepatozellulären 
Karzinom (HCC). Durch den Vergleich neoplastischer mit benachbarter nicht-neoplastischer 
Gewebe habe ich proteomische Merkmale definiert, die den Tumor von peritumoralen Geweben 
unterscheiden. Eine Konzentrationsabnahme verschiedener mitochondrialer Proteine 
einschließlich Komponenten des NADH-Dehydrogenase-Komplexes I, weist möglicherweise auf 
eine metabolische Neuanordnung im HCC hin. In morphologisch homogenen Proben von HCC 
geht die proteomische Heterogenität über genetische Variationen hinaus und beeinflusst 
verschiedene biologische Prozesse. Mehrere klinisch relevante Marker waren differentiell 
exprimiert, im Vergleich mehrerer Tumore oder sogar innerhalb eines Tumors, was die 
Bedeutung von ITH-Studien unterstreicht. 
 
Im zweiten Teil meiner Arbeit beschäftigte ich mich mit der funktionellen Charakterisierung von 
gp210 - einer Transmembrankomponente des Kernporenkomplexes (NPC). In eukaryotischen 
Zellen bildet die Kernhülle eine Barriere, die das Kernplasma und Zytoplasma trennt. Der 
Transport von Makromolekülen zwischen beiden Kompartimenten erfolgt durch Kernporen 
(NPCs), die Kanäle über die innere und äußere Membran der Kernhülle bilden. NPCs sind auch 
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an anderen zellulären Prozessen wie Chromatinorganisation, Regulation der Genexpression oder 
Differenzierung beteiligt. Der NPC besteht aus mehreren Kopien von etwa 30 Proteinen, die 
Nukleoporine genannt werden (insgesamt etwa 1000 Proteine). Während die Stöchiometrie der 
Gerüstkomponenten über Zelllinien hinweg konstant ist, wurden Unterschiede in der 
Zusammensetzung der peripheren Bereiche der Kernpore beobachtet. Ein Beispiel für ein 
zelltypspezifisches Nukleoporin ist gp210. Es ist ein transmembranes Nukleoporin, das über 
seine kurze C-terminale Domäne mit dem NPC assoziiert ist. Der verbleibende, größere Teil des 
Proteins befindet sich innerhalb des perinukleären Raums und ist für die Interaktion mit dem 
NPC nicht erforderlich. Die luminale Funktion von gp210 wurde bisher mit der 
Muskelzelldifferenzierung in Verbindung gebracht, aber abgesehen davon ist seine Rolle 
weitgehend unbekannt. Um die luminale Funktion von gp210 zu untersuchen, habe ich eine 
Karte mit möglichen interagierenden Proteinen entworfen. Dies wurde durch in situ 
Umgebungsmarkierung in Kombination mit auf Massenspektrometrie basierender Proteomik 
unter Verwendung der sogenannten BioID Methode erreicht. Daten, die in BioID Experimenten 
erhalten wurden, weisen auf eine funktionelle Verbindung zwischen gp210 und mit dem 
endoplasmatischen Retikulum (ER) verwandten biologischen Funktionen hin. Ich habe mehrere 
Faktoren identifiziert, die an der Regulierung von ER Stress beteiligt sind, und verschiedene 
Proteine, die an der Bindung von Glycophosphatidylinositol Ankern beteiligt sind. 
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and intra-tumor heterogeneity of hepatocellular carcinoma” and the corresponding method 
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Beck, M., 2018. Spatial Tissue Proteomics Quantifies Inter- and Intratumor Heterogeneity in 
Hepatocellular Carcinoma (HCC). Mol. Cell. Proteomics 17, 810–825. 
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Data together with corresponding figures and methods that were not generated by myself are 
approprietly marked in the text. 
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1.	  General	  introduction	  to	  mass	  spectrometry	  based	  proteomics	  	  
1.1.	   Proteomics	  
	  
Proteomics is a general term that describes areas of research focusing on large-scale 
characterization of proteins. This includes identification and quantification of proteins, their 
conformation, stability and turnover, the analysis of protein-protein interactions, characterization 
of post-translational modifications (PTMs) and others. The most common technique used in the 
field of proteomics is mass spectrometry (MS) – an analytical technique that measures the mass-
to-charge ratio (m/z) of ionized molecules. In MS based proteomics, the two major approaches 
can be distinguished, namely the “top-down” and the “bottom-up” proteomics. The “top-down” 
approach is used to characterize intact proteins.  In bottom up proteomic experiments, proteins 
from entire tissues, cells or purified organelles are solubilized and digested into shorter peptides 
and these are analyzed by the MS. Usually the trypsin is a protease of choice, mainly due to its 
high specificity. It cleaves a peptide chain at the carboxyl side of a lysine and arginine (unless 
followed by a proline). While the top-down strategy is powerful to analyze individual proteins in 
ensemble, i.e. to probe their conformation, sequence or even interactions, it is difficult to apply 
to complex protein mixtures. In bottom up proteomics, contextual information on the protein 
level is lost, however, compositionally complex samples can be analyzed. 
 
1.2.	   Mass	  spectrometry	  based	  proteomics	  
	  
The principal function of a mass spectrometer is the determination of the m/z values of ions. 
This in achieved in three steps: (i) ionization of the analyzed molecules, (ii) ion sorting 
according to their m/z, and (iii) recording of the signal intensity. A plot of intensity versus m/z 
ratio is called a mass spectrum. The initial role of top-down mass spectrometry in proteomics 
was limited to the identification of previously purified proteins and analysis of samples of 
moderate complexity. The number of proteins being identified in a single experiment was limited 
to few hundreds, primarily due to the available instrumentation. Several innovations led to the 
more comprehensive analysis of proteomes. The introduction of the electrospray ionization (see 
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1.2.1) that allows for generating gas-phase ions from a solution was an important steps towards 
enabling the MS analysis of proteins and peptides with high throughput (Fenn et al., 1989). This 
was an important prerequisite for the on-line coupling of mass spectrometers with liquid 
chromatography (LC) in order to enable the analysis of more complex samples by separation of 
peptides prior to MS analysis (Link et al., 1999). At last, the introduction of the orbitrap mass 
analyzer in the year 2000 (Makarov, 2000) is considered as a breakthrough innovation in mass 
spectrometry based proteomics. Thanks to outstanding sensitivity, mass accuracy and nowadays 
also scanning speed, the orbitrap mass analyzer allows for the identification of thousands of 
proteins in a single run. Since it was introduced, the proteomes of various organisms have been 
investigated with in-depth proteomic coverage.  
 
1.2.1.	   Ionization	  
 
In MS-based proteomics, peptides are usually ionized using electrospray ionization (ESI). In ESI 
the solution with an analyte is passed through a thin capillary with a constant flow rate. In order 
to disperse the solution into fine aerosol, a high voltage is applied to the liquid via the capillary. 
In the presence of an electric field, the meniscus at the end of the capillary forms a Taylor cone 
that later transforms into the liquid jet. Due to electrostatic repulsion of charged ions the jet is 
unstable and collapses into small charged liquid droplets (Figure 1) (Fenn et al., 1989). 
 
Figure	  1.	  Electrospray	  Ionization	  
 (A) Schematic representation of ESI. (B) Comparison of CRM and IEM models. 
 
There are two models, namely the charge residue model (CRM) and the ion evaporation model 
(IEM), which propose how ions are transferred from solution to the gas phase. According to the 
CRM, solvent evaporates from droplets during ESI until the charge density at the surface reaches 
the Rayleigh limit, which leads to Coulomb fission of the droplet into multiple smaller droplets. 
This process is repeated until droplets consist of only a single analyte ion and the solvent fully 
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evaporates (Dole et al., 1968). Alternatively, the IEM has been proposed (Iribarne and Thomson, 
1976). In this model droplets undergo fissions until they reach a size of about 20 nm in diameter 
and then as evaporation proceeds, ions are constantly expelled from the droplet. Currently, it is 
believed that larger molecules (above 1kDa) can be generated in agreement with the CRM 
model, while smaller ions can be ejected from nanodroplets according to IEM (Konermann et al., 
2013).  
 
1.2.2.	   Mass	  analyzers	  
 
Ionized peptides are subsequently separated in the mass analyzer. Currently, three types of MS 
analyzers are used in mass spectrometers dedicated to proteomic research. These are 
quadrupoles, ion traps and orbitraps. The quadrupole mass analyzer is built from four parallel 
cylindrical electrodes that are positioned around a common axis. The opposite electrodes are 
electrically paired by applying a radio frequency (RF) and direct current (DC) voltage and 
generate an electric field, which imposes a specific trajectory on the ions passing through the 
quadrupole that depends on their m/z. This can lead to one of the following situations: (i) the 
amplitude of the trajectory is too large and the ions are lost from the quadrupole, (ii) an ion’s 
movement is not affected by the RF voltage leading to the DC voltage causing the ion to crash 
with the electrode, (iii) the ions have a stable trajectory throughout the quadrupole and thus reach 
the detector (Figure 2). By adjusting the parameters of the electric field, specific m/z ratios are 
selected. 
 
Figure	  2.	  Schematic	  representation	  of	  the	  quadrupole	  mass	  analyzer	  
A quadrupole mass analyzer is built from four parallel rod shaped electrodes imposing an electric field.  
This can either cause unstable (in blue) or stable (in green) trajectories for analyzed ions. 
 
An ion trap is built from a quadrupole and two hyperbolic cap electrodes positioned on opposite 
ends of the quadrupole. In an ion trap, the RF voltage applied to the quadrupole electrodes 
confines the ions radially. At the same time, a static voltage applied to the end cap electrodes 
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restricts the ions’ movement axially. The combination of both RF and DC voltage is used to 
orient ions in the center of the trap. Changing the RF voltage can be used to alter the stability of 
ion positioning within the trap and, eventually, is used to expel ions from the trapping zone. To 
acquire an MS spectrum the RF voltage is adjusted in a controlled manner, thus allowing ions of 
a defined m/z to leave the trap and finally to be recorded by the detector. Ion traps can also act as 
mass filters by ejecting all ions from the trap except for the ones with selected m/z (Vachet and 
McElvany, 1999). 
Orbitrap mass analyzers consist of an outer barrel-like electrode and an inner spindle-shaped 
electrode positioned along the same axis. These electrodes act together to trap ions in an orbital 
movement around the spindle. First, the electric field between the electrodes is reduced and ion 
packets are injected into the trap. Introduced ions then start oscillating around the spindle in a 
movement that can be described by the following parameters: i) frequency of radial oscillations, 
ii) frequency of rotation around the central electrode, and iii) frequency of oscillations along the 
z-axis. The last depends on an ion’s m/z.  As ions are injected, the voltage on the central 
electrode is ramped up to increase the electric field, thus squeezing ions towards the center of the 
analyzer, until the ions’ radial oscillation is stabilized and they reach their final orbit within the 
orbitrap. At this point the electric field is stabilized and packets of ions with the same m/z form 
rings that oscillate along the central axis. The outer electrodes record these oscillations as an 
image current that is later transformed to a mass spectrum using Fourier transformation (Figure 
3).  
 
Figure	  3.	  Orbitrap	  mass	  analyzer	  
A model of the orbitrap mass analyzer. Ions are oscillating between a central spindle-like electrode (a) 
and an outer barrel-shaped electrode (b). The frequency of oscillations along z-axis is recorded and 
further Fourier transformed to obtain a mass spectrum. Modified from (Scigelova and Makarov, 2006) 
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1.2.3.	   Peptide	  identification	  
 
Even a highly accurate m/z value of a given peptide ion is not sufficient to identify peptides in 
complex samples. Therefore in proteomics a so-called tandem MS approach (also known as 
tandem MS/MS) is used. In tandem MS, first the m/z of analyzed peptides is recorded as a full 
scan (MS1) and then the precursor ion of interest is isolated (either by a quadrupole or within an 
ion trap) and fragmented by breaking the peptide bonds. Several molecules of the same ion are 
fragmented, resulting in multiple different fragments. The mass spectra of all of them are then 
acquired and used for identification (MS2). In order to identify a peptide, measured MS2 spectra 
of fragment ions (MS2) are matched to a database containing all possible theoretical MS2 
spectra of peptides that can be derived from the set of proteins in the database.   
One of the most common fragmentation type used in MS based proteomics is collision-induced 
dissociation (CID) that takes place either in an ion trap or a quadrupole (Cooks, 1995). By 
raising the RF voltage on the quadrupole, ions are accelerated within the trap and their kinetic 
energy increases. A collision of accelerated ions with neutral gas molecules induces ion 
vibrations. As a consequence, a weak chemical bond breaks (usually the peptide bond), dividing 
the parental ion into so-called –b and –y ions (Figure 4). Mass spectra of the fragment ions are 
then acquired for each precursor peptide. A drawback of CID fragmentation is the fact that low-
mass fragment ions are not efficiently trapped in ion traps (Louris et al., 1987). This is a major 
limiting factor for experiments where peptides are labeled with isobaric tags (see section 1.3.1), 
since the reporter ions are usually small and can be lost after fragmentation. To overcome this 
issue, higher-energy C-trap dissociation (HCD) was developed (Olsen et al., 2007). In HCD, the 
fragmentation is spatially separated from the ion trap and happens in a gas-tight shroud octopole 
directly connected to the C-trap (an ion storage prior the orbitrap analyzer). After the 
fragmentation ions are pushed to the C-trap and later injected into an orbitrap for mass analysis.  
The other major type of fragmentation used in proteomics is electron transfer dissociation (ETD) 
(Louris et al., 1987). Mass spectrometers with ETD capability are equipped with an additional 
ETD source, in which radical anions are generated through chemical ionization of polycyclic 
aromatic hydrocarbon molecules. These are then transferred to an ion trap where they can react 
with multiply charged peptide ions.  In the reaction an unpaired electron from the radical is 
transferred to the peptide ion forming an unstable radical cation with reduced charge that breaks 
along the N – C alpha bond forming so-called -c and -z fragment ions (Figure 4).  ETD 
fragmentation is frequently used for the identification of post-translational modifications 
(Wiesner et al., 2008). It has been also shown that ETD is advantageous in cross-linking mass 
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spectrometry as it enhances identification of peptides covalently linked by MS-cleavable cross-
linkers (Liu et al., 2015). 
 
Figure	  4.	  Peptide	  fragmentation	  pattern	  
Fragment ions called a, b and c correspond to the N-terminal part of the fragmented peptide, while ions x, 
y, z correspond to the C-terminal side.  
 
1.3.	   Quantitative	  proteomics	  
 
The general aim of quantitative proteomics is to identify and accurately quantify proteins in a 
sample, usually in order to compare their abundances across different biological conditions. 
Various approaches, in which different acquisition and quantification strategies are employed, 
have been developed to enable such analysis. These can be divided into three major categories: 
(i) data dependent acquisition (DDA), (ii) targeted proteomics and (iii) data independent 
acquisition (DIA). The appropriate method from the proteomic toolbox is selected based on the 
particular question being asked, the number of samples to be analyzed, available instrumentation 
etc.  
 
1.3.1.	   Data	  dependent	  acquisition	  (DDA)	  –	  shotgun	  proteomics	  
 
Data dependent acquisition (DDA), also known as shotgun or discovery proteomics, refers to all 
types of measurements where ions are selected for fragmentation based on their intensity in the 
MS1 scan. After each full MS1 scan, the most intense ions are isolated, fragmented and analyzed 
on MS2 level (Figure 5). This approach is called TopN mode, where N is a number of ions 
selected for fragmentation from each MS1 scan.  
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Figure	  5.	  Data	  dependent	  acquisition	  strategy	  
Throughout the entire length of the LC gradient the full MS1 scans are acquired. The top most intense 
ions (in green) are selected for fragmentation. MS2 spectra of fragment ions are recorded and during the 
analysis step matched against the database. Red peaks correspond to the ions included in the database. 
Peaks in black represents ions that cannot be explained by the theoretical spectrum. 
 
Label free quantification 
Although each peptide has different properties that affect its overall MS intensity (efficiency of 
ionization, transfer, and detection etc.), the signal of ions derived from ESI is highly 
reproducible and the MS intensity of a peptide correlates with its concentration. These two 
properties are the basis for the label free quantification (LFQ) approach. In LFQ, MS2 spectra 
are used to identify peptides (using the database search described earlier), while MS1 intensities 
of corresponding peptides are extracted (based on their m/z and retention time) and used to 
calculate the relative quantities of peptides. The advantage of LFQ over label-based approaches 
is its cost and time efficiency and that the number of samples is not limited to the number of 
possible labels. However, the LFQ approach has certain limitations. Due to the low number of 
fragmentation events and the semi-stochastic nature of precursor selection, any DDA 
measurement (and LFQ in particular) suffers from the missing values problem. Because of this, 
it is not the method of choice for experiments with large sample sizes. Additionally, it is not a 
suitable method for experiments where deep proteome coverage is desired, since an additional 
off-line fractionation step is usually required to significantly increase the depth of coverage. 
Since in LFQ each sample is measured separately, such an approach would drastically elongate 
the total measurement time.  
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Label-based quantification 
In label-based approaches, peptides derived from different samples are pooled and 
simultaneously analyzed during a single MS run. This way, errors derived from sample handling 
and instrument instabilities are minimized and the total measurement time is reduced. One of the 
first successful labeling approaches was stable isotopic labeling by aminoacids in cell culture 
(SILAC)(Ong et al., 2002). In SILAC, cells are grown in a culture medium where lysine and 
arginine are substituted with the same amino acids containing the heavy 13C or 13C and 15N 
isotopes in all positions of the molecules. Since trypsin cleaves after lysines and arginines, each 
peptide in a tryptic digest carries at least one heavy labeled aminoacid and can be therefore 
distinguished from the non-labeled sample based on the defined mass shift in the mass spectrum. 
Since not all types of samples are amenable for metabolic labeling other methods including 
either enzymatic (Yao et al., 2001) or chemical (Gygi et al., 1999; Jue-Liang Hsu et al., 2003) 
labeling have also been introduced. Experiments using isotopic labels allow for simultaneous 
analysis of up to three conditions at the same time. However, pooling differentially labeled 
peptides increases sample complexity. Enzymatic and chemical isotopic labeling have been 
recently almost entirely replaced by isobaric labeling, which does not affect sample complexity 
(Dayon et al., 2008; Ross et al., 2004; Thompson et al., 2003). An example of such labeling is 
known as tandem mass tagging (TMT) that currently allows for multiplexing up to 10 samples 
during a single MS run (Figure 6).  
 
Figure	  6.	  Tandem	  mass	  tagging	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(A) Chemistry of the TMT reagent set. (B) Peptides labeled with different TMT channels are 
indistinguishable at the MS1 level. Upon HCD, TMT fragments and generated reporter ions can be 
quantified 
 
In TMT, all 10 tags are different isotopomers of the same reagent therefore they all have exactly 
the same mass. The tagging reagent is built from three regions: (i) an amine reactive group, (ii) a 
mass normalizer group and (iii) a reporter group. During labeling, the amine reactive group 
covalently binds to primary amines (N-termini of peptides or the amine group of lysine 
residues).  Thusly labeled peptides are not distinguishable at the MS1 level, however upon the 
HCD fragmentation the bond between the reporter group and mass normalizer breaks generating 
reporter fragment ions of different m/z. The intensities of these reporter ions are used for 
quantification.   
 
1.3.2.	   Targeted	  proteomics	  
 
In shotgun proteomics a large number of proteins can be identified, however the dynamic range 
of such measurements is limited. Due to preferential selection of highly intense ions (in DDA), 
proteins of low abundance are often not detected in such analyses. In contrast to DDA, in 
targeted proteomics precursor ions are selected for fragmentation based on a predefined 
inclusion list of m/z values regardless of their intensities. Thus even low abundant proteins can 
be quantified (Lange et al., 2008). On the other hand, such strategy applies only for hypothesis 
driven research, since it provides information only about pre-selected proteins. In a classical 
targeted proteomic experiment (also called selected reaction monitoring, SRM), after LC 
separation peptides are injected into a mass spectrometer that contains three connected 
quadrupoles (Q1-Q2-Q3). In the first quadrupole Q1, selected precursor ions are filtered and 
passed to the second quadrupole Q2 that acts as a collision cell. Here peptides are CID 
fragmented and transferred to Q3, which selects for predefined fragment ions (Figure 7A). These 
ions are then passed to a detector, resulting in traces of signal intensity versus retention time for 
each selected precursor-fragment ion pair (also called SRM transitions). The intensity of a MS2 
signal is used for quantification. To increase the total number of peptides that can be measured 
during a single run, the acquisition of specific transitions is scheduled only around a known 
peptide elution time (Escher et al., 2012). A similar strategy has been developed for instruments 
with a quadrupole followed by a high mass accuracy analyzer, like the Q-Exactive (quadrupole – 
orbitrap). Similarly to SRM, the precursor ion is selected by the quadrupole and passed further 
for fragmentation. The difference is that all fragment ions are analyzed at once in the orbitrap 
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mass analyzer, therefore such approach is called parallel reaction monitoring (PRM, Figure 7B) 
(Gallien et al., 2012). In addition, synthetic heavy labeled peptides of the exactly same sequence 
are often spiked into samples to act as internal standards for the quantification. Using accurately 
quantified heavy labeled (AQUA) peptides allows also for the determination of absolute 
abundance of selected peptides (Kettenbach et al., 2011). 
 
 
Figure	  7.	  Targeted	  proteomic	  approaches	  
In SRM (A) each fragment ion is analyzed separately by the third quadrupole while in PRM (B) are 
fragments are simultaneously analyzed by the orbitrap mass analyzer. Modified from (Titz et al., 2014). 
 
1.3.3.	   Data	  Independent	  Acquisition	  
 
Data independent acquisition (DIA), also known as Sequential window acquisition of all 
theoretical fragment ions (SWATH), has been introduced as an approach that is not affected by 
missing value issues (like DDA), but at the same time is not limited to only a small number of 
identified proteins (like SRM) (Doerr, 2015; Gillet et al., 2012). In DIA, each full MS1 scan is 
divided into consecutive small m/z window scans. In each of these scans, all ions within the 
given m/z range are isolated by a quadrupole. They are then subjected to HCD fragmentation and 
then simultaneously analyzed on a high-resolution mass analyzer. Short cycles of isolations are 
repeated until the entire m/z range is covered (Figure 8). The challenging part of DIA 
experiments is the data analysis step. Due to the fact that multiple peptides are fragmented 
together at the same time, MS2 spectra are highly convoluted and as such they cannot be used 
directly to search against a database. Instead, before a DIA data analysis, a DDA-based spectral 
library needs to be generated. For this, a representative sample is measured multiple times in 
DDA mode to obtain sufficient proteomic coverage. All acquired MS files are then subjected to 
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the standard library based search in order to assign peptides to the experimental fragmentation 
patterns. Identified MS2 spectra are compiled into the spectral library. During the analysis step, 
MS2 spectra of DIA files are searched against the previously generated library and fragment ion 
spectra corresponding to each peptide are extracted from the complex MS2 scans. In order to 
reduce the computational requirement and ensure confident assignment, fragment ions of 
particular peptides are only considered in spectra acquired around the expected retention time of 
the peptide (Bruderer et al., 2015).   
 
 
Figure	  8.	  Data	  Independent	  Acquisition	  Strategy	  
(A) Comparison of DDA (on the left) and DIA (on the right) acquisition approaches. In DDA, narrow m/z 
window is used to isolate only the most intense ion. In DIA, all ions within a wide m/z window are 
subjected to fragmentation. Cycles of isolation are subsequently repeated until the whole m/z range is 
covered. (B) Data analysis pipeline. Complex MS2 spectra are matched against a DDA-based peptide 
library. Fragment ion peptides are extracted based on the experimental fragmentation pattern throughout 
the predicted retention time resulting in traces of signal intensity versus retention time.  
 
 26 
2.	  Spatial	  tissue	  proteomics	  as	  a	  tool	  to	  investigate	  the	  inter-­‐	  and	  
intra-­‐tumor	  heterogeneity	  of	  hepatocellular	  carcinoma	  
 
2.1.	   Introduction	  
 
2.1.1.	   Intratumoral	  heterogeneity	  
 
Although a single mutation is sufficient to initiate tumor formation (Fialkow, 1979), it does not 
mean that a single tumor entity is comprised of identical cells that are clones of a precursor 
cancer cell. Most common cancer mutations affect genes involved in processes that regulate cell 
fate, cell survival and chromosome maintenance (Vogelstein et al., 2013). Because of this, 
cancer cells divide in a fast, uncontrolled manner and often fail during DNA repair mechanisms. 
As a consequence, they acquire and propagate mutations more frequently as compared to normal 
cells. Genetic instability is therefore an intrinsic feature of cancer cells, and distinct cell 
populations (each carrying its own particular set of mutations) can often be identified within a 
single tumor mass. This phenomenon is known as intra-tumor heterogeneity (ITH) and has been 
described for a range of solid tumors as well as for hematopoietic malignancies (Gay et al., 
2016). Currently, there are two models to explain the development of ITH, namely the cancer 
stem cell model and the clonal evolution model. Although slightly different, they do not 
contradict each other and both are believed to contribute to ITH (Kreso and Dick, 2014; Marusyk 
and Polyak, 2010). The cancer stem cell (CSC) model defines a tumor as a mixture of cells of 
different properties. Among these, only certain subsets of cells have features that resemble the 
characteristics of stem cells: a high capacity of cell-renewal and ability to differentiate into 
various other cell types. All other cells present within a tumor are considered to be an outcome 
of the aberrant differentiation of CSCs. In comparison to CSCs, the remaining cells have limited 
mitotic capacity and are thought not to be involved in tumor progression (Dick, 2008). The 
experimental evidence underlying the CSC model originally came from a study in which acute 
myeloid leukemia (AML) cells were sorted based on their surface antigen and transplanted into 
severe combined immune-deficient (SCID) mice (Lapidot et al., 1994). Only in mice 
transplanted with certain types of AML cell types (CD34+, CD38-), the formation of re-growing 
colonies was observed, whereas the remaining ones did not induce tumor growth. Even though 
the CSC model was originally proposed for hematopoietic malignancies, it has also been shown 
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to be applicable for multiple solid tumors (Alvero et al., 2009; Li et al., 2007; Schatton et al., 
2008; Zhang et al., 2008).  Nevertheless, certain aspects of it still remain under debate (Marusyk 
and Polyak, 2010). It has been shown that variations in experimental conditions can drastically 
increase the number of cells identified as CSCs, thus suggesting a significant role for the 
microenvironment in tumor progression (Quintana et al., 2008).   
In the clonal evolution model, a tumor is compared to an evolving population that undergoes 
Darwinian selection (Nowell, 1976). In this model, the whole population of cancer cells 
frequently acquires random mutations or epigenetic marks, out of which some may have an 
advantage for tumor progression. As a consequence, cells carrying such advantageous mutations 
expand faster and overgrow the remaining cells. At the beginning of tumor development usually 
only few such dominant clones can be distinguished, but as tumorigenesis progresses more 
branching events can usually be observed (Gerlinger et al., 2012). In the case of clonal evolution, 
the selective pressure is driven by the complex tumor microenvironment. This includes: (i) 
systemic regulators of a host (hormones, growth factors, components of immune response etc.), 
(ii) local conditions such as presence of metabolites, access to oxygen and nutrients, as well as 
physical constraints which include mechanic pressure from surrounding tissues, composition of 
extracellular matrix etc. (Greaves and Maley, 2012).  As these factors may vary both spatially 
and temporally, there is no guarantee that a certain mutation will have an equal selective 
advantage during all stages of tumor progression or within all of the tumor’s volume, therefore 
tumors constantly co-evolve together with their microenvironment (Polyak et al., 2009).   
 
2.1.2.	   Biological	  implication	  of	  the	  intratumoral	  heterogeneity	  
 
Intratumoral heterogeneity and diagnostics: 
In standard pathology workflow, a diagnosis is frequently primarily based on phenotypic traits. 
The workflow usually combines overall histological analysis of tissue architecture with 
immunohistological assays that monitor the expression of cancer-specific biomarkers. For 
example, breast cancer biopsies are routinely tested for the expression of three biomarkers: (i) 
estrogen hormone receptor (ER), (ii) progesterone hormone receptor (PR) and (iii) receptor 
tyrosine-protein kinase erbB-2 (HER2) (Hammond et al., 2010). Based on the expression of 
these receptors, breast cancers can be classified into three major groups: (i) luminal (positive for 
ER, PR or both), (ii) HER2 positive (positive for HER2 but negative for ER and PR) and (iii) 
triple negative, in which the expression of none of the markers is observed (Sinn and Kreipe, 
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2013).  This classification has prognostic value (Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG), 2005) and influences further patient treatment (Harris et al., 2016).  However 
it has been shown that the expression of standard breast cancer markers can be highly variable 
within a single tumor entity (Nassar et al., 2010; Turashvili and Brogi, 2017) resulting in 
difficulties during the diagnostic process. To minimize the impact of ITH on tumor diagnostic, 
several biopsies of the same tumor are being independently inspected, if possible, and the overall 
diagnosis is based on the region with the most aggressive phenotype. Nevertheless, there is still a 
risk of undersampling, and as such analyzed regions may not reflect the actual state of the tumor. 
This is of particular importance especially for larger tumors, where only a small percentage of 
the total tumor mass is inspected by a pathologist. 
 
Intratumoral heterogeneity and cancer therapies  
Even though a tremendous effort is dedicated into cancer research, most malignancies still 
remain incurable. The only way for successful treatment and prevention of disease recurrence is 
the entire removal of cancer cells. However in many cases surgical resections are not possible, 
for example, due to the localization of the tumor close to important organs or blood vessels. 
Another issue is that tumors are often detected at the metastatic stage, meaning that cancer cells 
have already migrated into other tissues. In the case of non-operative malignancies, patients are 
usually treated either with unspecific (chemo- or radiotherapy) or targeted therapies. Although 
the initial response to the treatment is usually very promising, in many cases the patients relapse 
and resulting recurrent tumors are no longer sensitive to the same type of treatment. For 
example, the mechanism of resistance to lung cancer therapy has been described for a patient 
with a ROS1 translocation (Awad et al., 2013). In this case study, the patient received treatment 
with Crizotinib (Sahu et al., 2013), a multi-target tyrosine kinase inhibitor. The treatment 
resulted in a strong initial response, but a relapse was observed. Sequencing analysis of the 
recurrent primary tumor as well as metastatic sites revealed a mutation in the ROS1 kinase 
domain. The substitution (G2032R) caused steric interference affecting inhibitor binding, and 
therefore made the mutated ROS1 resistant to inhibition by the drug. Similar mechanisms have 
been observed for the resistance of lung adenocarcinomas to the treatment with epidermal 
growth factor receptor (EGFR) inhibitors. Here, the treatment frequently results in the T970M 
mutation in the kinase domain of EGFR leading to insensitivity to the initial drugs (Pao et al., 
2005; Sequist et al., 2011).  It is frequently proposed, that during therapy, cancer cells acquire 
mutations providing resistance to the drugs and these are then propagated according to the clonal 
expansion model(Greaves and Maley, 2012; Iwasa et al., 2005). Other research suggests, that 
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such mutations occur independently to the drug admission and cells carrying the resistance 
mutations are already present in pretreated tumors, albeit at very low abundance (Shaw et al., 
2016; Yu et al., 2014). This would indicate that tumors are dynamic entities capable of fine-
tuning their clonal composition to adjust to the current microenvironmental requirements. This 
model is supported by the observation that for some patients the post-treatment domination of 
EGFR inhibitor-resistant clones is only temporal, and few months after the drug withdrawal the 
T970M mutation is not detectable. Possibly, in the absence of the inhibitor, the mutation is no 
longer advantageous for tumor progression. Nevertheless, the drug readmission immediately 
triggers outgrowth of T970M positive cells (Sequist et al., 2011). 
 
2.1.3.	   Methods	  to	  study	  intratumoral	  heterogeneity	  
 
Genetic heterogeneity 
First reports regarding the genetic heterogeneity of tumors were based on karyotype analysis and 
revealed that within a single tumor, different cells may have different types of chromosomal 
abnormalities (Nowell, 1976). Currently, most ITH studies are based on next generation 
sequencing (NGS) approaches that allow detecting sequence variants and calculating their 
frequency within the ensemble of DNA molecules derived from the bulk of a tumor. A whole 
cancer genome sequencing was reported for the first time for a patient with FAB M1 subtype of 
AML (Ley et al., 2008). This particular subtype was selected for the analysis due to the lack of 
signs of heterogeneity, meaning that no chromosomal abnormalities and no somatic copy 
number alterations had been observed before. Authors of this study identified 10 somatic 
mutations, out of which one had a significantly lower allelic frequency indicating a presence of 
more than one clone of AML cells. Later, the same approach was used to characterize a large 
cohort of both primary and recurrent cases of AML revealing that heterogeneity frequently 
occurs in AML (Ley et al., 2013). NGS analysis of ITH has also been employed for a number of 
solid tumors (Jacoby et al., 2015). For example, multiregional whole exome sequencing of renal 
carcinoma indicated a large degree of clonal heterogeneity but also revealed that the majority of 
mutations are not uniformly distributed throughout an individual’s tumors, thus revealing spatial 
heterogeneity (Gerlinger et al., 2014, 2012).  
Robust whole genome sequencing of tissue biopsies has significantly improved our 
understanding about tumor evolution and its heterogeneity. Nevertheless, some limitations 
especially for clinical applications remain. First of all, the detection of low frequency mutations 
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with whole genome/exome approaches (with allelic frequency > 1%) is still technically 
challenging (Alizadeh et al., 2015). This may be of high importance for designing targeted 
therapy strategies in cases where a drug resistant clone is present at very low abundance and 
cannot be detected with standard approaches. Detection of such mutations can be significantly 
improved by sequencing only selected genes. For example, a panel of 360 common cancer-
related mutations has been assembled and used to investigate ITH in a cohort of breast cancer 
biopsies (Yates et al., 2015). Another important clinical limitation directly derives from the large 
degree of intratumoral spatial heterogeneity. As shown for renal carcinoma, not all mutations are 
evenly distributed and the number of identified genetic variants increases with the number of 
sequenced regions (Gerlinger et al., 2012). Furthermore, biopsy collection is frequently an 
invasive procedure and as such there is no possibility for multiple region probing during most 
diagnostic procedures. As a consequence, there is a high probability of missing important 
mutations due to undersampling of the tumor. It has been proposed that sequencing of free 
circulating tumor DNA (ctDNA) obtained through non-invasive liquid biopsies (from blood) 
could provide a solution to this problem (Dagogo-Jack and Shaw, 2017).  Circulating DNAs are 
small fragments of nucleic acids found in the bloodstream. Although, the exact mechanism of 
ctDNA release still remains unclear, it has been proposed that it occurs during necrotic and 
apoptotic events (Siravegna and Bardelli, 2016).  Sequencing of ctDNA from breast, ovarian and 
lung cancer resulted in identification of known mutations that were previously detected from 
standard biopsies of the same tumors (Murtaza et al., 2013). The same study showed that 
sequencing ctDNA from liquid biopsies is a suitable tool for rapid detection of drug related 
mutations and as such could be used to monitor drug response during therapies. In a cohort of 
140 patients with metastatic colorectal cancer it has been shown that mutational analysis of 
ctDNA can identify more mutations than sequencing of tissue biopsies from the same patients 
(Thierry et al., 2017). 
 
Non-genetic heterogeneity 
Genetic heterogeneity provides comprehensive information regarding tumor evolution and its 
current state of development. The information about clonal composition has been shown to have 
an impact on both diagnostics and targeted treatment design. In addition, the level of genetic ITH 
can be easily assessed even from the whole tumor, which minimizes experimental effort. It is 
therefore understandable that the majority of ITH research focuses solely on genetics. 
Nevertheless, ITH can be manifested also in different ways. Long-term exposure of a tumor to 
unfavorable conditions (for example drug treatment) will impose selective pressures and trigger 
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clonal evolution. However, local or short-term changes in the tumor microenvironment are more 
likely to be reflected at the transcriptome and proteome level rather than the genome. Due to 
various technical limitations, however, these types of ITH remain understudied. Thus, 
understanding non-genetic ITH requires further method development.  
Although RNA sequencing (RNA-seq) methods are well established, their applications to study 
transcriptomic heterogeneity are still limited. Traditional RNA-seq of bulk tumors provides only 
an averaged expression profile of all cells present in the analyzed sample. Since it is nearly 
impossible to estimate the contribution of particular cells to the entire pool, information about 
heterogeneity remains lacking. In addition, unrelated cell types such as infiltrating immune cells 
or components of the vascular system are frequently present within solid tumors, and thus also 
contribute to the overall RNA pool. These are likely to be unevenly distributed across the whole 
tumor and as such random sampling of multiple tumor regions does not necessarily solve the 
issue of convoluted signals. Single cell RNA sequencing has been proposed as an approach that 
allows to overcome aforementioned problems (Patel et al., 2014). However, since transcriptomes 
are highly dynamic it is also possible that cells respond to the stress derived from the cell 
separation procedure, which may be a source of additional bias.  
With the contemporary pathology toolset, however, analysis of heterogeneous protein expression 
is more feasible and it can be performed also with fixed tissues. Using immunohistochemistry 
(IHC), the presence of a protein of interest can be visualized with high spatial resolution, which 
additionally allows direct comparison of protein expression with morphological features. Indeed, 
heterogeneous protein expression assessed by IHC has been reported for some tumors (Nassar et 
al., 2010; Turashvili and Brogi, 2017). Importantly, it has been shown that ITH also affects 
clinically relevant biomarkers, thus underlining the importance of proteomic ITH studies. A 
major drawback of antibody-based approaches is their low throughput. Even with automated 
systems, immuno-staining can only be performed for a limited number of targets, for which 
suitable antibodies are available. MS-based approaches, which could circumvent many of these 
limitations, and which have been successfully used for general cancer proteomics, have not 
previously been applied to the study of ITH due to multiple technical limitations (described in 
section 2.1.6.). 
 
2.1.4.	   Hepatocellular	  Carcinoma	  
 
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the 
second most frequent cause of cancer related death (El-Serag and Kanwal, 2014). Its incident 
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rate is rapidly increasing with an annual increase of 2%, as estimated in the USA (Stewart and 
Wild, 2014). Around half of HCC cases are associated with Hepatitis B Virus (HBV) infection 
and around 25% are the consequence of Hepatitis C Virus (HCV). The most important among 
the remaining risk factors are alcoholic fatty liver disease and nonalcoholic steatohepatitis 
(Sanyal et al., 2010). Current therapeutic options for HCC patients include partial hepatectomy 
or liver transplantation, however less than 20% of HCC patients are amenable for such treatment 
(Raza and Sood, 2014). The prognosis of HCC patients is very poor, with a five-year-survival 
rate of less than 5%. Successful therapy accompanied by the increase in survival rate largely 
depends on the time and accuracy of diagnosis, indicating a strong and urgent need for better 
understanding of the disease and identification of effective biomarkers. Importantly, at the 
histomorphological level, the heterogeneity of HCC is less apparent when compared to other 
solid tumors. Therefore, changes at the protein expression level, if present, are not direct 
consequences of differences in cellular composition, which make HCC a suitable model system 
for proteomic ITH studies. In addition, the molecular basis of HCC development and diversity 
have so far been mainly studied using genomic and transcriptomics approaches (Boyault et al., 
2007; Guichard et al., 2012; Roessler et al., 2010; Schulze et al., 2015). However, disease 
relevant alterations at the proteomic level, particularly in the spatial context, remain poorly 
defined.  
 
2.1.5.	   Tissue	  preservation	  	  
 
To prevent degradation of biological material derived from patients, surgically removed tissues 
need to be preserved as quickly as possible. Preservation happens either through immediate 
tissue freezing or via fixation with a 4% formaldehyde solution (formalin). Thanks to 
preservation of non-modified proteins and nucleic acids, freezing is advantageous for molecular 
biology and biochemical analyses. On the other hand, freezing often affects tissue architecture 
and morphology, which makes frozen samples not ideal for histological analysis. Additionally, 
storage of freshly frozen tissues is inefficient in terms of space and cost. Due to these reasons, in 
most cases freezing is not the preservation method of choice and the availability of these types of 
samples is limited only to specialized research groups that are in close collaboration with tissue 
banks and hospitals. In contrast, formalin-fixation and paraffin embedding (FFPE) provides 
excellent preservation of tissue architecture, which is of high importance especially for ITH 
studies. FFPE fixation also allows long-term storage at room temperature without any impact on 
the sample quality (Karlsson and Karlsson, 2011). Because of this, FFPE tissues are the standard 
 33 
sample type in routine pathology diagnostic workflows worldwide. Since only a small fraction of 
preserved material is used for diagnostics, the remaining parts are archived and can also be 
exploited for research purposes. Consequently, FFPE tissues available for researchers are often 
associated with clinical records and multiple pathology analyses making them a valuable source 
for cancer research in general.  
Formalin fixation is a chemical process in which multiple covalent bonds between nucleic acid, 
polysaccharides, and proteins are formed (crosslinks). Tissues are immersed in formaldehyde 
solution that can penetrate around 20 mm of specimen in 24 h (Fox et al., 1985). In terms of 
protein crosslinking, formaldehyde has been shown to be reactive towards multiple amino acids 
including lysine, arginine, histidine and cysteine, resulting in the formation of methylene bridges 
between them (Thavarajah et al., 2012). Such cross-linked tissues are then dehydrated by 
sequential immersions in several solutions of increasing ethanol concentrations and subsequently 
embedded in paraffin. 
 
2.1.6.	   Challenges	  in	  FFPE	  tissue	  proteomics	  
 
Although formalin fixation is compatible with histological analyses of tissues, FFPE samples are 
challenging for biochemical experiments, in particular for proteomics. One of the major reasons 
why FFPE tissues were considered unsuitable for mass spectrometry for a long time is the 
presence of multiple unspecific protein modifications introduced during fixation. Since these 
sites of modification cannot be entirely predicted, they cannot readily be included in databases, 
and as such modified peptides are not accessible for MS analysis. In addition, the extraction of 
proteins from such samples is inefficient. Efficient solubilization of FFPE material can be 
achieved only under very harsh conditions in the presence of highly concentrated detergents 
(Shen et al., 2015). These are, however, not compatible with downstream MS analysis. In 
addition, yields of such extractions are usually low and thus, a large amount of starting material 
is required.  
 
2.1.7.	   Strategies	  to	  enable	  FFPE	  proteomics	  
 
Crosslinking reversal 
Apart from standard histological evaluation based on haematoxylin and eosin (H&E) staining, 
FFPE tissues are frequently subjected to IHC analysis. As a consequence of chemical 
crosslinking, however, some epitopes may not be accessible to antibodies. To overcome this 
 34 
problem, several antigen retrieval approaches have been developed. The most common one, 
known as Heat Induced Antigen Retrieval (HIAR) is based on the heat-induced reversion of 
formaldehyde crosslinks. It has been shown that incubation of FFPE tissues at high temperatures 
significantly improves antibody based staining, without affecting tissue architecture (Shi et al., 
1991). The high temperature treatment is believed to reverse formaldehyde crosslinks by 
breaking methylene bridges (Shi et al., 1991). Although the exact mechanisms as well as the 
efficiency of this process are not known, HIAR is routinely used for IHC of FFPE tissues. 
Crosslinking reversal is also beneficial for biochemical applications, including mass 
spectrometry. Reducing the number of crosslinks enhances sample solubilization prior to 
enzymatic digestion. 
Detergent removal 
Presence of detergents in samples can affect MS measurements in multiple ways. Common, non-
ionic surfactant (e.g. Triton X-100, NP40, or Tween20) ionize with much higher efficiency than 
peptides.  Because of their polymeric nature, detergents characteristically cause multiple 
regularly spaced peaks in a single MS spectrum. Due to the higher ionization efficiency, the 
intensity of such signals is often orders of magnitude higher than the signal derived from 
peptides, therefore surfactants can completely mask the signals of interest. The presence of ionic 
detergents, such as SDS, interferes with the ionization processes. This leads to weak MS signals 
and significantly reduced sensitivity of measurements. Additionally SDS, as a harsh ionic 
detergent, inhibits the enzymatic activity of trypsin and as such needs to be removed from the 
sample before the digestion step. Due to the presence of hydrophobic chains, surfactants bind to 
the C18 resin and frequently elute throughout the entire gradient, affecting the whole analysis. 
Moreover, they also have a tendency to stick to the tubing system, resulting in a long lasting and 
difficult-to-remove detergent contamination. Due to surfactant’s affinity to the C18 resin, they 
cannot be removed from the MS samples by standard methods used for the peptide purification. 
It is therefore recommended to entirely avoid using them for MS sample preparation. On the 
other hand, the use of detergents is beneficial while analyzing membrane proteins. To enhance 
their solubilization, MS-compatible surfactants have been developed. An example of such a 
compound is RapigestSF® (Waters), which undergoes hydrolysis in acidic conditions and 
therefore can be removed from the sample prior to MS analysis. RapigestSF enhances the 
solubilization of membrane proteins and does not affect the enzymatic activity of trypsin; 
therefore it is now routinely used in proteomics workflows. It is, however, considered rather as a 
mild detergent, and hence is not the primary choice for the extraction of cross-linked proteins 
from FFPE tissues. 
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Detergents forming micelles of relatively small sizes (such as SDS) can be removed by filter-
aided sample preparation (FASP) (Manza et al., 2005). In this approach, samples are first 
solubilized in the presence of SDS and then urea is added to a final concentration of 8 M. 
Samples are then placed on an ultrafiltration membrane with a 30 kDa cut-off. Subsequent steps 
of concentration by centrifugation followed by dilutions with SDS-free urea solution allow for 
removal of detergent from samples.  The presence of urea prevents the precipitation of SDS-
soluble proteins. Finally, the concentration of urea is reduced to enable enzymatic digestion. 
Detergent free peptides can be eluted by an additional step of centrifugation and desalted using 
C18 resin.   
A Single-Pot Solid-Phase-enhanced Sample Preparation (SP3) protocol has been recently 
introduced as an alternative approach. It utilizes carboxylate-coated paramagnetic beads that can 
immobilize proteins and peptides on their hydrophilic surface (Hughes et al., 2014). In SP3, a 
suspension of beads is first added to an aqueous solution of proteins. Upon the addition of an 
organic solvent, proteins are trapped on the surface of the hydrophilic beads forming a solvation 
layer. Protein-coated beads can be washed with a range of organic solvents on a magnetic rack. 
This way detergents, chaotropes and salts can be removed from the sample. After several wash 
steps, proteins are eluted again into aqueous buffer for digestion. A similar procedure is 
performed after digestion on the peptide level to remove components of the digestion buffer. An 
additional peptide labeling step can be added before peptide cleanup, if needed. It is also 
possible to include a step of peptide fractionation based on their hydrophobicity. This can be 
achieved by subsequent washes with buffers of decreasing concentration of organic solvent. SP3 
has been shown to outperform FASP especially when it comes to small amount of samples 
(Sielaff et al., 2017), and it has also been applied to the FFPE tissues successfully (Hughes et al., 
2016). 
Successful proteomic analyses of FFPE tissues have been previously reported. Nevertheless, in 
the majority of studies comparisons of bulk tumor versus healthy tissues were presented. 
Proteomic analysis of FFPE tissues has not yet been used to systematically analyze ITH. 
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2.2.	   Aims	  
 
Although various studies have recently demonstrated the power of mass spectrometry based 
proteomic to study cancer specimens, the potential of the technology to study ITH has not been 
fully explored. It thus remains a matter of debate, to which extent the genetic and morphological 
variations are reflected at the proteome level, and whether an additional layer of heterogeneity 
can be unrevealed by measuring the abundance of thousands of proteins. The aim of this study 
was to quantify the tumor heterogeneity on the proteome level using hepatocellular carcinoma as 
a model system. This was achieved with the following steps: 
 
1. Development of the efficient protocol allowing for the proteomic analysis of limited 
amount of FFPE material 
2. Comparison and selection of the most suitable quantification strategy 
3. General characterization of the hepatocellular carcinoma proteome 
4. Proteomic analysis of different tumor regions derived from the same tumors. 
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2.3.	   Results	  
 
 
PART	  I:	  Development	  and	  validation	  of	  a	  quantitative	  proteomic	  approach	  for	  FFPE	  tissues	  
 
2.3.1.	   Reproducibility	  of	  the	  SP3	  sample	  processing	  workflow	  for	  FFPE	  tissues	  
 
During the SP3 procedure, all sample processing steps are performed in a single test tube to 
minimize sample loss. The approach is therefore suitable for applications where the amount of 
starting material is limited. Additionally, it allows for the complete removal of reagents that are 
non-compatible with MS, including commonly used detergents. Detergent-based solubilization 
facilitates the extraction of proteins from FFPE specimen. The SP3 protocol was therefore 
adapted for the processing of small amounts of FFPE material. To test the quality of MS samples 
derived from FFPE material, two consecutive tissue sections (of 10 µm in thickness) of HCC 
were processed separately for comparison. 25 mm2 tissue areas of both, HCC and adjacent 
peritumoral tissue, were extracted from each slide, solubilized and further processed using the 
SP3 protocol. From each sample, 10% of the total peptide material was analyzed by shotgun 
proteomics using LFQ approach. The quality of the MS data was assessed by quantification 
across the two consecutive sections as well as by manual inspection of the chromatogram and 
comparison of the number of peptide identifications. The MS base peak chromatogram (BPC) of 
FFPE samples looked comparable to HeLa cell lysate (used as a standard quality control), 
indicating the successful peptide extraction and removal of contaminants, such as salts and 
detergent. On average, around 20% of the acquired MS/MS spectra were matched against the 
human proteome database. For comparison, around 50-60% of MS/MS spectra are usually 
assigned when non-fixed lysates were analyzed (e.g. HeLa cell lysate). This indicates that 
peptides with chemical modifications were abundant in the analyzed sample and that the reversal 
of formaldehyde crosslinks was incomplete. As a consequence, the overall number of identified 
proteins is lower as compared to non-fixed samples. Nevertheless, a high correlation coefficient 
(>0.95) was observed for protein abundances across both sections as determined by LFQ, thus 
confirming the reproducibility of approach (Figure 9).  
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Figure	  9.	  Quality	  control	  of	  SP3	  based	  FFPE	  tissue	  processing	  
(A) Base peak chromatograms of peptides extracted from FFPE tissue (top panel) and HeLa cell lysate 
(bottom panel). (B) Pearson correlation of protein abudances between different FFPE sectors (HCC and 
peritumoral tissue). High correlation values between replicates of the same tissue area indicate very good 
reproducibility. 
 
2.3.2.	   Selection	  of	  the	  optimal	  sample	  for	  the	  analysis	  of	  ITH	  
 
In order to asses if proteomic ITH goes beyond morphological and genetic heterogeneity, the 
following approach was used: For several HCC patient samples obtained from the Heidelberg 
tissue data bank, the level of heterogeneity was assessed based on tissue morphological analysis 
according to standard diagnostic procedures. This was done by Dr. Stephan Singer, a pathologist 
from the University of Heidelberg. An HCC specimen with no apparent differences at the 
morphological level was selected for further analysis as indicated by the H&E stain (Figure 
10B). For subsequent proteomic and genetic analysis, half of the encapsulated spherical solid 
tumor was stained using H&E stain. In total, 5 different tissue sectors were analyzed. These 
were: (i-iii) three concentric rings within the tumor tissue, (iv) tumor capsule formed by the 
connective tissue, (v) adjacent peritumoral tissue (Figure10A). The genetic analysis (NGS) was 
performed by Dr. Volker Endris from the Heidelberg Institute of Pathology. The different tissue 
areas were subjected to NGS targeting a panel of genes that are frequently mutated in 
HCC(Guichard et al., 2012). Only three mutations were found in the following genes: DNA 
(cytosine-5)-methyltransferase 3A (DNMT3A Y247F), Myosin Heavy Chain 11 (MYH11 
L1563P) and Cyclin-dependent kinase 12 (CKD12 H369R). Nevertheless, the identified 
mutations showed similar allelic frequency (with the exception of CDK12) across all analyzed 
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tumor sectors indicating that the analyzed specimen is largely homogenous also on the genetic 
level (supplementary table 1).   
 
 
Figure	  10.	  Morphologically	  homogenous	  tumor	  used	  for	  the	  ITH	  analysis	  
(A) Macroscopic picture of the HE-stained HCC specimen (scale bar = 5 mm). As indicated with the 
arrows, 5 different tissue sectors were analyzed. These include three tumor sectors, adjacent peritumoral 
tissue and tumor capsule. A blood vessel localized to the middle of specimen and was removed during 
LCM procedure (B) Microscopic images (40x, scale bar is 200 µm) of the analyzed sectors. Modified 
from (Buczak et al., 2018) IHC images were provided by dr. Stephan Singer. 
 
For the proteomic analysis, two consecutive slides of the same tumor sample were subjected to 
the laser capture microdissection (LCM) and subjected to two different quantitative experiments 
(TMT and DIA; see materials and methods for detail). The sectors indicated in Figure 10A were 
collected for the analysis (around 0.4 mm3 of tissue of each sector). To avoid contamination with 
unrelated cell types, the blood vessel localized in the central part of the specimen was removed.  
 
2.3.3.	   Comparison	  of	  different	  quantification	  approaches	  
 
In this section, I will compare different mass spectrometric quantification experiments, to assess 
the experimental reproducibility of FFPE tissue analysis but also to comment on which MS 
workflow permits the most comprehensive analysis of such samples. Each sector was analyzed 
with both DIA and TMT quantification strategies. For DIA analysis, the generation of a spectral 
library by label-free DDA (shotgun) analysis is a prerequisite, which also offers the opportunity 
to compare the DDA and DIA workflows. To this end, I first used a Q-Exactive HF mass 
spectrometer and analyzed all five sectors by label-free DDA. Specifically, after each full MS1 
scan, the 20 most intense ions were isolated for fragmentation. On average 3018 proteins were 
identified in single DDA run with only 2142 being detected across all measured samples (Figure 
11A).  Next, the spectra from all runs were combined, resulting in the spectral library of 32681 
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peptides belonging to 4004 proteins. For DIA analysis, the m/z range of interest (400-1200m/z) 
was divided into 38 windows. After every full MS1 scan, each m/z window was subsequently 
isolated and all ions present within a single m/z window were fragmented an analyzed 
simultaneously in the orbitrap mass analyzer. To minimize the MS2 spectra complexity, the 
widths of m/z windows were adjusted to the precursor ion density across the m/z range, as 
reported in (Bruderer et al., 2015). The DIA dataset was almost complete with minimal number 
of missing values as compared to the spectral library. On average 95% of proteins were 
identified in single DIA runs and 93% of them were detected across all measured samples 
(Figure 11B). The DIA workflow thus permits considerable better cross-quantification as 
compared to label-free DDA.   
 
 
Figure	  11.	  Shotgun	  and	  DIA	  datasets	  comparison	  
Heatmaps indicating the normalized intensity values for all quantified proteins in (A) shotgun and (B) 
DIA datasets. White spots represent the missing values.  Number of missing values is significantly 
reduced in DIA dataset when compared to shotgun experiment. 
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The issue of missing values is to quite some extent addressed by TMT workflows that rely on 
reporter ions for quantification. To analyze the five sectors for the specimen, a TMT 6-plex 
reagent was used with the 6th channel containing a repeat sector. To measure the efficiency of 
labeling, 10% of each sample was analyzed separately by shotgun proteomics with the TMT 
label being considered as a variable peptide modification. The labeling efficiency was > 95%.  
For TMT analysis, peptides from all 6 channels were pooled and fractionated using offline high-
pH reverse phase fractionation. In total, 16 fractions were collected and analyzed using Orbitrap 
Fusion mass spectrometer. To minimize the reporter ion ratio distortion resulting from the 
fragmentation of co-isolated interfering ions, an additional step of fragmentation was used. 
Specifically, quadrupole-isolated ions were fragmented and their spectrum was acquired in the 
ion trap. The 8 most intense MS2 fragment ions were isolated using synchronous precursor 
selection (McAlister et al., 2014) and their MS3 spectrum was acquired using the orbitrap mass 
analyzer. To enhance the reporter ion signal, LysC was used for enzymatic digestion. LysC 
cleaves the peptide bonds only after lysine residues but not arginines and, as a consequence, each 
peptide carries two tags at the primary amines of the N-terminus and the C-terminal lysine 
residue. In total, 4570 proteins were detected across all analyzed samples, thus outperforming the 
above-discussed DIA analysis in terms of protein identification. 
 
The DIA and TMT differ in terms of the sample processing after protein extraction, the selection 
of precursor ions for fragmentation, the quantification methods and the proteolytic digestion. 
Thus, the directly observed signal for each protein from each sector cannot be directly compared 
between two datasets. I therefore compared the protein ratios observed across different sectors. 
A significant positive correlation of log2-transformed fold changes calculated for different 
sectors confirms the consistency between DIA and TMT datasets (Figure 12). The application of 
the two quantitative strategies to the same specimen therefore provided complementary 
quantitative information and demonstrated the compatibility of presented workflow with both 
approaches.  
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Figure	  12.	  Comparison	  of	  protein	  fold-­‐changes	  measured	  with	  DIA	  and	  TMT	  approaches	  
To compare both datasets, log2-transformed fold-changes calculated for different sectors were compared. 
Representative examples are presented (A-F). Differences between non-tumor tissues, either peri-tumor 
(PT), or tumor capsule (TC), and tumor sectors (TS1-TS3) are more pronounced and show a high degree 
of linearity (A-D). Differences between tumor sectors (TS1-TS3) are less pronounced. Therefore, the 
correlation between fold-changes derived from DIA and TMT methods are lower, although still positive 
(E-F). Proteins identified as differentially expressed between tumor center and its periphery are 
highlighted in red. Modified from (Buczak et al., 2018) 
 
2.3.4.	   Analysis	  of	  proteome	  profiles	  of	  HCC	  
 
I first compared the overall proteome profiles across different tissue sectors. For this, I calculated 
the Pearson correlation of normalized expression values (Figure 13A). High correlation values 
(>0.9) between tumor sectors and peritumoral tissues were observed. The proteome of tumor 
capsule formed from the connective tissue can be clearly separated from other sectors mainly 
due to the high abundance of extracellular matrix proteins, which are absent in other regions. 
The observed high similarity between the peritumoral tissue and tumor sectors is consistent with 
the fact that the sample used for the analysis was a well-differentiated HCC and reminiscent of 
non-tumorous liver tissue in terms of pathological morphology (Figure 10). Nevertheless, soft 
clustering analysis of protein abundances using the fuzzy c-means algorithm (Kumar and E 
Futschik, 2007) identified a subset of proteins that clearly separate HCC from the  surrounding 
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non-neoplastic hepatocellular tissue (Figure 13B). I applied the same strategy to identify proteins 
with heterogeneous expression within the three tumor sectors (other sectors were not included). 
The soft clustering indicated a prominent subset of proteins with an increased expression level at 
the tumor periphery when compared to its center (Figure 13B). Taken together this analysis 
indicated, that despite the overall proteomic similarity, the ITH on the proteome level can be 
detected with mass spectrometry. 
 
 
Figure	  13.	  Proteome	  profiles	  of	  HCC	  
(A) Heatmap representing the Pearson correlation coefficient of the analyzed sectors. (B) Soft clustering 
analysis of HCC spatial proteome using the fuzzy c-means algorithm (Kumar and E Futschik, 2007). The 
optimal number of clusters was estimated using the “elbow” algorithm (Schwämmle and Jensen, 2010).  
The upper panel includes all measured sectors (including tumor capsule and peri-tumoral tissue). The 
lower panel shows clusters calculated only for the three tumor sectors. The DIA dataset was used to 
create this figure. The TMT data are shown in the supplementary figure 1. Modified from (Buczak et al., 
2018) 
 
2.3.5.	   Functional	  analysis	  of	  heterogeneously	  expressed	  proteins	  
 
In order to assess whether the above identified proteins affected by ITH are functionally related, 
I performed a network analysis on proteins that displayed heterogeneous expression, as 
described in the following. As indicated by the proteome profiles (Figure 12B), the most 
pronounced differences were observed between tumor center (T1) and its periphery (T3). 
Therefore, T3 vs T1 fold changes were calculated for all the identified proteins. A two 
component model was then fitted on the centered ratio distribution using fdrtool R package 
(Strimmer, 2008). Proteins with a q value < 0.2 were considered as differentially expressed 
between both tumor sectors. TMT and DIA datasets were treated separately (Figure 14).  
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Figure	  14.	  Statistical	  models	  for	  TMT	  and	  DIA	  datasets	  
Histograms and the densities of the fitted two-component models (null component = proteins with no 
differential expression; alternative component = proteins with differential expression) are shown. Models 
were fitted on median centered log2- transformed fold-changes (z). Proteins with q-values < 0.2 were 
considered as differentially expressed. Modified from (Buczak et al., 2018) 
 
To combine the quantitative information from both datasets, I extracted proteins that were: (i) 
consistently differentially expressed in both datasets (q value < 0.2), (ii) differentially expressed 
in only on of the datasets (q value < 0.2) but not detected in the other or  (iii) classified as 
differentially expressed in only one of the datasets (q value < 0.2) with the log2 of fold change 
>|1| and the same fold change sign in the other one. In total, 230 proteins were extracted (Figure 
12F) and analyzed with the STRING database (Jensen et al., 2009) using high confidence score 
(>0.7). The thus derived network of protein-protein interactions was further analyzed with 
cytoscape. Specifically, the MCODE plugin (Bader and Hogue, 2003) was used to extract the 
sub-network modules that were subsequently subjected to the functional enrichment analysis 
using ClueGO (Bindea et al., 2009). A list of all the identified proteins was used as a background 
gene list. A strong enrichment of ribosomal proteins was observed at the tumor periphery, 
possibly indicating the higher translational activity. Such heterogeneous expression patterns 
were also detected for proteins involved in the regulation of cell migration. For example, the 
small GTPases RAC1 and CDC42 that control the formation of lamellipodia and filipodia 
together with the regulators of actin cytoskeleton dynamics, like Actin-related protein 3 
(ACTR3), showed higher expression levels at the tumor periphery.  Also proteins that regulate 
the cell migration at the extracellular level, such as Integrin beta 1 (ITGB1) and Integrin beta 2 
(ITGB2), displayed similar expression profiles.  
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Figure	  15.	  Network	  analysis	  of	  proteins	  differentially	  expressed	  across	  the	  HCC	  
Proteins differentially expressed across the HCC specimen were subjected to a network analysis, as 
described in the main text. The presented network modules were extracted with MCODE.  The GO term 
enrichment within each module was assigned with ClueGO. The barplots displayed next to each network 
node indicate the calculated fold-change for both, the DIA (left) and TMT dataset (right). Modified from 
(Buczak et al., 2018) 
 
2.3.6.	   Validation	  of	  proteomics	  data	  with	  immunohistochemistry	  	  
 
The IHC analysis presented in this section was performed by the tissue bank of the National 
Center for Tumor diseases (NCT) Heidelberg. 
 
The differences in the number of ribosomes across the tumor sectors may be a consequence of 
different proliferation rates in distinct tumor areas. This could potentially affect the proteome 
profiles. Thus, to rule out this additional source of heterogeneity the expression level of Ki-67, 
which is a proliferation rate marker protein (Gerdes et al., 1983), was assessed. Since it was not 
detected in the MS analysis, an immunohistochemical staining (IHC) was performed. As shown 
in the Figure 16, in all sectors similar low proliferation rates were observed. IHC was also used 
to validate the mass spectrometry data. A subset of proteins with different expression patterns 
was selected for this analysis: (i) Hepar-1 antigen, marker of hepatocellular tissues (Butler et al., 
2008), as a protein with even expression  (ii) Decorin, which was strongly enriched in the tumor 
capsule, (iii) Rac1, showing a gradient of increased expression towards the periphery. Light 
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microscopy images presented on the Figure 16 indicate that the IHC is consistent with proteomic 
data. 
 
 
 
Figure	  16.	  Immunohistochemical	  validation	  of	  proteomic	  data	  
(A) Consecutive tissue sections of the analyzed specimen were stained with antibodies against Ki67, 
Hepar-1 antigen, Decorin and RAC1 (scale bars = 200um). IHC images were provided by dr. Stephan 
Singer  (B) Expression profiles based on the proteomic dataset for comparison. Modified from (Buczak et 
al., 2018). 
 
 
PART	  II:	  Comprehensive	  analysis	  of	  HCC	  proteome:	  
 
In the first part of my work I showed that the analysis of very limited amounts of FFPE material 
with deep proteomic coverage is possible and that the developed approach is sensitive enough to 
detect proteomic intratumoral heterogeneity. As a next step, I analyzed the HCC proteomes from 
5 additional patients (for patient characteristics see supplementary table 2). Like in the previous 
analysis, only morphologically homogenous tumors were analyzed. In this chapter, I discuss the 
proteomic analysis of HCC across different patients that includes on one hand tumor versus 
peritumor comparison and on the other a comparison of different sectors within each sample. For 
the first part, I will also refer to other datasets that were not generated by me. One of them is the 
publicly available gene expression data, which was derived from 241 HCC patients (Roessler et 
al., 2010). I also compared human HCC proteome with proteomes derived from murine HCC 
models. These models were generated by transposon-based gene transfer of different oncogenes 
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(N-rasG12V, Myc, and myriostylated Akt1) into wild type mice, as well as into mice with 
homozygous or heterozygous deletions of the tumor suppressor genes CDKN2aARF and Trp52 
(Dauch et al., 2016). In total, 12 fresh frozen tissues of murine livers were provided by Dr. 
Daniel Dauch and Prof. Lars Zender from the University Hospital Tübingen (11 HCC livers and 
one control). The proteomic data of murine liver tissues that are mentioned below was obtained 
by Dr. Alessandro Ori using a label free quantification approach. 
 
2.3.7.	   Proteomic	  comparison	  of	  tumor	  and	  surrounding	  peritumoral	  tissue	  
 
I separated the bulk tumor from the adjacent peritumoral tissue using LCM. To avoid 
contamination with unrelated cell types, I removed the tumor capsule, fibrous septa, and blood 
vessels where relevant. 5 tumors and 5 peritumors were combined into a single TMT 10-plex 
experiment. Peptides were fractionated using high pH reverse phase chromatography and 
measured on an Orbitrap Fusion Lumos. This analysis quantified 5838 proteins with at least two 
proteotypic peptides across the respective conditions. Pearson correlation (Figure 17A) indicated 
that peritumoral tissues are highly similar across individuals and can be distinguished from 
malignant areas. In contrast, correlation values for the analyzed tumors were generally lower, 
indicating the high level of inter-patient heterogeneity. One of the samples, labeled as tumor 1, 
appeared as an outlier and was more similar to the peritumoral tissues of the other specimens. 
Motivated by this finding, Dr. Stephan Singer inspected the respective clinical records and found 
that the corresponding patient received transarterial chemoembolization (TACE) treatment 
before the surgery. Since the impact of TACE treatment on the HCC proteome is not known, this 
sample was excluded from some of the following analyses (as specified below). Also for the 
other 4 specimens, a relatively high degree of inter-tumor heterogeneity was observed. I 
therefore decided quantitatively analyze each tumor-peritumor pair separately. 
To investigate which proteins and functional modules are affected by HCC, I performed the gene 
ontology (GO) enrichment analysis using single ranked list algorithm (Eden et al., 2009). The 
list of identified proteins was sorted based on the calculated fold-change (tumor vs. peritumor). 
Enrichment of GO-terms in “biological processes” category was calculated for both up- and 
down-regulated proteins for each tumor-peritumor pair separately. The redundancy of the 
identified GO-terms was reduced using REVIGO (Supek et al., 2011). Although for each sample 
a slightly different set of enriched GO-terms was retrieved, certain similarities were observed. 
For example, among the proteins up-regulated within the tumors, I found multiple proteins 
involved in the transcription and RNA processing, suggesting higher rates of transcription in the 
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cancer cells. Among the down-regulated proteins, I found enrichment for several mitochondria 
related processes possibly indicating an alteration of the energy metabolism in hepatocellular 
carcinoma (Figure 17B).   
 
Figure	  17.	  Tumor	  vs.	  peritumor	  comparison	  
(A) Pearson correlation between samples used for neoplastic vs. non-neoplastic tissue comparison. (B) 
Ranked gene ontology enrichment of proteins differentially expressed in tumor vs. peritumor comparison. 
The blue color corresponds to proteins that were down-regulated in the tumor. The red color indicates up-
regulated proteins. Representative terms from each cluster are displayed next to the heatmap. Modified 
from (Buczak et al., 2018) 
 
 
2.3.8.	  	   Comparison	  of	  proteomic	  and	  transcriptomic	  changes	  in	  HCC	  
 
As a next step, I attempted to derive an expression signature of HCC containing proteins and 
genes that are differentially expressed in the HCC as compared to non-neoplastic tissue. For this 
purpose, I integrated publicly available gene expression data (Roessler et al., 2010) with the 
proteomic data of human samples and the proteomic data of genetically defined HCC mouse 
models that closely resemble human hepatocarcinogenesis (Dauch et al., 2016), as follows. To 
define the HCC signature, I combined genes and proteins that showed consistent fold changes in 
gene expression and protein levels in both: tumor versus peritumor tissues, in both patients and 
murine models. I did not take into consideration Tumor 1 because it appeared as an outlier in 
previous analysis. Due to the low coverage of murine proteomes, missing values were allowed 
for this dataset. In total 755 proteins were selected, out of which some had already been 
previously linked to the HCC development (Figure 18A). For example, multiple components of 
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minichromosome maintenance complex (MCM complex) were found to be expressed at higher 
levels in the analyzed tumors (Figure 18B) and the up-regulation of MCM proteins has been 
previously linked with multiple cancers including HCC (Das et al., 2014). In fact, one of the 
subunits, namely MCM6, was proposed as a novel HCC marker (Zheng et al., 2014). Other 
proteins there were not yet connected to the HCC development, such as fatty acid binding 
protein (FABP4), which is involved in the lipid transport or Zing finger protein 207 (ZFP207), 
which is a kinetochore and microtubule binding protein. These findings indicate that the acquired 
dataset does not only recapitulate multiple known HCC factors, but also identify new proteins 
that may be involved in the process of liver tumorigenesis. In particular because of the relatively 
small number of human patient samples included into my study, these however need to be 
further investigated in the future. 
 
 
Figure	  18.	  HCC	  expression	  signature	  
(A) Heatmap highlighting the expression changes of 755 proteins identified as regulated in HCC. T1 was 
not considered for this analysis but included in the heatmap for comparison. (B) Boxplot indicating the 
expression changes of MCM protein complex. All subunits were included. Modified from (Buczak et al., 
2018) 
 
Since the gene expression data had been previously explored for its prognostic value (Roessler et 
al., 2010), I also tested whether the identified signature correlated with a more aggressive tumor 
phenotype. Since the latency of analyzed murine models was previously defined, I first 
correlated it with the expression of proteins included in the proteomic signature. A significantly 
 50 
higher expression of the respective proteins in HCC models of 4 weeks latency in comparison to 
the moderately aggressive HCCs with the latency of 8-12 weeks was observed (Figure 19A). In 
the following, it was also tested if the corresponding expression profiles of the transcript levels 
were also associated with the poor clinical outcome in HCC patients (this part was done by dr. 
Stephanie Roessler). Survival risk prediction using the number of 755 genes included in the 
signature derived from the combined transcriptomic and proteomic analysis resulted in a high 
(n=122) and low (n=119) risk group of patients (permutation p=0.001). Indeed, as the Kaplan-
Meier survival curves demonstrate that HCC patients defined as high risk by the proteomic 
signature had significantly shorter overall survival than low-risk patients (lon-rank p-value < 
0.001, Figure 19B)  
 
 
Figure	  19.	  Survival	  risk	  prediction	  based	  on	  the	  HCC	  expression	  signature	  
(A) The boxplot (below) shows fold changes of up-regulated proteins from the HCC signature across 
different murine models. The barplot (above) indicates the tumor latency of corresponding models (given 
in weeks after cells injection), as proxy for tumor aggressiveness. (B) Survival risk prediction analysis 
was performed on a cohort of 241 human HCC patients. The cohort was dichotomized into high and low 
risk patients according to the prognostic index derived from the HCC gene signature. Plot on the panel B 
was provided by dr. Stephanie Roessler. 
 
2.3.9.	   Analysis	  of	  proteomic	  changes	  that	  are	  not	  reflected	  at	  the	  gene	  expression	  level	  
 
Next, I asked whether the proteomic data could reveal biological insights that would not emerge 
from the solely from the transcriptomic data. This analysis was performed using HCC proteomic 
data (excluding tumor 1) and previously aforementioned gene expression dataset of large cohort 
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of HCC patients. In order to define proteins that are consistently differentially expressed, I 
calculated the average fold change for all quantified proteins together with their statistical 
significance. Only hits with q value < 0.2 were considered as differentially expressed 
(supplementary figure 3). From these, I further selected for hits that showed either no or modest 
change at the gene expression level (with the log2-transformed fold change < |0.5|). In total 148 
proteins were extracted (Figure 20). Among them I observed several members of mitochondrial 
NADH dehydrogenase complex I, which is a part of mitochondrial respiratory chain. Although 
remaining components of the complex did not pass the significance scores, for a majority of 
them negative values of fold changes were observed, possibly indicating rearrangements in the 
inner mitochondrial membrane or general differences in subcellular compartmentalization. In 
order to verify whether this was a common feature of various types of HCC, I also compared the 
expression of NADH in murine models. Consistently with the human samples, the majority of 
NADH dehydrogenase complex I components were expressed at lower level in HCC when 
compared to the healthy liver.  
 
 
Figure	  20.	  Proteomic	  changes	  not	  detected	  by	  the	  gene	  expression	  analysis	  
(A) Comparison of changes of gene expression and protein abundance. The highlighted proteins (blue and 
red) are either down-regulated (blue) or up-regulated (red) at the proteome level, but their expression is 
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not affected at the transcriptome level. Green points indicate NADH dehydrogenase complex I 
components. (B) Heatmap showing the expression of NADH dehydrogenase complex I components. The 
upper panel includes hits with q value < 0.2. The remaining components of the complex are displayed in 
the bottom panel. Modified from (Buczak et al., 2018) 
 
2.3.10.	  Analysis	  of	  the	  mitochondrial	  content	  in	  HCC	  
 
The proteomic analysis indicated that multiple mitochondrial proteins are expressed at lower 
levels in tumors as compared to non-neoplastic liver tissue, possibly indicating a reduced number 
of mitochondria. To check whether other mitochondrial proteins are also affected I analysed on 
the proteomic changes within each subcellular compartment separately. For this analysis, I 
focused on four compartments namely nucleus, cytoplasm, mitochondrion and extracellular 
components. For each quantified protein, I assigned a subcellular location using biomart R 
package as annotated in uniport (Durinck et al., 2009). To visualize the differences, the 
distributions of fold changes within different compartments were plotted for each of analyzed 
specimen (Figure 21). Proteins with multiple annotated localizations were included in each 
identified compartment. In case of murine HCCs, a clear separation between mitochondrion and 
remaining compartments was observed indicating that overall amount of mitochondrial protein 
content is significantly reduced and therefore supporting the hypothesis that tumor cells contain 
lower number of mitochondria. In case of human HCC the difference is much less pronounced. 
Nevertheless, in 4 out of 5 cases still significant (as estimated by the Kolmogorov-Smirnov test).  
 53 
 
Figure	  21.	  Distribution	  of	  fold-­‐changes	  for	  different	  subcellular	  compartments	  
Density plots show the compartment specific distribution of fold-changes between neoplastic and non-
neoplastic tissue. Barplots show the difference in fold-changes of mitochondrial proteins and proteins 
localized to all other compartments. A representative murine model was selected for comparison. 
Modified from (Buczak et al., 2018) 
 
In order to validate this finding, I quantified the mitochondrial content in analyzed human HCC 
specimens with an independent approach. Such quantification is commonly achieved by 
measuring the activity of either citrate synthase (Mogensen et al., 2006) or the electron transport 
chain (Picard et al., 2011). Due to fixation such metabolic assays are however not possible in 
FFPE tissues. I therefore decided to quantify the mitochondrial DNA (mtDNA) content. 
Although, there are other factors that can affect the abundance of mtDNA, it has been shown that 
it can be used as a proxy of mitochondrial content (Larsen et al., 2012). The pool of DNA 
including both mitochondrial and nuclear DNA (mtDNA and nDNA respectively) was isolated 
from consecutive slides of analyzed FFPE tissues. It was then used as a template for quantitative 
PCR (qPCR). For mtDNA two genes were selected as targets for qPCR: MT-TL1 encoding the 
12S rRNA and MT-RNR1 encoding tRNA-leu. The signal was normalized to the amount of 
nDNA (target gene was B2M), which is expected to be constant in all analyzed tissues. The 
mtDNA/nDNA ratios were compared between tumor and peritumoral tissues. As a control, I 
performed similar analysis for two renal oncocytoma (RO) specimens – a type of tumor for 
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which the increased number of mitochondria has been previously reported (Joshi et al., 2015). 
As expected, an enhanced level of mtDNA was observed in RO. Similarly, the amounts 
quantified for HCC specimens were in agreement with the proteomic data. For tumor 4, I was 
not able to perform the qPCR due to the lack of the peritumoral tissue in the remaining FFPE 
block. Nevertheless for other specimens the constant decrease of around 2-fold was observed. 
Tumor 1 showed increased level of mtDNA, which is line with the increase of the mitochondrial 
protein expression observed for that sample (Figure 22).  
 
 
Figure	  22.	  Quantification	  of	  mitochondrial	  DNA	  
The barplot shows the fold change (log2) of mtDNA abundance of tumor in comparison to peritumoral 
tissues. Two mitochondrial genes (MT-RNR1 and MT-TL1) were analyzed using qPCR and normalized to 
the nuclear gene B2M. Modified from (Buczak et al., 2018) 
 
PART	  III:	  Proteomic	  ITH	  in	  HCC	  
 
2.3.11.	  Proteomic	  comparison	  of	  tumor	  center	  to	  its	  periphery	  
 
To investigate the intratumoral heterogeneity I used consecutive slices, adjacent to the 
previously analyzed 5 patient HCC specimens. Using LCM, I separated tumor center and its 
periphery (10 samples in total) and assembled them into a TMT experiment. In total 5659 
proteins were quantified across all analyzed samples with at least two unique peptides. Statistical 
significance was calculated separately for each sample as before (supplementary figure 4). As 
expected, differences between patients were more pronounced than these observed within a 
 55 
single tumor (indicated by the Pearson correlation, Figure 23A). Nevertheless proteomic ITH 
was still observed, however up to different extent between the analyzed tumors (Figure 23B). 
Ranked GO enrichment analysis showed that within each tumor, proteins of distinct functions 
were affected by ITH. 
 
 
Figure	  23.	  Overall	  heterogeneity	  comparison	  
(A) Pearson correlation between samples used for tumor periphery vs. tumor center comparison. (B) 
Ranked gene ontology enrichment of differentially expressed proteins. The blue color corresponds to 
proteins that were down-regulated in the tumor. The red color indicates up-regulated proteins. 
Representative terms from each cluster are displayed next to the heatmap. Modified from (Buczak et al., 
2018) 
 
In order to assess, whether proteins affected by ITH are functionally related, I performed a 
network analysis of significantly regulated proteins. For each tumor, significant hits (q value < 
0.2) were mapped to the STRING network using the high confidence score (> 0.7). The resulting 
networks were analyzed in Cytoscape using MCODE (Bader and Hogue, 2003) and ClueGO 
plugins (Bindea et al., 2009) as described before. Selected modules of interaction networks are 
presented in the Figure 24.  Among the proteins that were differentially expressed within tumor 2 
and 3, I found an enrichment of cytochrome P450 enzymes. Some of them were previously 
identified as a part of the expression signature of HCC. This finding indicates that markers that 
are up-regulated in HCC, are not necessarily expressed evenly within a single specimen. The 
remaining samples displayed different characteristic of ITH. In tumor 4 for example, I observed 
the increase of proteins involved in the mRNA processing at the center (including multiple 
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components of the spliceosome). Interestingly, the overexpression of splicing related genes has 
been previously shown to be common for aggressive types of HCCs (Liu et al., 2014). In tumor 
5, I have observed an increase of extracellular matrix proteins, which might indicate that this 
area was infiltrated with the components of tumor stroma (connective tissue etc.) 
 
 
Figure	  24.	  Network	  analysis	  of	  ITH	  observed	  across	  different	  specimens	  
Proteins with heterogeneous intra-tumor expression (from each sample separately) were extracted and 
subjected to network analysis. The presented network modules were extracted with MCODE.  The GO 
term enrichment within each module was assigned with ClueGO. The color code of the network nodes 
indicate the observed fold-change 
 
2.3.12.	  	  Identification	  of	  proteins	  commonly	  affected	  by	  ITH	  
 
Although the observed proteomic patterns seem to be tumor-specific, I attempted to identify 
proteins that appear to be frequently affected by ITH. For this purpose, I extracted proteins from 
the entire dataset that were significantly changed in at least two out of five specimens included in 
the analysis. In total 43 of such cases were identified (Figure 25A). The most striking example 
was the expression of SerpinB3 (SPB3) and SerpinB4 (SBP4) also known as squamous cell 
carcinoma antigens (SCCAs) (Figure 25B). Importantly, SCCAs have been previously linked to 
the liver cancer and even proposed as histological markers of HCC (Zhao et al., 2013).  Only in 
one of the analyzed tumors (T2) a homogenous expression was observed. In the other specimen, 
I observed strong expression changes (up to 16-fold) between the tumor sectors. SPB3 and SPB4 
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were quantified with 5 and 3 unique peptides respectively. None of these peptides were detected 
in the center of the tumor 1 indicating that the protein amount in this sector is below the level of 
detection. All of these peptides were quantified in the periphery of the same tumor. I thus 
concluded that also within the tumor 1 a heterogeneous expression of serpins is apparent. In 
some cases, SCCAs were found to be upregulated at the periphery, while in others I observed an 
increased expression in the center. This data suggest that the ITH of SSCAs might be 
independent from the tumor geometry. The spatial cue driving the ITH remains to be 
characterized.   
 
 
Figure	  25.	  Proteins	  frequently	  affected	  by	  ITH	  in	  HCC	  
(A) Heatmap showing the protein abundance changes between tumor center and its periphery. It includes 
only proteins that were differentially expressed in at least 2 of the analyzed specimens. For displaying 
purposes, the fold change values were limited between -1 and 1. (B) Graphical representation of 
normalized SCCAs expression across tumor sectors. For each tumor, three sections are displayed that 
correspond to the expression of Serpin B3 (sectors TS1 and TS3) on the left side, Serpin B4 (sector TS1 
and TS3) on the right side. The center section is for tumor vs. peritumor comparison and contains 
information about both of the proteins (both proteins are merged because due to the sequence similarity 
they were identified as a single protein group in the tumor vs. peritumor TMT experiment). Modified 
from (Buczak et al., 2018) 
 
Apart from SCCAs, other HCC relevant proteins were differentially expressed in more than one 
case. For example, two proteins that are required for the cell migration in HCC, namely 
microtubule-interacting protein stathim (STMN1) (Singer et al., 2007) and myristoylated 
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alanine-rich C-kinase substrate (MARCS) (Song et al., 2015) were enhanced at the periphery 
(Figure 26A and B). This is consistent with the section 2.3.5 above, were multiple proteins 
involved in cell migration were upregulated at the tumor periphery. Also STMN1 has been 
proposed as negative prognostic marker in the HCC (Yuan et al., 2006). At last, I identified 
proteins that show a consistent difference between tumor and surrounding non-malignant tissue, 
but at the same time appear to be evenly expressed in distinct tumor areas. For example, 
hepatocyte nuclear factor 4-alpha (HNF4A) and quinone oxidoreductase PIG3 (QORX) (Figure 
26C and D). This analysis strongly underscores the importance of proteomic studies of ITH, 
especially during diagnostic marker validation. These findings indicate that the outcome of 
diagnosis may drastically differ if distinct areas of tumor are inspected during routine clinical 
analysis.  
 
 
Figure	  26.	  Expression	  of	  clinically	  relevant	  markers	  
Graphical representation of the normalized expression of (A) Stathmin (STMN1), (B) Myristoylated 
alaniche-rich C-kinase substrate (MARCS), (C) Hepatocyte nuclear factor 4-alpha (HNF4A) and (D) 
Quinone oxidoreductase PIG3 (QORX) across different specimen. For each tumor, two sections are 
displayed that represent the expression within the tumor (TS1 vs. TS3) on the left side, and expression of 
non-neoplastic vs. neoplastic tissue (T vs. PT) on the right side. Modified from (Buczak et al., 2018) 
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2.4.	  Discussion	  
 
HCC as a model system to investigate inter- and intra- tumor heterogeneity 
In this work, I focused on the proteomic characterization of hepatocellular carcinoma 
investigating both overall differences between malignant and non-malignant tissue as well as 
alterations of protein expression between distinct regions of the same specimen. HCC was 
selected as a model system for this study for two reasons. First, HCC currently represents the 
second most deadly cancer. Multiple environmental and genetic factors connected to liver 
carcinogenesis have been studied (Boyault et al., 2007; Guichard et al., 2012; Schulze et al., 
2015), nevertheless the proteomic alteration in HCC are still poorly characterized and require 
further investigation. Second, HCC is largely homogenous in terms of morphology as compared 
to other solid tumor types. This makes it a good model for studying proteomic ITH, since it is 
less likely that the variations in protein expression are simply direct consequences of differences 
in cellular composition and genetic diversity.  
 
Development of efficient tool to comprehensively investigate proteomes of limited amount of 
FFPE material 
In recent years a significant increase of in-depth quantitative analysis has been applied in the 
field of cancer biology. This is mainly due to the rapid development of the genome sequencing 
technologies. The genetic analysis provides valuable information about the tumor development 
and its heterogeneity, nevertheless on its own it is not sufficient to provide a complete picture of 
the tumor state. Therefore, it should be also supported by the analysis of more dynamic 
components such as protein expression. Although MS based approaches to study proteomes are 
well established, for a long time their application to the clinical material such as FFPE tissues 
was rather limited. Successful attempts to analyze proteomes from fixed specimens have been 
reported, however the majority of them was based on the analysis of relatively large amount of 
material that is not always available, depending on specimen size. It has been shown that deep 
proteomic coverage can be achieved from FFPE tissues (Ostasiewicz et al., 2010; Wiśniewski, 
2013) by employing extensive off-line fractionation steps. This approach however significantly 
increases the total measurement time per sample and as such makes it unsuitable for a clinical 
setting.  
Here, I developed a workflow that enables efficient protein extraction from limited amounts of 
FFPE tissue. This was achieved by the enhanced protein solublization in the presence of high 
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concentration of SDS combined with the heat-induced formalin fixation reversal. Protein 
retrieval was followed by the SP3 based peptide purification allowing for the complete detergent 
removal with minimal sample loss. The developed workflow is fully compatible with state of art 
MS-based approaches. In combination with TMT labeling, it allows for the detailed proteomic 
analysis with coverage close to non-fixed samples. Samples generated with presented approach 
can also be analyzed by DIA. Due to the lack of off-line fractionation step, protein coverage is 
slightly reduced, however the required measurement time is significantly shorter.  Importantly, 
for DIA only 10% of obtained peptide material was used, meaning that the amount of starting 
material can be even further reduced and the number of investigated tissue areas can be 
increased. In addition, the DIA is not affected by the missing values, even for experiments with 
large sample sizes, therefore it is suitable tool for clinical studies were hundreds of samples need 
to be analyzed. 
 
Significance of spatial proteomics 
The majority of cancer proteome studies do not take the advantage of the excellent preservation 
of the tissue architecture provided by the formalin fixation. This preservation is valuable not 
only for the proteomic ITH but also for the general comparison of bulk tumor with the 
corresponding non-malignant tissues. For example, in liver malignancies fibrous septa (also 
forming the tumor capsule) are frequently observed within the tumor nodule.  While the entire 
tumor nodule can be relatively easily separated from the surrounding peritumoral tissue by 
manual macrodissection, the fibrous septa cannot be removed in this way.  The presence of 
fibrotic tissue was also observed in the first HCC specimen presented in this study, but due to the 
precision of LCM, I was able to remove such regions. As indicated in the Figure 13A, this area 
has a distinct proteome profile when compared to the analyzed tumor sectors and thus should not 
be considered as part of the tumor. The same is true for other non-related cell types that can be 
frequently found within the tumor. This includes infiltrating components of the immune system, 
blood vessels or necrotic areas.  Nevertheless, the major advantage of combining the LCM of 
FFPE tissue with the comprehensive MS analysis is the possibility to investigate the ITH at the 
proteome level.  Here I demonstrated that within specimens which appear largely homogenous 
morphologically, another level of yet uncharacterized heterogeneity is observed at the proteome 
level. The fact that the proteomic ITH affects also clinically relevant marker proteins 
underscores the importance of characterizing proteomic ITH. 
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Robust expression pattern of HCC 
The proteomic analysis of several hepatocellular carcinoma specimens indicates that HCC 
contain a high level of inter-tumor heterogeneity. While the variation between proteome profiles 
was observed for the analyzed tumors, the corresponding peritumoral tissues appeared to be 
relatively similar. As such, the degree of inter-tumor heterogeneity is only partially explained by 
the fact that the analyzed tumors were of different etiology, including patients with HBV, HCV 
and steatohepatitis, since the impact of the disease on the overall liver proteome appears 
minimal. Inter-tumor heterogeneity is thus more likely to be a consequence of exposure to 
different microenvironmental conditions. Nevertheless, certain features, although manifested up 
to a different extent, can be identified across several of the analyzed samples. Such features 
overlap to a large extent with murine models of HCC and transcriptomic data obtained from an 
independent human patient cohort. By extracting reoccurring features, I was able to derive an 
expression signature of HCC that contains factors previously linked to HCC as well as some that 
so far has not been investigated in the context of liver tumorigenesis. Interestingly, the derived 
signature correlates with the aggressiveness of the murine models, independently of their genetic 
background. In addition, the expression signature predicts a patient survival in a cohort of human 
HCCs, thus demonstrating its potential prognostic value.  
 
Proteomic analysis reveals changes that are not reflected at the transcriptome level 
The aforementioned expression signature of HCC was derived in a way that in contains solely 
proteins for which changes in abundances were observed at both proteins and transcript levels. 
As such, it could be potentially applied to predict a patient survival from either transcriptomic or 
proteomic data. However, there are multiple other regulatory mechanisms that affect the protein 
abundances regardless of their transcript levels. These can for example be: (i) modulations of 
translation rates, (ii) regulation of protein stability via post-translational modifications, (iii) 
activation of protein degradation pathways, and many others. As a consequence, the overall 
correlation between mRNAs and corresponding protein abundances is usually low (Vogel and 
Marcotte, 2012) and certain alterations in proteins expression may not be directly reflected at the 
transcript level. Such cases were also identified in analyzed HCC specimens. Among them I 
observed an enrichment for members of NADH dehydrogenase complex I, which is a component 
of mitochondrial electron respiratory chain.  Although no changes of mRNA levels of the 
complex subunits were observed for HCC patient cohort (Roessler et al., 2010), at the protein 
level consistent down regulation of many of them was detected across nearly all of the analyzed 
specimen (both human HCC and murine models). In addition, the proteomic data indicated the 
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general decrease of mitochondrial proteins suggesting that the total mitochondrial volume is 
lower in tumor cells than in surrounding normal hepatocytes. Aforementioned example indicates 
that proteomic analysis can point also to the morphological changes on the cellular level 
(changes in the number or size of particular organelle). 
 
Mitochondria in hepatocellular carcinoma 
In normal cells, energy is primarily produced via the mitochondrial oxidative phosphorylation. 
Only in the absence of oxygen, pyruvate – a metabolic product of glycolysis is retained in the 
cytoplasm and it is converted to the lactic acid. In contrast, in cancer cells, even under the 
aerobic conditions, glycolysis followed by the lactic acid fermentation is a predominant way of 
energy production. This phenomenon is widely known as Warburg effect (Warburg, 1956) and 
has been observed for a vast majority of tumors, including HCC (Sawayama et al., 2014). 
Therefore, the decrease of NADH dehydrogenase complex I can possibly be a consequence of 
such metabolic switch in HCC. It can also reflect the presence of mitochondrial dysfunctions in 
HCC due to the accumulation of mutations in mtDNA.  The analysis of mtDNA from 88 HCC 
individuals revealed that mutation in mitochondrial genes encoding six subunits of NADH 
complex I are frequently observed in HCC (Li et al., 2017). In addition, the authors of this study 
observed general decrease of mtDNA in HCC when compared to the healthy liver, which is in 
agreement with the reduced mtDNA content in HCC specimens analyzed in this work. Finally, 
the overall decrease of mitochondrial proteins (including NADH dehydrogenase complex I) and 
mtDNA can be also explained by an increase in the mitophagy activity, which selectively 
removes dysfunctional mitochondria from HCC. In fact, it has been already reported that 
enhanced mitophagy is required to promote the hepatocarcinogenesis by controlling the activity 
of the tumor suppressor protein p53 (Liu et al., 2017). 
 
Intra-tumor heterogeneity 
A major motivation for this study was to show that the local proteome within tumors intrinsically 
differs, thus contributing to the overall tumor ITH. By proteomic analysis of different sectors 
within the same tumor I could show that indeed heterogeneous protein expression is frequently 
observed in HCC, even in seemingly homogenous specimens. Although the proteomic ITH was 
observed in all analyzed specimens, for each tumor a distinct set of differentially expressed 
proteins was identified. Taking into account that the tumor vs. peritumor comparison indicated 
the large degree of inter-tumor heterogeneity, such outcome was expected. Nevertheless, I 
identified several proteins that were significantly differentially expressed in multiple HCC 
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specimens. However, the spatial patterns of these changes were not always the same, suggesting 
that the proteomic ITH is independent from the tumor geometry.  Interestingly, the identified 
proteomic ITH of HCC is up to some extent functionally related with the proteomic features that 
distinguish HCC from the normal liver tissue. It therefore highlights the importance of proteomic 
ITH for biomarker discovery studies and diagnostic applications. For example, ribosomal 
proteins that were generally upregulated in HCC were also frequently affected by the ITH. 
Another example is the expression of the fatty acid binding protein-4 (FABP4), which so far has 
not been investigated in regards of HCC. The expression of FABP4 was generally higher in 
analyzed tumor when compared to peritumoral tissue, and at the same time it displayed uneven 
distribution in some of specimens. This could possibly mean that the analyzed tumors comprise 
of distinct cell populations, out of which some have more aggressive phenotype and some might 
partially resemble the non-neoplastic tissue of origin.  
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3.	  	  Functional	  characterization	  of	  the	  nucleoporin	  gp210	  
 
3.1.	  Introduction	  
 
3.1.1.	   The	  nucleocytoplasmic	  transport	  system	  
 
In eukaryotes, the nuclear envelope (NE) constitutes a physical barrier that separates the 
nucleoplasm and cytoplasm. The eukaryotic cell requires transport of macromolecules between 
these compartments to function properly.  This transport occurs through the cells’ largest discrete 
protein complex – the nuclear pore complex (NPC). The NPC forms a channel across the inner 
and outer membrane of the NE and is the sole gateway between the two cellular compartments. 
Molecules smaller than 40 kDa can freely diffuse through the NPC. However, the shuttling of 
large cargo requires interaction with nuclear transport receptors (NTR) that mediate active 
transport through the NPC (Panté and Kann, 2002). While the primary role for components of 
this nucleocytoplasmic transport system (NTS) is the facilitation of macromolecular transport 
through the NPC, they have been implicated in other cellular processes. These include processes 
such as chromatin organization and regulation of the gene expression (Akhtar and Gasser, 2007; 
Brown and Silver, 2007; D’Angelo et al., 2012).  
 
3.1.2.	   NPC	  composition	  and	  architecture	  	  
 
The vertebrate NPC is comprised of approximately 1000 copies of roughly 30 different proteins 
collectively termed nucleoporins (nups). Nups are organized into small, repeating subcomplex 
units, each comprised 3-10 individual proteins (Ori et al., 2013).  The total molecular weight of 
the human NPC is approximately 112 MDa (Schwartz, 2016). It is a highly organized 
macromolecular machine, which exhibits an eight-fold rotational symmetry about the axis of 
transport. The NPC occupies sites in the NE where the inner and outer nuclear membranes fuse 
and forms a channel of ~60nm in diameter. The structural scaffold of the NPC is built from three 
major elements, (i) the inner-ring which is sandwiched between two outer-rings, (ii) the 
cytoplasmic and (iii) nucleoplasmic rings. The principle component of both outer rings 
(indicated in dark orange and purple in Figure 27) is the Nup107-subcomplex and these rings 
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thus display a highly similar architecture(Bui et al., 2013). This ten-protein subcomplex has a 
characteristic Y shape and is frequently called the Y-complex. In humans, 32 copies of the 
Nup107 complex manifest the cytoplasmic and nucleoplasmic rings. Each ring is composed of 
eight pairs of (inner- and outer-) Y-complexes. They are organized into two reticulated rings 
with 16 copies each and exhibit eight-fold rotational symmetry about the axis of transport (Bui et 
al., 2013). The inner-ring is comprised of the five-member Nup93 and three-member Nup62 
subcomplexes (shown in blue in Figure 27). The architectural principles of the inner-ring and 
two outer-rings are similar. The four core modules of the inner-ring (constituted from members 
of the Nup93 and Nup62 subcomplexes) are repeated 8 times around the rotational axis. Two of 
which, are stacked together in a C2-symmetric fashion and form the inner-ring, yielding an 
overall assembly with a total of 32 copies of each subcomplex (Kosinski et al., 2016). In addition 
to this structural scaffold, peripheral nucleoporins are attached to both cytoplasmic and nuclear 
sides of the NPC. These are known respectively as cytoplasmic filaments and the nuclear basket. 
Furthermore, the NPC central channel is filled with nucleoporins of intrinsically disordered 
regions that are enriched in phenylalanine and glycine repeats and called FG-nups. Although, the 
exact organization of FG-nups within the central channel is not known, a disordered meshwork 
with liquid-liquid like phase separation characteristics is proposed to constitute the permeability 
barrier of the NPC (Lemke, 2016). FG-nups interact in a transient manner with nuclear transport 
receptors (NTRs), and mediate the transport of cargo bound to the receptor across the NPC. 
Finally, the NPC contains three transmembrane nucleoporins: NDC1, Pom121 and Gp210.  
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Figure	  27.	  Schematic	  representation	  of	  the	  Nuclear	  Pore	  Complex	  (NPC)	  
The left panel illustrates the NPC located within the nuclear envelope. Cytoplasmic face (in yellow) 
consists of the filaments and the cytoplasmic ring. FG-nucleoporins bound to the inner ring (in blue) 
localize in the middle part of the pore.  The nucleoplasmic face (in purple) consists of the nuclear ring 
connected to the nuclear basket. The right panel indicates the nucleoporins involved in the formation of 
different subcomplexes. Modified from (Beck et al., 2017) 
 
3.1.3.	   Dynamic	  composition	  of	  the	  nuclear	  pore	  complex	  
 
 The NPC is a highly dynamic macromolecular assembly with respect to its composition. 
Measurements of the residence time for different nucleoporins at the NPC indicate that while 
some nups constitutively associate with the NPC through the cells entire lifespan, others are 
constantly replaced with new molecules. The residence time of nucleoporins at the NPC ranges 
from seconds to hours. For example, Nup50 that interacts with cargo at the nuclear basket has a 
residence time of approximately 20 s, while the inner ring component, Nup93 maintains its 
association with the pore for around 70 h (Rabut et al., 2004). In general, peripheral Nups tend to 
associate with the NPC for a shorter time. In contrast, the scaffolding nucleoporins are more 
stably associated with the NPC (Rabut et al., 2004). In at least some cell types, they exhibit 
extremely slow turnover rates (Toyama et al., 2013). Targeted proteomic analysis of NPC 
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components across different cancer cell lines indicates that NPC composition is cell type 
specific. While structural components are expressed at comparable levels across cell types, 
significant variation in was observed in the expression of peripheral Nups (Ori et al., 2013) 
(Figure 28). Together these data suggest that dynamic rearrangements of NPC stoichiometry can 
be adjusted to the context specific requirements. However, regulatory mechanisms and 
functional consequences of changes in the NPC composition remain largely elusive. 
 
Figure	  28.	  Cell	  type	  specific	  expression	  of	  NPC	  components	  
(A) Targeted proteomics measurement of nucleoporin abundance across different cell lines. Proteins 
highlighted in red, showed similar pattern in the mRNA expression analysis (B) mRNA expression 
pattern of selected nucleoporin across various tissues. (C) Components of the NPC are colored according 
to expression. Scaffold nups are more stable than transmembrane or peripheral nucleoporins. Modified 
with permission from (Ori et al., 2013) 
 
3.1.4.	   The	  nucleocytoplasmic	  transport	  system	  in	  cancer	  
 
Multiple studies suggested that cancer driver pathways impact the NTS. For example, the 
eukaryotic translation initiation factor 4E (eIF4E), classified as an oncogene, can reprogram the 
NPC to promote mRNA export (Culjkovic-Kraljacic et al., 2012). In this study, it was shown 
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that overexpression of eIF4E results in alteration of the NPC’s cytoplasmic face by a ~3-fold 
reduction of Nup358, which leads to increased eIF4E-dependent mRNA export. Overexpression 
of Nup358 was sufficient to inhibit the oncogenic transformation by eIF4E. Another striking 
example of nucleoporin involvement in cancer is the overexpression of Nup88.  First found to be 
overexpressed in 75% of ovarian tumors, (Martínez et al., 1999), subsequent analysis revealed 
that Nup88 is also upregulated in a variety of other cancers (Gould et al., 2000). Although the 
functional link between Nup88 overexpression and cancer development is still unclear, some 
mechanisms have been suggested. For example, it has been shown that the loss of Nup88 inhibits 
nuclear accumulation of NF-κB upon TNF (Tumor Necrosis Factor) stimulation suggesting that 
Nup88 is required for the transport of NF-κB (Takahashi et al., 2008). Nuclear accumulation of 
NF-κB is a recurring feature in multiple cancers, therefore it has been proposed that 
overexpression of Nup88 may cause an increase of NF-κB import to the nucleus leading to the 
upregulation of its target genes.  
In HCC, overexpression of several NTRs namely exportin-1, exportin-2, importin-α1 and 
importin-α5 have been observed. The functional characterization of exportin-2 and importin-α1 
suggest that they act as anti-apoptotic factors and whose expression is p53-dependent and thus 
indicate that its upregulation supports the survival of tumor cells (Winkler et al., 2014). Other 
NTRs components, like exportin-4 and Nup98 have been shown to have a tumor suppressive role 
in liver cancer and consistently found to be downregulated in HCC. The targeted proteomic 
analysis of liver cancer related cell lines (Figure 29A) indicate that NPC composition adapts 
upon malignant transformation, even among cells of the same origin (Ori and Singer, 
unpublished data). One such nucleoporin, with altered expression among liver cancer cell lines is 
gp210. For instance, in Hep3B, HuH7 and HuH6 cells, gp210 expression was significantly 
greater than in other common liver cell lines, such as Sk-Hep1 and HLF. More significantly, the 
proteomic analysis of an HCC cohort of 48 patients indicates that the expression of gp210 can 
vary extremely between the individuals (Ori and Singer, unpublished data). In some cases, the 
abundance of gp210 was drastically higher (up to 14-fold) than in the surrounding healthy tissue, 
while in others, a decrease in the expression was observed (Figure 29B). Analysis of the NPC 
stoichiometry suggests that within a single pore there are 32 copies of gp210 (Ori et al., 2013). It 
is therefore unlikely, that in cases of strong gp210 overexpression all molecules can be 
accommodated within NPCs. This hints at a role for excess gp210 apart from the NPC. 
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Figure	  29.	  Gp210	  expression	  in	  liver	  cell	  lines	  and	  HCC	  
(A) Nucleoporin abundance measured across seven liver cell lines using targeted mass spectrometry. (B) 
Gp210 abundance for the 48 HCC patients cohort. Barplot indicates the abundance in the tumor 
normalized to the surrounding peritumoral (PT) tissue. 
 
3.1.5.	   Structural	  analysis	  of	  gp210	  
 
Gp210 is a 210 kDa, type I integral membrane glycoprotein (Wozniak et al., 1989). A large part 
of the protein is localized to the perinuclear space (Greber et al., 1990) and its not required for 
the targeting to the NPC (Gomez-Cavazos and Hetzer, 2015). Its transmembrane domain is close 
to the C-terminus, and leaves only a short (58 amino acid) region extending out of the membrane 
to interact with other NPC components. In yeast, the presumed homolog of gp210 is pore 
membrane protein 152 (pom152) (Wozniak et al., 1994). It also contains the large luminal 
domain and short NPC-associated region, however unlike in vertebrates, the C-terminus 
localizes to the perinuclear space and the N-terminal domain faces the cytosolic side thus 
interacting with other NPC components.  The structural analysis of pom152 revealed that its’ 
luminal region is an approximately 40 nm long, flexible strand of nine Ig-like domains (Figure 
30) (Upla et al., 2017). The authors of this work propose a model in which pom152 dimerizes in 
an anti-parallel fashion and 8 copies of such dimer form a ring around the NPC. Although the 
structure of gp210 is not known to date, the sequence-based predictions suggest that its 
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architecture resembles the fold of pom152 (Gomez-Cavazos and Hetzer, 2015; Upla et al., 
2017).  
 
Figure	  30.	  Structural	  analysis	  of	  pom152.	  The	  yeast	  homologue	  of	  gp210	  
(A) Negative-stain electron density map of pom152, (B) A model in which 16 copies of Pom152 were fit 
into the yeast NPC map (Alber et al., 2007) in an anti-parallel fashion. Reproduced from (Upla et al., 
2017) 
 
3.1.6.	   Gp210	  and	  NPC	  assembly	  
 
Historically, gp210 was proposed to be involved in NPC formation and in the anchoring of the 
pore to the nuclear membrane (Wozniak et al., 1989). This hypothesis was supported by a study 
in which Xenopus extract was used to investigate NPC assembly (Drummond and Wilson, 2002). 
The authors showed that blocking the C-terminal domain (either by recombination or by using an 
antibody against the C-terminus of the protein) resulted in the arrest of the NPC formation at an 
early intermediate step. Later, it was shown that depletion of gp210 affects HeLa cell viability 
and NPC assembly in C. elegans (Cohen et al., 2003). However, other studies seem to contradict 
this hypothesis. Analysis of gp210 content in mice embryos revealed that it is absent in some of 
the tissues (Olsson et al., 2004). Other groups have shown that depletion of gp210 does not 
affect NPC assembly (Antonin et al., 2005; Eriksson et al., 2004; Stavru et al., 2006). These 
findings highlight the possibility that gp210 may be required only in certain cell types and not 
others. Nevertheless, its exact function at the NPC and beyond remains unclear. 
 
3.1.7.	   Gp210	  in	  differentiation	  
 
There is strong evidence indicating important roles for gp210 in non-NPC related contexts. For 
example, there is evidence to suggest that gp210 is important for myogenic differentiation 
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(D’Angelo et al., 2012). Using the C2C12 cell line – a well-established murine myogenic model, 
it was shown that gp210 is absent in myoblasts, however induction of the expression is observed 
during myotube formation. Depletion of gp210 inhibits the differentiation process by 
downregulation of genes related to muscle differentiation. In contrast, the overexpression of 
gp210 results in the acceleration of myotubes formation (D’Angelo et al., 2012). Further studies 
indicate that localization to the NPC is not required for this process to be rescued as expression 
of gp210 lacking its’ pore-targeting domain was sufficient to restore differentiation in gp210-
depleted cells. The reduction of unfolded protein response and blocking the ER-stress related 
apoptotic pathway with a chemical chaperone - tauroursodeoxycholic acid also restored 
myotubes formation in gp210-depleted cells suggesting that the pathway for gp210 control of the 
mygonic differentiation involves regulating ER stress (Gomez-Cavazos and Hetzer, 2015). On 
the other hand, analysis of muscle differentiation in Danio Rerio suggests that gp210 is required 
at the NPC to enable the assembly of Myocyte-specific enhancer factor 2C (MefC2) complex, 
which is needed for efficient expression of genes that control muscle structure (Raices et al., 
2017). 
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3.2.	  Aims	  
 
Based on the expression analysis and measurement of NPC residence time, gp210 can be 
classified as one of the most dynamic component of the NPC. The function of this nucleoporin 
and whether it is required for the proper functioning of the NPC remains unclear. Several lines of 
evidence indicate that gp201 has non-NPC related functions in development, however the details 
remain to be characterized. Further, gp210 has been linked to liver disorders. Its expression 
drastically varies in HCC, but besides this it has been also linked to the primary biliary cirrhosis 
– an autoimmune liver disease.  
 
In order to further characterize gp210 function and to establish it’s links with other cellular 
processes, I used the following two approaches: 1. Proximity labeling combined with mass spectrometry using BioID system in order to 
understand cellular interactions of gp210 2. Proteomic analysis of gp210 depleted cell lines to understand its impact onto different 
functional modules of the cell  
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3.3.	  Results	  
 
3.3.1.	   Analysis	  of	  the	  gp210	  localization	  
 
To get further insights into potential roles of gp210 away from the NE, I first analyzed the 
localization of gp210 in different cell lines using the immunofluorescence microscopy. The 
following cell lines were selected for the analysis: Sk-Hep1 and HLF as liver cell lines with low 
expression of gp210, Hep3B and HuH6 as liver cell lines with high abundance of gp210 and 
finally HeLa and Hek293 cell lines with the moderate level of gp210 expression (Figure 31). In 
case of HeLa, the signal was observed mainly at the nuclear envelope, indicating that majority of 
the gp210 molecules are localized to NPCs. A similar pattern was observed for Hek293, 
nevertheless some signal was also observed in other compartments (ER). For cells with low 
expression level (Sk-Hep1 and HLF) a weak signal was observed around the nucleus. For cells 
with high expression level of gp210 (Hep3B and HuH6) in addition to the NE, a strong ER 
signal was also observed. These results indeed show that gp210 also localizes away from the 
NPC.  
 
Figure	  31.	  Immunofluorescence	  analysis	  of	  gp210	  in	  different	  cell	  lines	  
Cells were stained with anti-gp210 antibody. 
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3.3.2.	   Generation	  of	  cell	  lines	  expressing	  BirA*-­‐tagged	  gp210	  
 
In order to map the gp210 interacting proteins I used the BioID approach (Roux et al., 2012). 
This system utilizes the biotin ligase (BirA) from Escherichia coli, which biotinylates the biotin 
carboxyl carrier protein (BCCP), a subunit of acetyl-CoA carboxylase (Chapman-Smith and 
Cronan Jr, 1999) that has been genetically modified to become promiscuous. The biotiniylation 
of the target protein requires two steps: (i) activation of biotin molecule with ATP to form 
biotinoyl-5’-AMP and (ii) release of the active biotin in the presence of target sequence. It has 
been shown that BirA with R118G mutation (BirA*) has two orders of magnitude lower affinity 
to the biotinoyl-5’-AMP than the wild type enzyme and therefore the active biotin is released 
from the BirA even without the presence of the target sequence (Kwon et al., 2000). Therefore 
free biotinoyl-5’-AMP can react with primary amines that are in the close proximity. The 
mutated BirA is fused to a protein of interest. Once the culture medium is supplemented with 
biotin, the biotin ligase is provided with its substrate and neighboring proteins are covalently 
labeled with biotin. Those are subsequently purified using the streptavidin beads and analyzed 
with mass spectrometry. Such approach has been successfully used in the past to study the 
interactions of different range of proteins, for example to map specific cargos of nuclear 
transport receptors (Mackmull et al., 2017).  
 
Using Hek293 Flp-In T-REx cells, I generated stable a cell line with the inducible expression of 
BirA*-gp210. To enable the proper localization of the fusion protein, BirA* was inserted into the 
luminal part of gp210, right after the ER localization signal peptide. The radius of biotin labeling 
with BirA* has been estimated to be around 10 nm (Kim et al., 2014). Therefore, assuming that 
human gp210 has similar architecture to the yeast homolog pom152 (Upla et al., 2017), it is 
possible that using N-terminally fused BirA*, the C-terminal interactors may be missed. To 
obtain a better coverage and information about the domain-specific interactions I also designed 
constructs in which BirA* was inserted at different positions within the gp210 sequence. 
Additionally, the sequence between signal peptide and the insertion site was removed. To design 
the BirA insertion sites, the secondary structure of gp210 was predicted (done by Dr. Jan 
Kosinski). Based on these predictions, putative IgG-like domains were identified within the 
gp210 sequences. For BirA insertion, only sites in linkers between domains were selected. In 
addition, a FLAG-tag was introduced into each construct to enable monitoring of the protein 
expression and the proper localization. In total 5 different cell lines were generated (summarized 
in the Table 1)  
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Table	  1.	  Generated	  BirA*-­‐gp210	  constructs	  
Construct name Residues removed Length of construct  
Full length - 1886 aa 
Asn 287 27-287 1625 aa 
Ser 869 27-869 1043 aa 
Ser 1589 27-1589 323 aa 
Arg 1789 27-1789 123 aa 
 
To confirm the expression and proper localization of these constructs, each cell line was 
analyzed by immunofluorescence. In all the constructs, a similar level of BirA* expression was 
observed. As expected, the recombinant gp210 was primarily localized to the nuclear envelope; 
nevertheless a subset of it was retained in the ER. Representative examples are shown on the 
Figure 32. 
 
 
Figure	  32.	  Immunofluorescence	  of	  BirA*-­‐gp210	  constructs	  
Cells were stained with anti-gp210 antibody (green) and anti-flag (red). For comparison full-length and 
arg1789 constructs were selected.  
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I checked the distribution of proteins that were biotinylated by BirA*. As shown in the Figure 
33, biotinylated proteins were dispersed throughout the ER and also localized to the nuclear 
envelope. This observation indicates that either gp210 interactors are mobile within the ER or 
alternatively gp210 is not constitutively associated with NPCs, as previously suggested (Rabut et 
al., 2004). 
 
Figure	  33.	  Distribution	  of	  biotinylated	  proteins	  
Cells were stained with anti-gp210 antibody (green) and streptavidin conjugated to alexa647 (red). For 
comparison only full-length and arg1789 constructs were selected.  
 
3.3.3.	   Identification	  of	  gp210	  interactome	  
 
For the BioID experiments, the expression of the BirA*-gp210 fusion proteins was induced for 
48h and subsequently biotin was added to the cell culture medium to proceed with the biotin 
labeling for another 48h. Cells were collected and biotinylated proteins were purified using 
streptavidin beads. Due to the extremely strong interaction between streptavidin and biotin 
(Green, 1975), the protein digestion was performed directly on the beads. To obtain the 
information about biotinylation sites, peptides remaining on the beads were eluted under very 
harsh condition (80% acetonitrile, 20% formic acid) as previously suggested (Mackmull et al., 
2017). To identify non-specific hits, such as naturally biotinylated proteins or proteins that bind 
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to the beads in an unspecific manner, non-modified Hek293 cells were used as a control. Three 
independent biological replicates of each experiment were performed. As interactome of gp210, 
I considered proteins that were: (i) identified in at least 2 biological replicates of at least one 
construct and never detected in the control samples or (ii) enriched in the BirA cell line sample 
in comparison to the control (log2 of fold change > 2, adj. p.value < 0.05). The entire dataset was 
comprised of 3531 proteins out of which 854 were classified as specific hits according to 
aforementioned criteria. This rather large number might indicate that many ER proteins are 
labeled by gp210. These proteins were subjected to the gene ontology analysis. GO term 
enrichment was calculated for three categories: “Cellular Component”, “Biological Process” and 
“Molecular Function” (Figure 34). As background proteome I used the list of proteins that are 
usually identified in the shotgun analysis of Hek293 cell lysate (in total 3540). In terms of the 
cellular components, a strong enrichment of ER resident proteins was observed, which agrees 
with the subcellular localization of gp210 and the immunofluorescence analysis of biotinylated 
proteins. With respect to GO terms related to biological process, an enrichment of proteins 
involved in the protein folding and glycosylation was observed. These proteins are ER-resident 
as well and likely to be involved in the processing of the gp210 polypeptide chain in the ER 
lumen.  
 
 
Figure	  34.	  GO	  term	  enrichment	  analysis	  of	  gp210	  interactome	  
GO-enrichment for (A) Cellular Component, (B) Biological process and (C) Molecular function, were 
calculated for the identified gp210 interactome. 
 
I identified a number of proteins that are involved in the ER stress regulation and ER-associated 
degradation (ERAD) pathway, which is a part of unfolded protein response (UPR). Since the 
BirA*-gp210 fusion protein was not expressed at the endogenous level, this could indicate that 
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gp210 overexpression on its own may trigger ER stress and identified proteins are not specific 
gp210 interactors. In order to rule out such a scenario, I checked whether the UPR is triggered 
upon gp210 expression. For this I used the X box-binding protein 1 (XBP1) mRNA splicing 
assay (van Schadewijk et al., 2012). Accumulation of unfolded proteins in the ER triggers the 
phosphorylation of Inositol-requiring enzyme 1 (IRE1). Phosphorylated IRE1 then triggers the 
unconventional splicing of XBP1 (Yoshida et al., 2001). The XBP1 protein from alternatively 
spliced mRNA is then transferred to the nucleus and induces the transcription of ER-associated 
protein degradation (ERAD) pathway components. XBP1 mRNA splice variants differ in size, 
and therefore can be resolved on agarose gels (figure 35A). The presence of a lower molecular 
weight fragment indicates the activation of UPR. To investigate, whether the expression of 
gp210 triggers the UPR, cells with the full-length BirA*-gp210 were induced with tetracycline. 
After 48 h and 72 h (these times correspond to the addition of biotin and cell collection in BioID 
experiments), RNA was extracted and cDNA was generated by reverse transcription. In the 
following, the cDNA was used as a template for a PCR in which XBP1 was amplified. PCR 
products were analyzed on agarose gel. As a positive control, cells were treated with 
thapsigargin – an inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) that is 
frequently used to induce the UPR and ER stress (Lytton et al., 1991). As shown in the Figure 
35B, in case of thapsigargin treatment, the low molecular splice variant was detected indicating 
the induction of UPR as expected. For the mRNA isolated from cells expressing gp210, only 
higher molecular splice variant was detected, suggesting that the gp210 overexpression does not 
trigger the UPR.   
 
 
Figure	  35.	  ER	  stress	  control	  
(A) Schematic representation of the XBP1 assay. Modified from (Kennedy et al., 2015). (B) The XBP1 
assay was performed on cells either treated with thapsigargin (left panel) or with induced overexpression 
of gp210 (right panel). 
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3.3.4.	   Functional	  analysis	  of	  gp210	  interactors	  
 
Identified gp210 interactome can be arbitrarily classified into three groups: (i) proteins involved 
in the gp210 polypeptide processing and (ii) proteins interacting with gp210 because of its 
function and (iii) non-interacting proteomic neighborhood of gp210. 
The first group contains factors involved in the processing of the polypeptide chain such as 
translation, folding, post-translational modifications, proper localization of gp210 or its 
degradation if failed to fold properly. Proteins identified within this group presumably do not 
provide meaningful information about the function of gp210. Nevertheless, they indicate which 
pathways are involved in its processing (Figure 36). For example, I identified multiple ribosome 
components together with several signal recognition particle subunits and other proteins 
involved in the processing of ER targeting sequence. These are likely to be early interactions: i.e, 
taking place soon after the translation of BirA. Similarly, the presence of multiple folding 
chaperones, among all identified proteins, can be explained. Another identified network module 
contains the most of the members of the endoplasmic reticulum membrane complex (EMC) 
components. Although the exact function of this complex remains uncharacterized, it has been 
recently proposed that its role is to insert certain type of membrane proteins (with moderately 
hydrophobic membrane domain) into the ER membrane(Guna et al., 2018; Shurtleff et al., 2018). 
High enrichment of EMC components in gp210 interactome indicates that EMC may be also 
responsible for proper insertion of C-terminal trans-membrane domain of gp210. Finally, several 
components of endoplasmic reticulum associated degradation (ERAD) pathways components 
were identified. As shown before, gp210 overexpression on its own does not induce ER stress 
due to the increased accumulation of unfolded proteins, therefore most of these interactions are 
probably due to the components involved in degradation of naturally occurring, improperly 
folded proteins. 
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Figure	  36.	  Proteins	  involved	  in	  the	  processing	  of	  gp210	  polypeptide	  chain	  
An interaction network among gp210 interacting proteins was generated. Sub-networks of proteins that 
are involved in the processing of gp210 polypeptide chain are displayed. Proteins with biotinylation sites 
identified are marked with the green frame.  
 
The second group consists of proteins that are likely to interact with gp210 because of its 
function (Figure 37). Three functionally related clusters can be distinguished within this group: 
I) Nuclear envelope related proteins: 
Several inner nuclear membrane (INM) proteins were identified such as Lemd3, Emerin, Lamin 
B-receptor and Lamina associated polypeptide proteins. These are known to interact with the 
nuclear lamina. Within this group, I also identified several components of the nuclear pore, 
which was expected since gp210 is a member of the NPC. 
II) Collagen biosynthesis pathway: 
The collagen biosynthesis pathway can be subdivided into three major steps: i) translation of the 
pre-collagen into ER, ii) hydroxylation of the proline and lysine residues by prolyl and lysyl 
hydroxylases, iii) glycosylation of hydroxylated lysine residues by procollagen 
galactosyltransferases. Several procollagen chains together with enzymes involved in both 
collagen hydroxylation and glycosylation were identified in the BioID experiment. Multiple 
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biotinylation sites identified for different proteins involved in the pathway strongly indicate that 
there is a connection of gp210 with collagen biosynthesis pathway.  
III) GPI anchored proteins 
Another group of functionally related proteins that have been identified in the BioID experiment 
is comprised of proteins involved in glycosylphosphatidylinositol (GPI) anchor processing. The 
gp210 interactome contains several proteins involved in the assembly of the GPI-anchor. In the 
ER, the C-terminal GPI attachment of the signal peptide is cleaved and replaced with the 
preassembled GPI. This process is mediated by the complex called GPI-anchor transamidase 
(Fraering et al., 2001). All 5 components of the complex were also identified in the BioID 
experiment.  
 
Figure	  37.	  Ptoteins	  potentially	  interacting	  with	  gp210	  
A network among gp210 interacting proteins was generated. Sub-networks of proteins interacting with 
gp210 based on their function are displayed. Proteins with biotinylation sites identified are marked with 
the green frame.  
 
Finally, the third group contains proteins that are in the close proximity of gp210, nevertheless 
these are unlikely to be its specific interactor. This group contains mainly highly abundant ER 
resident proteins, for example Calumenin and Calreticulin, which are found throughout the entire 
ER.  At this point, it is important to mention that some of the proteins included in the previous 
groups may also be unspecific, nevertheless due to the functional relations to other proteins, they 
were classified as potential interactors of gp210. 
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3.3.5.	   Analysis	  of	  domain	  specific	  interactions	  
 
Next I checked whether there are any differences in interactomes of distinct regions of gp210. 
For this, I calculated the Pearson correlation of protein abundances observed in all samples. As 
shown in the Figure 38A, high correlation values were observed for proteome profiles of longer 
constructs (full length, Asn287, Ser869). The construct lacking the luminal domain of gp210 
(Arg1789) seems to have different set of interactors as compared to remaining cell lines. 
Nevertheless, the majority of previously mentioned proteins (components of the EMC complex, 
or members of the collagen synthesis and GPI-anchor pathways) were also identified as part of 
the C-terminal domain interactors. The analysis of biotinylation sites of gp210 indicates that the 
BirA fusion proteins interact with their endogenous counterpart. For example, in the cell line 
expressing BirA and the C-terminal domain, biotin was still detected at the N-terminal part of the 
protein. It is therefore possible, that some of the interactions are identified because of the close 
proximity or oligomerization with the endogenous full-length gp210. A pairwise comparison 
between the Arg1789 and full-length constructs indicates that C-terminal part of gp210 mainly 
interacts with proteins involved in the nuclear envelope organization (Lemd3, Emerin, Lamin B-
receptor, Lamina associated polypeptide-2 and SUN1 – a member of LINC complex). Although 
all of these proteins were identified in on-bead digestion in each BirA*-gp210 cell line, the 
biotinylated peptides were only detected for shorter constructs.   
 
 
 
Figure	  38.	  Comparison	  of	  cell	  lines	  with	  different	  length	  of	  gp210	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(A) Heatmap depicting Pearson correlation coefficients of different gp210 constructs. One replicate of 
Asn287 cell line appears as an outlier. This is possibly a consequence of inefficient biotinylation. (B) 
Pairwise comparison of Arg1789 and full length constructs. Proteins with large fold changes (highlighted 
in red) are involved in the organization of the nuclear envelope. 
 
3.3.6.	   Generation	  of	  CRISPR-­‐Cas9	  knock	  out	  of	  gp210	  
 
In order to investigate the impact of gp210 depletion, I used the CRISPR-Cas9 system to 
generate a gp210 knockout cell line. The target sequences were designed using the DESKGEN 
cloud online software tool (Hough et al., 2016). Sequences with top specificity and efficacy 
scores were further tested using an in-vitro cleavage assay to select the most prominent target. 
Hek293 cells were transfected with preassembled gRNA (guide RNA) -Cas9 complex to allow 
genome editing. To achieve homogenous cell populations, cells were subjected to the single cell 
sorting using flow cytometry 48 hours after transfection. After clonal expansion of isolated cells, 
the genomic DNA was extracted and DNA fragments containing the targeted sequence were 
amplified and analyzed by sequencing. Around 20% of isolated clones carried a mutation in the 
target region. Based on the sequencing results, 3 clones were selected for further analysis. In 2 of 
them heterozygous DNA was observed, suggesting that NHEJ (non-homologous end joining) 
introduced different mutations in different chromosomes. Nevertheless, deconvolution of 
sequencing chromatogram traces by TIDE (Brinkman et al., 2018) suggested that none of the 
chromosomes remained unmodified. In case of the third clone, a double nucleotide deletion was 
observed in both chromosomes.  
To confirm the successful knockout of gp210, the generated cell lines were analyzed with 
immunofluorescence microscpy. Cells were stained with anti-gp210 antibody that targets its C-
terminal domain and, as a control, with monoclonal antibody 414 (mab414) that recognizes FG 
(phenyloalanine-glycine) rich nucleoporins. As shown on the Figure 39, in case of heterozygous 
cell lines, a decrease in gp210 signal was observed, however the protein still could be detected. 
This possibly indicates that despite the mutations introduced, one of the copies still leads to the 
synthesis of functional protein. In case of homozygous cell line with a frame shift, no signal for 
gp210 was observed, providing an additional source of evidence for successful knockout. 
Additionally, cells with gp210 knockout (KO) had an aberrant morphology with frequently large 
and amorphous nuclei. Another feature observed for the gp210 KO cells, was the differential 
distribution of FG-nucleoporins. While in wild-type cells, these are mainly localized to the 
nuclear envelope, with only few spots observed outside of the NE, in the KO apart from NE 
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stain, the signal was strongly dispersed in KO cells. Although more detailed evaluation of this 
phenotype is required, it may indicate imperfect NPC assembly in these cells.   
 
 
Figure	  39.	  Immunofluorescence	  of	  gp210	  knockout	  cells	  
Cells were stained with anti-gp210 antibody (green) and mab414 targeting FG-nups (red).  
 
3.3.7.	   Proteomic	  characterization	  of	  gp210	  knock	  out	  cell	  line	  
 
In order to investigate proteomic changes induced by the depletion of gp210, I collected wild-
type (WT) and the KO cells from three consecutive passages. After protein extraction and 
digestion, peptides were labeled with TMT reagents, fractionated using high pH fractionation 
and analyzed using Orbitrap Fusion Lumos. In total 6301 proteins with at least two unique 
peptides were quantified. A summary of the quantitative data is displayed in the Figure 40. 
Although the overall proteome profiles of these cell lines were mostly similar, some significant 
differences were still detectable. Interestingly, multiple proteins previously identified as gp210 
interactors were affected by the gp210 knockout further confirming the functional link between 
gp210 and non-NPC related processes. Among differentially expressed proteins I observed an 
enrichment of proteins involved in GPI anchor biosynthesis. In total, 10 out of 22 proteins 
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involved in GPI-anchor biosynthesis pathway were identified in this experiment. The abundance 
of 7 of them was significantly affected, with the majority of them being down regulated. All 5 
components of GPI-transamidase complex were expressed at lower level in gp210-depleted cell 
line in comparison to the wild type condition.  
 
 
Figure	  40.	  Pairwise	  comparison	  of	  gp210	  KO	  cell	  line	  and	  non-­‐modified	  Hek293	  cell	  line	  
Proteins highlighted in green correspond to the quantified nucleoporins. Hits labelled in yellow are 
involved in the GPI-anchor processing. 
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3.4.	  Discussion	  
 
BioID as a tool to map the protein interactions 
Several lines of evidence suggest that gp210 acts also away from the NPC, nevertheless it 
remains unclear how and in which other cellular pathways it is involved. To better understand 
the non-NPC related function of gp210, I attempted to identify its interactome. Traditionally, this 
is done by the affinity purification, followed by the MS analysis. However, gp210 is a 
transmembrane protein and because of that its native purification is challenging. In addition, it 
does not allow for the identification of transient interactions, which may by highly informative 
with regards of the function in case of such a dynamic protein. Instead, I used the BioID system, 
in which proteins that are in the close proximity of bait are biotinylated and therefore can be 
purified under more stringent conditions. Furthermore, neither direct nor indirect interactions 
between BirA* and proteins that become biotinylated are required. As such non-interacting but 
proximal proteins can also be detected providing the additional information about the proteomic 
neighborhood of the target. At the same time, this can be considered as a major drawback of the 
approach as it can lead to the number of unspecific identifications, which includes also proteins 
that are further than theoretical biotinylation radius. For example, if the number of exposed 
primary amines from truly interacting protein is low, or they are already modified, the free active 
biotinoyl-5’-AMP might diffuse further away, thus biotinylating surrounding non-specific 
proteins. This can for example happen if the labeling time in cell culture is too long. 
Nevertheless, even though the proximity labeling based approach does not ultimately prove the 
physical interaction, it indicates potential functional links to other proteins and therefore it is a 
valuable tool to characterize the proteins of elusive functions.  
 
Interaction of gp210 with the nuclear envelope proteins 
The NPC-associated portion of gp210 is in close proximity to proteins that specifically localize 
to the inner nuclear membrane. Several of such proteins were identified in the BioID experiment, 
including lamina interacting proteins such as Lemd3, Emerin, Lamin B-receptor and Lamina 
associated polypeptide-2. Interestingly, these proteins were significantly enriched in pull-down 
experiments of constructs that contain only the C-terminal domain of gp210. This suggests that 
the C- and N- terminal ends of gp210 are distant to each other.  In the model proposed by Upla et 
al., 2017, the yeast homolog of gp210 (pom152) forms a head-to-tail dimer that oligomerizes as 
a ring around the INM at the site of NPC. If the same is true for human gp210, a similar protein 
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neighborhood would be expected for its C- and N- terminal ends. This, however does not seem 
to be the case and possibly suggests a different conformation of the dimer. Due to the presence 
of multiple IG-like fold repeats, gp210 is structurally similar to cadherins – a type of cell 
adhesion molecule, which dimerizes in a head-to-head manner (Troyanovsky et al., 2003). 
Therefore, it could be speculated that gp210 forms a similar type of dimer, and is not parallel to 
the membrane as proposed for yeast (Upla et al., 2017).  Nevertheless, this hypothesis requires 
further validation. 
  
 
Gp210 and ER stress 
Among the identified interactome of gp210 I observed an enrichment of proteins involved in ER 
stress and the UPR including the key regulatory components of the pathway. During either 
physiological or pathological stimuli the proper ER homeostasis may be impaired resulting in the 
accumulation of misfolded proteins in the ER causing the cellular stress. Upon the ER stress 
three parallel signaling pathways can be activated initiating UPR. Each of them is mediated via 
the interaction with Binding immunoglobulin protein (BiP, also known as GRP78 or HSP70), 
which is a molecular chaperone located in the lumen of the ER (Dorner et al., 1987; Gething, 
1999). In non-stress conditions, BiP is bound to the IRE1, PRKR-like endoplasmic reticulum 
kinase (PERK) and Activation transcription factor 6-alpha (ATF-6α) preventing their activation 
(Marcu et al., 2002; Wang and Kaufman, 2014). Upon accumulation of misfolded proteins, BiP 
is sequestered by newly synthetized polypeptides thus leading to the activation of 
aforementioned factors. BiP free IRE1 forms a homodimer and via autophosphorylation it 
activates its endoribonuclease activity. Activated IRE1 cleaves Xbp1 mRNA initiating its 
alternative splicing, which in turn leads to the synthesis of transcription factors that regulates the 
expression of UPR related genes in the nucleus (Yoshida et al., 2001). Similarly, ER retention of 
BiP triggers the dimerization and autophosphorylation of PERK that can then phosphorylate 
Eukaryotic translation initiation factor 2A  (EIF2A), which in consequence attenuate translation 
(Scheuner et al., 2001). Finally, dissociation of BiP from the ATF-6α releases it from the ER 
membrane. ATF-6α is transported to the Golgi apparatus, where it is cleaved by site-1-proteoase 
(S1P) protease to form an active transcription factor that induces the expression of genes 
involved for the ERAD pathway (Ye et al., 2000). Both BiP as well as its binding partners 
(IRE1, PERK, and ATF-6α) were identified in the BioID assay, however only for BiP 
biotinylated peptides were observed. Since BiP is an abundant ER chaperone involved in the 
folding of newly synthetized ER proteins, such interaction is expected. Therefore it is also 
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possible that the remaining factors were identified only because of the strong interaction with 
biotinylated BiP rather than due to the proximity to gp210 and thus it is not yet a convincing 
evidence for a role of gp210 in ER stress.  The biotinylation sites (indicating the close proximity) 
were however identified also for two other proteins that seem to be involved in the negative 
regulation of the UPR, namely reticulocalbin 1 (RCN1) and nucleobindin 1 (NUCB2). RCN1 
has been shown to suppress the ER stress induced apoptosis by affecting the PERK signaling 
(Xu et al., 2017), while NUCB2 inhibits the signal cascade triggered by the ATF-6α activation 
(Tsukumo et al., 2007). Taken together, the outcome of the BioID experiment points to the link 
between gp210 and regulation of the ER stress in the investigated experimental system. The 
overexpression of luminal proteins may on its own trigger the high folding demand and as such 
trigger ER stress. Such scenario was however excluded by the analysis of the Xbp1 splice 
variants upon the gp210 overexpression, indicating that gp210 indeed may be involved in the ER 
stress.  As a matter of fact, a previous study already has suggested that gp210 may regulate the 
ER stress during muscle cell differentiation, however no mechanistic details were provided 
(Gomez-Cavazos and Hetzer, 2015) and remain to be further investigated in the future. 
 
Gp210 and GPI-anchor biosynthesis pathway 
 
Among proteins classified as members of the gp210 interactome, I identified a group of 
functionally related proteins, which contains components of the ER resident GPI transamidase 
complex. This is an enzymatic complex that mediates the attachment of GPI moiety to the 
proteins, which later are going to be anchored to the outer leaflet of the plasma 
membrane(Kinoshita, 2014). GPI-anchored proteins are usually associated with the membrane 
rafts and they are proposed to be involved in the signal transduction(Saha et al., 
2016). Interestingly, the abundance of components of the GPI transamidase complex as well as 
other proteins involved in the GPI-anchor biosynthesis pathway was significantly affected by the 
depletion of gp210 in Hek293 cell line. Taken together, these independent experiments, for the 
first time suggest that gp210 may be involved in the regulation of the GPI-anchor attachment 
pathway. However, its role in the process remains elusive and difficult to explain with the 
current state of knowledge. To draft any conclusions, further characterization of this link is 
required. 
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4.	  Materials	  and	  Methods	  
 
4.1.	  FFPE	  tissue	  proteomics	  
4.1.1.	   Source	  of	  tissue	  specimens	  
 
Formalin-fixed and paraffin-embedded tumor tissues were provided by the tissue bank of the 
National Center for Tumor Diseases (NCT, Heidelberg, Germany) in accordance with the 
regulations of the tissue bank and with the approval of the ethics committee of Heidelberg 
University and the European Molecular Biology Laboratory. Only tissue specimens of high 
quality (high tumor cell content, lack of significant necrotic and fibrotic changes, etc.) as judged 
by a trained pathologist were included and each selected tumor was re-evaluated regarding its 
grading. Patient characteristics (age, sex, pT-stage, tumor grading and etiology) are provided in 
the supplementary table 2. Fresh frozen tissue samples of murine HCCs were generated by Dr. 
Daniel Dauch and Prof. Lars Zender. 
4.1.2.	   Laser	  microdissection	  of	  human	  HCC	  specimens	  
 
The specimens were cut on a microtome into 10 µm thick sections and processed as follows: 
sections were mounted on membrane slides (PEN-membrane, 1 mm glass, Carl Zeiss 
MicroImaging GmbH), deparaffinized in 2x xylene for 3 minutes, rehydrated in 2x 100% 
ethanol for 2 minutes and then washed in 90% (v/v), 70% (v/v) and 50% (v/v) ethanol. Finally, 
the sections were stained for 15 s in cresyl violet acetate (1 % (w/v) in ACS-grade ethanol 
(Sigma-Aldrich)). Subsequently, the slides were washed in 50% (v/v), 70% (v/v), 90% (v/v) and 
100% ethanol and incubated for 5 minutes in xylene. After air-drying the slides were mounted 
onto the stage of an inverted microscope of a Microbeam LMPC System (Carl Zeiss 
MicroImaging GmbH). The RoboLPC method was employed to microdissect and capture the 
different tumor sectors, capsule and non-tumorous tissue. For each sector I collected ~40 mm2 of 
tissue (400 nL).  
4.1.3.	  	   Immunohistochemistry	  staining	  and	  evaluation	  
 
“Immunohistochemical staining was performed with an automated immunostaining instrument 
(BenchMark ULTRA IHC/ISH Staining module, Ventana Medical Systems). The OptiView 
DAB IHC Detection Kit (Ventana Medical Systems) was used based on the manufacturer’s 
protocol. The procedure included the following steps: 4 min deparaffinization at 62°C, rinsing 
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with EZ Prep (Ventana Medical Systems) and incubation with Cell Conditioner No. 1 (Ventana 
Medical Systems) for 40 min at 90°C. Primary antibody treatment was performed using the 
following antibodies: RAC1 (GeneTex) diluted 1:25, Decorin (Thermo Scientific) diluted 1:300, 
HEPAR 1 (Cell marque) and Ki67 (clone MIB1, DAKO) diluted 1:200 for 24 min at 36°C. This 
was followed by exposure to Optiview Peroxidase Inhibitor for 4 min, 12 min incubation with 
Optiview HQ Universal Linker, 12 min treatment in Optiview HRP Multimer, 8 min incubation 
with a mixture of Optiview H2O2 and DAB, 4 min exposure to Optiview copper The samples 
were counterstained with Haematoxylin for 12 min and incubated for 4 min with Bluing 
Reagent. These incubation steps were followed by multiple rinsing steps in reaction buffer 
manufactured by Ventana Medical Systems. Dehydration of each FFPE slide was performed as 
follows: 1 x 5 min 70% (v/v) ethanol, 1 x 5 min 96% (v/v) ethanol, 2 x 5 min 100% ethanol, 1 x 
5 min Xylene by using the Leica autostainer XL. Finally the slides were mounted with cover 
slips (Leica CV5030)”.  Provided by dr. Stephan Singer 
4.1.4.	   	  Protein	  solubilization	  for	  FFPE	  samples	  
 
Tissue sections were collected in PCR tubes containing 100 µL of protein solubilization buffer 
(80 µM Tris pH 8.0, 80 µM DTT and 4% SDS) and processed directly. Samples were sonicated 
using a Bioruptor (Diagenode) for 22.5 minutes (15 cycles: 1 min on, 30 sec off) at the highest 
settings, and then heated for 1 h at 99°C. Sonication followed by heating was performed twice. 
Cysteine residues were alkylated by adding 200 mM iodoacetamide to a final concentration of 15 
mM (incubated for 30 min at room temperature in the dark). The reaction was quenched by 
addition of 10 µL 200 mM DTT. 
4.1.5.	   Protein	  purification,	  digestion	  and	  peptide	  desalting	  of	  FFPE	  samples	  
 
Sera-Mag Speed Beads (#45152105050250 and #65152105050250, Thermo Scientific) were 
mixed 1:1, rinsed with water and stored as a 40 µg/µL stock solution at 4°C as described in 
(Hughes et al., 2014). 4 µL of beads stock was added to the reaction tube and mixed by 
pipetting, then 100% acetonitrile (ACN) was added to a final concentration of 50% (v/v). 
Samples were incubated for 8 minutes at room temperature to allow protein binding to the beads. 
Next, the tubes were placed into a magnetic rack. Supernatant was removed and discarded. The 
beads were washed twice with 180 µL of 70% (v/v) ethanol and once with 180 µL of 100% 
ACN. After removal of ACN, the beads were air-dried for 60 seconds and then resuspended in 7 
µL of digestion buffer consisting of either 6 µL 4 M urea in 100 mM ammonium bicarbonate or 
100 mM HEPES pH 8.5 for the TMT experiment and 1 µL of 0.1 µg/µL of LysC (Wako). 
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Samples were sonicated for 5 minutes in a water bath sonicator, incubated for 5 minutes at 37°C 
and then mixed by pipetting. Digestion was allowed to proceed for 4 h at 37°C. After the first 
step of digestion beads were resuspended by pipetting, urea was diluted to a final concentration 
of 1.5 M and 1 µL of 1 µg/µL of sequencing grade trypsin (Promega) (1 µg/µL of LysC for 
TMT-6plex experiment) was added to the samples. Digestion was performed for 12 h at 37°C. 
After digestion the beads were resuspended by pipetting. 100% ACN was added to a final 
concentration of 95% (v/v) and samples were incubated for 8 min at room temperature. The 
tubes were placed into a magnetic rack and washed twice with 100% ACN. The supernatant was 
removed and beads air-dried and reconstituted in 9 µL of 2% DMSO followed by 5 min of 
sonication in a water bath. Samples were resuspended by pipetting and placed into a magnetic 
rack. The supernatant containing the peptides was transferred into a fresh tube and acidified with 
1 µL of 1% (v/v) formic acid.  
4.1.6.	   TMT	  labeling	  
 
TMT-6plex (for the initial experiment, Thermo Scientific) or TMT-10plex (for the 5 tumor 
analysis) reagents were reconstituted in 100% ACN according to the manufacturer's instructions. 
1 µL of 1 M HEPES pH 8.5 was added to 9 µL of digested and purified peptides. TMT labeling 
was performed by addition of 1 µL of the TMT reagent. After 30 minutes of incubation at room 
temperature a second portion of TMT reagent (1 µL) was added and the samples were incubated 
for another 30 minutes. The reaction was quenched with 1 µL of 20 mM lysine in 100 mM 
ammonium bicarbonate. 4 µL of beads stock solution was added to the sample. Peptides were 
bound to the beads, washed and eluted as described in the section 4.1.5. The labeled peptides 
were pooled together and fractionated. 
 
4.1.7.	   High	  pH	  peptide	  fractionation	  for	  TMT	  labeled	  samples	  
 
Offline high pH reverse phase fractionation was performed using an Agilent 1200 Infinity HPLC 
System equipped with a quaternary pump, degasser, variable wavelength UV detector (set to 254 
nm), peltier-cooled autosampler and fraction collector (both set to 10°C for all samples). The 
column used was a Gemini C18 column (3 µm, 110 Å, 100 x 1.0 mm, Phenomenex) with a 
Gemini C18, 4 x 2.0 mm SecurityGuard (Phenomenex) cartridge as a guard column. The solvent 
system consisted of 20 mM ammonium formate (pH 10.0) as mobile phase (A) and 100% ACN 
as mobile phase (B). The separation was accomplished at a mobile phase flow rate of 0.1 
mL/min using the following linear gradient for the TMT-6plex experiment: 99% A for 2 min, 
 92 
from 99% A to 37.5% B in 61 min, to 85% B in a further 1 min and held at 85% B for an 
additional 5 min, before returning to 99% A and re-equlibration for 18 min. Thirty seven 
fractions were collected along with the LC separation that were subsequently pooled into 16 
fractions. A slightly modified gradient was used for the TMT-10plex experiment, whereby the 
LC separation time was 100 min (from 10% to 40% B (column reconditioning to 85% B for 5 
mins and re-equilibration for 18 minutes (99%A) followed the gradient separation)) and 48 
fractions were collected over this separation time, which were subsequently pooled again into 16 
fractions. Pooled fractions were dried in a vacuum evaporator and then stored at -80°C until LC-
MS/MS analysis. 
4.1.8.	   Data	  acquisition	  of	  TMT	  labeled	  samples	  
 
For TMT 6-plex, samples were analyzed using nanoAcquity UPLC system (Waters) directly 
coupled to an Orbitrap Fusion (Thermo Fisher Scientific) using a Proxeon nanospray source. 
Samples were separated on the BEH C18 (2.5 µm, 75 µm x 500 mm) nanoAcquity UPLC 
column (Waters) using a stepwise gradient. Solvent A was water, 0.1% (v/v) formic acid and 
solvent B was ACN, 0.1% (v/v) formic acid.  Peptides were separated at a constant flow of 0.3 
µL/min at 55°C. During the elution step, the percentage of solvent B increased in a linear fashion 
from 5% to 7% in 10 minutes, then from 7% B to 30% B in a further 105 min and finally to 45% 
B by 130 min.  Full scan MS spectra with mass range 300-1500 m/z were acquired in profile 
mode in the Orbitrap with resolution of 60000 FMWH. The filling time was set at maximum of 
50 ms with an AGC target of 4x105 ions. The instrument was operated in the top20 mode. The 
most intense ions from the full scan MS were selected for MS2 using quadrupole isolation (the 
isolation window was 1.6 Da). CID fragmentation was performed in the ion trap with normalized 
collision energy of 35% and an intensity threshold of 5x103. A maximum fill time of 70 ms for 
each precursor ion was set, with an AGC target of 1x104. MS2 data were acquired in centroid 
mode. Only multiply charged (2+, 7+) precursor ions were selected for MS2. The properties of 
the dynamic exclusion list were as follows: a maximum retention period of 40 s, a relative mass 
window of 7 ppm and exclusion of isotopes. For MS3 the precursor selection window was set to 
a range of 400-1300 m/z with an exclusion width of 30 m/z (high) and 5 m/z (low). Isobaric tag 
loss exclusion was set to Reagent=TMT.  The most intense fragments from the MS2 experiment 
were co-isolated (isolation window 2Da, using Synchronus Precursor Selection = 10) and 
fragmented by HCD (collision energy, 65%). MS3 spectra were acquired in an Orbitrap mass 
analyzer over a mass range of 100-200 m/z with the resolution set to 30000.  The maximum 
injection time was set to 100 ms with an AGC target of 1x105 ions and 1 microscan. Data were 
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acquired in profile mode and the instrument was allowed to inject ions for all available 
parallelizable times. 
 
A similar strategy was used for the acquisition of TMT-10plex experiment, with the following 
exceptions: The analytical column used for the LC separation was 250 mm wide and MS data 
acquisition took place on an Orbitrap Fusion Lumos (Thermo Fisher). Full scan MS spectra with 
a mass range of 375-1500 m/z were acquired in profile mode in the Orbitrap with a resolution of 
60000 using quadrupole isolation. The filling time was set at maximum of 100 ms. HCD 
fragmentation was performed with collision energy of 35%. A maximum fill time of 50 ms for 
each precursor ion was set.  MS2 data were acquired with a fixed first mass of 120 m/z. For the 
MS3, the precursor selection window was set to a range of 400-2000 m/z, with an exclusion 
width of 18 m/z (high) and 5 m/z (low).  The most intense fragments from the MS2 experiment 
were co-isolated (using Synchronus Precursor Selection = 8). MS3 spectra were acquired in an 
Orbitrap mass analyzer over the mass range of 100-1000 m/z and resolution set to 50000.  The 
maximum injection time was set to 105 ms and the instrument was set not to inject ions for all 
available parallelizable times.  
4.1.9.	   TMT	  data	  processing	  
 
TMT-6plex data were processed using Proteome Discoverer v1.4 (Thermo Fisher Scientific). 
Data were searched against the Uniprot Human FASTA database (release 2014_07, 20230 
entries) using Mascot v2.2.7 (Matrix Science) with the following settings:  Enzyme was set to 
LysC, with up to 1 missed cleavage. MS1 mass tolerance was set to 10 ppm and MS2 to 0.5 Da. 
Carbamidomethyl cysteine was set as fixed modification and oxidation of Methionine as 
variable. Other modifications included the TMT-6plex modification from the quan method used. 
The quan method was set to reporter ions quantification with HCD and MS3 (mass tolerance, 20 
ppm).  The false discovery rate for peptide-spectrum matches (PSMs) was set to 0.01 using 
Percolator (Brosch et al., 2009).  
TMT-10plex data were processed using Proteome Discoverer v2.0 (Thermo Fisher Scientific). 
Data were searched against the Swissprot Human FASTA database (release 2016_11, 20211 
entries) using Mascot v2.5.1 (Matrix Science) with the following settings: Enzyme was set to 
trypsin, with up to 1 missed cleavage. Other settings were as for TMT-6plex search data, with 
the exception of the modifications from the quan method, which was set to TMT10 and Acetyl 
(Protein N-term) as a variable modification.  
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Reporter ion intensity values for the filtered PSMs were exported and processed using R scripts 
(written in-house) to remove common contaminants and decoy hits. Additionally only PSMs 
having reporter ion intensities above 1x103 in all relevant TMT channels were retained for 
quantitative analysis. 
4.1.10.	  Data	  acquisition	  of	  DIA	  samples	  
 
For DIA, samples were analyzed using EASY nano-LC directly coupled to a Q-Exactive HF 
mass spectrometer using the nanoelectrospray ion source (all from Thermo Fisher Scientific). 
Samples were separated on a RP-HPLC column (75 µm x 500 mm) packed in-house with 1.9 µm 
C18 resin (Reprosil-AQ Pur) using a linear gradient. Solvent A was water, 0.15% (v/v) formic 
acid, 2% (v/v) ACN and solvent B was ACN 0.15% (v/v) formic acid, 2% (v/v) water.  Peptides 
were separated at a constant flow of 0.2 µL/min at 60°C. During the elution step the percentage 
of solvent B increased in a linear fashion from 5% to 30% solvent B over 120 min. For spectral 
library generation (DDA) full scan MS spectra with a mass range of 350-1600 m/z were acquired 
in profile mode in an Orbitrap with a resolution of 120000 FWMH (at 200 m/z). The filling time 
was set to a maximum of 100ms with an AGC target of 3x106 ions. The instrument was operated 
in top20 mode. The most intense ions from full scan MS were selected for MS2, using 
quadrupole isolation (the isolation window was 1.4 Da). HCD fragmentation was performed in 
the HCD cell with normalized collision energy of 28% and an intensity threshold of 2x103. A 
maximum fill time of 50ms for each precursor ion was set with an AGC target of 1x105. MS2 
data were acquired in centroid mode using an Orbitrap mass analyzer with a resolution of 15000 
FWHM (at 200 m/z). Only multiply charged (2+, 7+) precursor ions were selected for MS2. The 
dynamic exclusion list was with a maximum retention period of 30 sec.  
For data-independent acquisition (DIA) analysis the same LC-MS platform and settings with a 
few modifications were employed. Specifically, a survey scan at a resolution of 120,000 FWHM 
(at 200 m/z) using a maximum of 5x106 ions and 100 ms injection time was followed by 38 DIA 
mass windows acquired at a resolution of 30,000 FWHM (at 200 m/z) accumulating a maximum 
of 3x106 ions and using an automated injection time. The mass range scanned was from 400 to 
1,220 m/z and a stepped normalized collision energy (22.5, 25 and 27.5) was employed. 38 
overlapping mass windows (Bruderer et al., 2015) splitting each mass window into equal halves 
were employed to cover the mass range of interest from 400 to 1,200 m/z. 
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4.1.11.	  DIA	  data	  processing	  
 
A spectral library was generated by acquiring 5 shotgun runs (one for each tumor sector). Raw 
files were processed using MaxQuant (version 1.5.2.8) (Cox and Mann, 2008) The search was 
performed against the human UniProt FASTA database (release 2014_07, 20230 entries) using 
the Andromeda search engine (Cox et al., 2011) and the following search criteria: enzyme was 
set to trypsin with up to 2 missed cleavages; Carbamidomethylation (C) as a fixed modification; 
oxidation (M) and acetylation (protein N-term) were set as variable modifications; mass 
tolerance of 10ppm (precursor ions) and 0.02 Da (fragment ions); and the minimal peptide length 
to 7 amino acids. The false discovery rate was set to < 0.01. A spectral library was generated in 
Spectronaut (Biognosys AG) using the default settings.  
DIA files were searched in Spectronaut against the generated spectral library using the default 
settings. For quantification only peptides with a q-value < 0.01 and a signal to noise ratio > 20 
were selected and exported. 
4.1.12.	  Quantitative	  analysis	  of	  FFPE	  samples	  
 
Both TMT and DIA data were analysed using the same R procedures based on the MSnbase 
package (Gatto and Lilley, 2011). Reporter ion (TMT) and peptide (DIA) intensities were log2-
transformed and normalized using the vsn package (Huber et al., 2002). Peptide-level data were 
summarized into their respective protein groups by taking the median value. For differential 
protein expression, each patient-sample was treated individually. Protein ratios were calculated 
for all the protein groups quantified with at least 2 peptides. The R-package ‘‘fdrtool’’ 
(Strimmer, 2008) was used to fit a two components model on the median centered log2 ratio 
distributions using the statistic ‘normal’. Protein groups with a ratio belonging to the alternative 
component (q-value < 0.2) were considered as differentially expressed between the conditions 
tested. 
4.1.13.	  Protein	  solubilization,	  digestion	  and	  peptide	  desalting	  for	  freshly	  frozen	  murine	  HCC	  
 
Freshly frozen tissue samples of murine HCCs (~60 mg per sample) were homogenized by bead 
beating in ice-cold PBS using a Precellys24 homogenizer (6,000 rpm, 30 s, repeated twice).  
Tissue debris were removed be a quick spin, and the supernatant was transferred to a fresh tube. 
To solubilize proteins 0.2 volumes of 2% Rapigest (Waters) in 10 mM AmBic was added. 
Samples were sonicated for 3x30 s (1 minute on ice in between the cycles). Subsequently 0.8 
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volumes of 10 M Urea in 250 mM AmBic were added to a final concentration of 4 M Urea. 
Samples were sonicated in the same way as before. To reduce the samples, DTT was added to a 
final concentration of 10 mM and samples were incubated 30min at 37°C. Cysteine residues 
were alkylated by addition of iodoacetamide to a final concentration of 15 mM (incubated 30 
min at RT in the dark). For protein digestion, LysC (Wako) was added in 1:50 w/w (enzyme to 
protein) concentration and incubated for 4 h at 37°C with 600 rpm shaking. Urea was then 
diluted to 1.5 M and sequencing grade trypsin (Promega) was added in 1:100 w/w concentration. 
Samples were incubated overnight at 37°C with 600 rpm shaking. After digestion, samples were 
acidified with 10% trifluoroacetic acid (TFA, to ~pH 2) and incubated for 30 min at 37°C to 
allow Rapigest cleavage. Peptides were clarified by centrifugation at 17000 g for 5 min and 
transferred to fresh tubes.  
Peptides were purified using C18 macro-spin colums (Harvard Apparatus). The resin was 
activated with 100% methanol and washed twice with wash buffer (5% ACN, 0.1% formic acid). 
Samples were loaded onto the column and washed four times with wash buffer. Peptides were 
eluted twice with elution buffer (50% ACN, 0.1% formic acid). The solvent was removed using 
vacuum evaporator. Peptides were reconstituted in MS buffer (5% ACN, 0.1% formic acid).  
4.1.14.	  Data	  acquisition	  for	  LFQ	  
 
For shotgun analysis samples were analyzed using a nanoAcquity UPLC system (Waters) 
directly coupled to an LTQ-Orbitrap Velos pro instrument (Thermo Fisher Scientific) using a 
Proxeon nanospray source. Samples were separated on a BEH C18 (1.7 µm, 75 µm x 500 mm) 
nanoAcquity UPLC column (Waters) using a stepwise gradient. Solvent A was 0.1% (v/v) 
formic acid in water and solvent B was 0.1% (v/v) formic acid in acetonitrile.  Peptides were 
separated at a constant flow of 0.3 µL/min at 55°C. During the elution step the percentage of 
solvent B increased in a linear fashion from 3% to 7% in 10 minutes, from 7% B to 25% B by 
110 min and from 25% to 40% by 120 min. Full scan MS spectra with mass range 375-1600 m/z 
were acquired in profile mode in an Orbitrap mass analyzer with a  resolution of 30000 FWMH 
(at 200 m/z). The instrument was operated in top20 mode. The top 20 most intense ions were 
CID fragmented in the ion trap with a normalized collision energy of 35% and analyzed in the 
LTQ. A maximum fill time of 50 ms for each precursor ion was set with an AGC target of 1x106. 
Only multiply charged (2+, 7+) precursor ions were selected for MS2. The dynamic exclusion 
list was with a maximum retention period of 60 sec. 
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4.1.15.	  Data	  processing	  for	  LFQ	  
 
Raw files were processed using MaxQuant (version 1.3.0.5) (Cox and Mann, 2008). The search 
was performed against the mouse Ensembl database (GRCm38.70, 50879 entries) using the 
Andromeda search engine (Cox et al., 2011) with the following search criteria: enzyme was set 
to trypsin with up to 2 missed cleavages; Carbamidomethylation (C) as a fixed modification; 
oxidation (M) and acetylation (protein N-term) were set as a variable modifications; mass 
tolerance of 20 ppm (precursor ions) and 0.5 Da (fragment ions); minimal peptide length of 7 
amino acids. The reversed sequences of the target database were used as a decoy database. 
Peptide and protein hits were filtered at a false discovery rate of 1%. Protein quantification was 
performed using the label-free quantification (LFQ) function of MaxQuant and the match 
between run option was selected using a time window of 2 min. LFQ values were extracted from 
the protein group table, log2 transformed and normalized by quantile normalization using the 
preprocessCore library (Gentleman et al., 2004). For each murine HCC protein fold changes 
were calculated against an average LFQ value measured from independent normal liver samples 
obtained from three different mice. 
4.1.16.	  Quantification	  of	  mtDNA	  level	  by	  qPCR	  analysis	  
 
Genomic DNA (including mtDNA) was isolated with the QIAamp DNA FFPE tissue kit. 
(Qiagen). A total of 20 ng was used as template for qPCR with SYBR Green PCR Master Mix 
(Applied Biosystems). qPCR reaction was performed according to the following protocol: 1× 95 
°C – 10 min (DNA denaturation and polymerase activation); 40 alternations of 95 °C − 15 s 
(melting) and 60 °C – 1 min (annealing/extension/read fluorescence). Mitochondrial DNA 
abundance was estimated based on the mitochondrial genes MT-RNR1 and MT-TL1 and 
normalized to a gene localized in the nucleus, B2M. Each qPCR reaction was performed twice to 
control for experimental errors. CT values were averaged from two technical replicates. The 
primers used for the analysis are listed in the Table 2. 
 
Table	  2.	  Primers	  used	  for	  the	  mtDNA	  content	  analysis	  
Gene name Forward primer Reverse primer 
MT-RNR1 CCACGGGAAACAGCAGTGAT CTATTGACTTGGGTTAATCGTGTGA 
MT-TL1 CACCCAAGAACAGGGTTTGT TGGCCATGGGTATGTTGTTA 
B2M TGGCCATGGGTATGTTGTTA TGCTGTCTCCATGTTTGATGTATCT 
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4.1.17.	  Survival	  risk	  prediction	  
 
“Survival risk prediction (SRP) was performed in a cohort of 247 HCC patients mainly with a 
history of hepatitis B virus (HBV) infection or HBV-related liver cirrhosis from the Liver Cancer 
Institute and Zhongshan Hospital (Fudan University, Shanghai, China). Disease-free survival 
and gene expression profiles were available at the GEO repository with accession number 
GSE14520 for 241 patients (Roessler et al. 2010). SRP of the gene expression data was 
performed with the BRB-Array Tools software (http://linus.nci.nih.gov/BRB-ArrayTools.html; 
Version 4.5.0) as described previously (Roessler et al. 2010). Briefly, genes whose expression 
was significantly related to survival were identified by applying univariate Cox proportional 
hazards regression followed by principal component analysis. This resulted in a regression 
coefficient (weight) related to survival time based on two principal components. Next, to 
compute a prognostic index, the weighted average of the principal component values was 
calculated, using the regression coefficients derived from the Cox regression, described above. 
Finally, samples were split into two groups (n=199 and n=122) by the median of the prognostic 
index calculated from the expression of the genes identified by the proteomic analysis. Thereby, 
a high value of the prognostic index corresponded to a high value of hazard of death (high risk), 
and consequently a relatively poor predicted survival. Kaplan-Meier survival curves for the 
predicted cases to have above average risk and the cases predicted to have below average risk 
were plotted. In order to evaluate the predictive value of the method, 10-fold cross-validation 
with 1000-fold random permutation of the Cox-Mantel log-rank test was performed. Kaplan-
Meier survival analysis was performed using GraphPad Prism software 6 (GraphPad Software, 
San Diego, CA) and the statistical p values were generated by log-rank test.” Provided by dr. 
Stephanie Roessler 
4.1.18.	  	  Next	  generation	  sequencing	  
 
“The multiplex PCR-based Ion Torrent AmpliSeqTM technology (Life Technologies) with the 
Comprehensive Cancer Panel (IonTorrent / Thermo Fisher Scientific, Waltham, USA), covering 
more than 400 cancer-relevant genes and a modified HCC-specific panel (including 29 genes), 
were used for library preparation. Amplicon library preparation was performed with the Ion 
AmpliSeq Library Kit v2.0 using approximately 40 ng of DNA. Briefly, 10 ng DNA were mixed 
with each of the 4 primer pools, containing all primers for generating ~16.000 amplicons, and 
the AmpliSeq HiFi Master Mix and were transferred to a PCR cycler (BioRad). After completion 
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of the PCR reaction primer end sequences were partially digested using FuPa reagent, followed 
by ligation of barcoded sequencing adapters (Ion Xpress Barcode Adapters, Life Technologies). 
Each individual primer pool was purified using AMPure XP magnetic beads (Beckman Coulter) 
and quantified using qPCR (Ion Library Quantitation Kit, Thermo Fisher Scientific) on a 
StepOne qPCR machine (Thermo Fisher Scientific). The individual library pools were diluted to 
a final concentration of 100 pM. In total 6 to 8 samples were pooled and processed for library 
amplification on Ion Spheres using an Ion PI™ Hi-Q OT2 200 Kit. Un-enriched libraries were 
quality-controlled using Ion Sphere quality control measurement on a Qubit instrument (Life 
technologies). After library enrichment (Ion OneTouch ES) the library was processed for 
sequencing using the Ion Torrent Hi-Q sequencing 200 chemistry and the barcoded libraries 
were loaded onto a PI v3 chip and sequenced on an IonTorrent Proton instrument.” Provided by 
Dr. Volker Endris 
4.1.19.	  Variant	  calling	  and	  annotation	  
 
“Data analysis was performed using Ion Torrent Suite Software (version 4.4.3). After base 
calling the reads were aligned against the human genome (hg19) using the TMAP algorithm 
within the Torrent Suite. Variant calling was performed with the variant caller plugin within the 
Torrent Suite Software and the IonReporter package using a corresponding bed-file containing 
the coordinates of the amplified regions. Only variants with an allele frequency > 5% and 
minimum coverage > 100 reads were taken into account. Variant annotation was performed 
using ANNOVAR (Wang et al., 2010). Annotations included information about nucleotide and 
amino acid changes of RefSeq annotated genes, COSMIC and dbSNP entries, as well as 
detection of possible splice site mutations. IGV browser was used to visualize the aligned reads 
for data interpretation and verification (Broad Institute) (Bader and Hogue, 2003) “Provided by 
Dr. Volker Endris 
 
4.2.	  Functional	  characterization	  of	  gp210	  
4.2.1.	   Insertion	  of	  the	  BirA*	  sequence	  into	  the	  pDONR221-­‐gp210	  vector	  
 
Using restriction free cloning (Bond and Naus, 2012) the pDONR221-gp210 vector (previously 
generated in the lab by Dr. Amparo Andres-Pons) was modified to introduce the BirA* sequence 
after the signal peptide of gp210. In the first step a so-called megaprimer was generated by 
amplifying the BirA*-FLAG-tag sequence (available in the lab) with overhangs that are 
complementary to the sequences flanking the insertion site on the pDONR221-gp210 primer. 
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The reaction mix was prepared by mixing: 1 µL of plasmid containing the BirA*-gp20 sequence 
(50 ng/µL), 2.5 µL of 10 µM forward primer, 2.5 µL of 10 µM reverse primer, 25 µL of 2x 
Phusion High-Fidelity PCR Master Mix with GC buffer (Thermo Fisher) and 19 µL of water. 
Primers used for the PCR are listed in the Table 3. The following PCR program was used: 30 
seconds of initial denaturation at 98°C, 35 cycles of denaturation (98°C, 10 seconds), annealing 
(57°C, 20 seconds) and extension (72°C, 30 seconds), followed by a final extension step (72°C, 
5 min).  
 
Table	  3.	  Primers	  used	  to	  insert	  BirA*	  sequence	  into	  gp210	  
Primer Sequence 
BirA*_forward GGCCCCTCCGCCGCTGCGGCCAAGGACAACACCGTGCCC 
BirA*_ reverse CAGCACTTTGGGGATGTTGAGCTTTTTATCGTCATCGTCTTTGTAGTCT 
 
The PCR product was purified using the QIAquick PCR Purification Kit (Qiagen). Next, the 
megaprimer was incorporated into the pDONR221-gp210 vector in the secondary step PCR. The 
reaction was prepared by mixing 100 ng of pDONR-gp210 and 250 ng of purified megaprimer. 
Reaction volume was adjusted to 10 µL with water and 10 µL of 2x Phusion High-Fidelity PCR 
Master Mix with GC buffer (Thermo Fisher) was added. The following PCR program was used: 
30 seconds of initial denaturation at 98°C, 15 cycles of denaturation (98°C, 8 seconds), 
annealing (61°C, 20 seconds) and extension (72°C, 10 minutes), final extension (72°C, 20 
minutes). After PCR the template DNA was digested by adding 1 µL of restriction enzyme DpnI. 
The reaction was allowed to proceed for 4 h at 37°C. Subsequently the enzyme was heat 
inactivated for 20 min at 80°C.  Chemically competent E. coli DH5α cells were transformed 
with the generated pDONR-BirA*-gp210 vector and plated on LB-Agar containing kanamycin. 
A single colony was expanded in liquid culture and plasmids were purified using the QIAprep 
Spin Miniprep Kit (Qiagen). 
As a next step an LR recombination reaction was performed using pDONR-BirA*-gp210 clone 
and pDEST-TFG vector (Flp-In T-Rex compatible) according to the manufacturer’s protocol. 
Chemically competent E. coli DH5α cells were transformed with the generated pDEST-TFG-
gp210 vector and plated on the LB-Agar containing ampicillin. A single colony was expanded in 
liquid culture and plasmids were purified using the QIAprep Spin Miniprep Kit (Qiagen).  
4.2.2.	   Generation	  of	  truncated	  pDEST-­‐BirA*-­‐gp210	  constructs	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Q5-site directed mutagenesis (New England Biolabs) was used to generate the truncated 
constructs. Primers used for the PCR are listed in the Table 4. Reaction mix was prepared by 
mixing 0.1 µL of pDEST-BirA*-gp210 (270 ng/µl), 1.25 µL of 10 µM forward and reverse 
primers (see Table 4), 12.5 µL of 2x Phusion High-Fidelity PCR Master Mix with GC buffer 
(Thermo Fisher) and 9 µL of water. The following PCR program was used: 30 seconds of initial 
denaturation at 98°C, 30 cycles of denaturation (98°C, 10 seconds), annealing (60°C, 20 
seconds) and extension (72°C, 6.5 min), final extension (72°C, 20 min). The KLD reaction was 
prepared by mixing: 1 µL of PCR product, 5 µL of KLD reaction buffer (2X), 1 µL of KLD 
enzyme mix (10x) and 3 µL of nuclease free water. The reaction was incubated for 5 minutes at 
room temperature. Half of the reaction was used for transformation of chemically competent E. 
coli DH5α cells. A single colony was expanded in liquid culture and plasmids were purified 
using QIAprep Spin Miniprep Kit (Qiagen). 
 
Table	  4.	  Primers	  used	  for	  generation	  of	  the	  truncated	  gp210	  constructs	  
Construct Forward Primer Reverse Primer 
Asn 287 AGCATCCCGGGCCCCGAAGGA TTTATCGTCATCGTCTTTGTAGTCTGGC 
Ser 869 TCTGCCAGAACAAAGCAGCCGCA TTTATCGTCATCGTCTTTGTAGTCTGGC 
Ser 1589 TCTAACCTGAGAGGCGAGTGCA TTTATCGTCATCGTCTTTGTAGTCTGGC 
Arg 1789 CGTGGGCCCGGTCCTTATGGA TTTATCGTCATCGTCTTTGTAGTCTGGC 
 
4.2.3.	   E.	  coli	  transformation	  
 
For all transformation reactions NEB® 5-alpha Competent E. coli (High Efficiency, New 
England Biolabs) cells were used. 15 µL of cell stock was used for the reaction. Cells were 
thawed on ice for 10 minutes. 2-3 µL of plasmid was added to the cells and mixed by gentle 
flicking. The reaction was incubated for 30 minutes on ice.  For heat shock cells were placed in a 
water bath (temperature set to 42°C) for 30 seconds and subsequently placed on ice for 5 
minutes. 700 µL of SOC medium at room temperature was added to the reaction and cells were 
incubated for 1 h at 37°C (with 250 rpm shaking). Cells were spun down at room temperature (3 
min, 3000 g) and the supernatant was removed. The pellet was resuspended in 50 µL of sterile 
water and placed on plates with the corresponding antibiotics. Plates were incubated overnight at 
37°C.  
4.2.4.	   Mammalian	  cell	  culture	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Modified human embryonic kidney cells 293 (HEK Flp-InTM T-RexTM 293 Cell Line, Life 
Technologies) designed for rapid generation of stably transfected cell lines with tetracycline 
inducible expression system were used. Cells were grown in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 5 g/L glucose and 10% heat inactivated fetal bovine serum (FBS, 
Sigma-Aldrich). Cells at 90% confluency were trypsinized with 0.25% trypsin with EDTA (Life 
technologies). Every second cell passage the following selection antibiotics were added to the 
culture medium: Blasticidin (15 µg/mL) and zeocin (100 µg/mL) for parental cell lines, 
blasticidin (15 µg/mL) and hygromycinB (100 µg/mL) after transfection. Cells were grown at 
37°C in 5% CO2. 
4.2.5.	   Stable	  cell	  line	  generation	  
 
24h prior to transfection, 2x104 cells were seeded per well on a 6-well plates (no selection 
antibiotics were used at this stage). For transfection 100 µL of DMEM (without FBS), 3 µL of 
X-tremeGENE9 transfection reagent (Roche), 100 ng of pDEST-TFG and 900 ng of pOG44 
plasmid (encoding a recombinase allowing for the integration of the plasmid to a modified site of 
genomic DNA, Life Technologies) were mixed, incubated 15min at room temperature and added 
to cells. Reaction without any pDEST-TFG vector was used as negative control. 24h later cells 
were trypsinized onto 150 mm diameter dishes. On the following day selective antibiotics were 
added (blasticidin, hygromycinB). Twice a week the medium was replaced and fresh antibiotics 
were added. Selection was carried out until there were no surviving colonies in the negative 
control dish. 
4.2.6.	   Immunofluorescence	  
 
All steps of staining were performed at RT. In between each step cells were washed 3 times with 
PBS. First, cells were fixed with 2% paraformaldehyde (PFA) in PBS for 15 minutes, washed 
and then permeabilized with 0.2% triton x-100 in PBS for 15 minutes. As a next step, blocking 
in blocking buffer  (2% BSA, 2% FBS in PBS) was performed for 1h. Cells were stained with 
primary and subsequently secondary antibodies diluted in blocking buffer for 1h each. Primary 
antibodies used were mouse mAb414 (1:2500, Covance) and rabbit anti-gp210 (1:500, Glavy 
lab, Stevens Institute of Technology). Secondary antibodies used were anti-mouse Alexa Fluor 
647, anti-rabbit Alexa Fluor 488 (both 1:1000, Life Technologies). To visualize biotinylated 
proteins streptavidin conjugated with Alexa Fluor 647 (1:1000, Thermo Fisher Scientific) in 
0.1% BSA in PBS was used. Labeling was performed for 10 minutes. To preserve the stained 
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cells cover slides were mounted in ProLongTM Diamond Antifade Mountant (Thermo Fisher 
Scientific). Mounted coverslips were dried for 24 h at RT and then stored at -20°C until imaging.  
4.2.7.	   BioID	  pull	  down	  experiments	  
 
2x106 cells were seeded per 500cm2 cell culture dish. On the following day tetracycline (Sigma-
Aldrich) was added (final concentration 1 µg/mL) to induce the expression of BirA*-gp210 
constructs. After 48 h biotin (Sigma-Aldrich) was added to a final concentration of 50 µM. 
Biotin labeling was allowed to proceed for 48 h. After this time cells were collected (4x107 per 
pull-down), snap frozen in liquid nitrogen and stored at -80°C until further processing. Cell 
pellets containing 4x107 cells were resuspended in 9.5 mL of lysis buffer (50 mM Tris pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% triton x-100, 10 µg/mL Aprotinin, 10 µg/mL 
Leupeptin, 25 U/mL Turbonuclease (Accelagen), 1 mM PMSF and 0.1% SDS). Cells were lysed 
for 1 h at 4°C rotating at 15 rpm. After this time samples were sonicated 5x 30 s on/off using the 
Bioruptor (Diagenode) at 4°C. To remove cellular debris cells were spun at 17000 g for 30 min 
at 4°C. Supernatant was collected and 80 µL of streptavidin-sepharose slurry beads (GE 
Healthcare) were added to the lysates. Beads were previously equilibrated with lysis buffer. To 
allow biotin binding to the beads samples were incubated for 3 h at 4°C, rotating at 15 rpm. After 
this time beads were spun down at 2000 g for 5 min. Supernatant was removed and beads were 
transferred to Snap Cap Pierce Spin Columns (Thermo Fisher Scientific). Beads were first 
washed with 800 µL of lysis buffer and then 5 times with 800 µL of 50 mM AmBic, pH 8.3. 
Using 3x 300µL of 50 mM AmBic beads were transferred to the 2 mL tubes. Samples were spun 
down at 2000 g for 5 min and around 700 µL of supernatant was removed. 1 µg of trypsin (mass 
spectrometry grade, Promega) was added and samples were incubated for 16 h at 37°C, shaking 
at 500 rpm. After this time an additional 0.5 µg of trypsin was added and digestion was allowed 
to proceed for another 2 h. Samples were then transferred to new Snap Cap Pierce Spin Columns 
(Thermo Fisher Scientific) and supernatant was collected. Beads were washed with 2x 150 µL of 
50 mM AmBic (each time the eluted liquid was collected). To elute the biotinylated peptides 
columns were transferred to new collection tubes and 2x 150 µL of 80% ACN and 20% TFA 
was added to the beads. Beads were pipetted up and down 5 times and the eluted liquid was 
collected. Samples were then dried using speed-vac concentrator. Peptides were reconstituted 
with 200 µL of 5% ACN and 0.1% TFA in water and desalted as described in the section 4.1.13 
(in this case micro-spin columns were used).  
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4.2.8.	   BioID	  shotgun	  proteomics	  
 
For on-bead digestion data were acquired with the same acquisition parameters as described in 
section 2.5.14. In case of peptides eluted from the beads the acquisition parameter were the same 
with the exception of the gradient length (60 instead of 120 min). 
4.2.9.	   BioID	  data	  analysis	  
 
Raw data were processed in MaxQuant using the same strategy as described in section 2.5.15. 
with the following exceptions: (i) Human Swiss-Prot entries of the Uniprot KB (database release 
2016_09, 19594 entries) was used, (ii) carbamidomethylation (C) as fixed modification was not 
set, (iii) N-term or (K) biotinylation was set as variable modification. Only proteins identified 
with at least 2 unique peptides were retained. For quantitative analysis of the on-bead digestion 
experiment a proteinGroups.txt output file was used. LFQ values were extracted and subjected to 
quantile normalization. For pairwise comparison the significance of differential expression was 
assessed using the Limma package in R (Smyth, 2005). To define the gp210 interactome proteins 
that were (i) identified in at least 2 biological replicates of at least one construct and never 
detected in the control samples or (ii) enriched in BirA cell line in comparison to the control 
(log2 of fold change > 2, adj. p.value < 0.05) were extracted.  
4.2.10.	  XBP1	  mRNA	  splicing	  assay	  	  
 
5 days prior the RNA extraction, 5x102 cells with inducible expression of BirA*-gp210 (full-
length) were seeded per well on a 6-well plate. Expression of recombinant protein was induced 
with 1 µg/mL tetracycline (Sigma-Aldrich) for either 48 h or 72 h (these times correspond to the 
addition of biotin and cell collection in BioID experiments). WT cell line was used as negative 
control. For positive controls, WT cells were treated for 1 h and 5 h with Thapsigargin (Sigma). 
Two concentrations were tested – 1 µM and 0.1 µM.  Cells from all conditions were harvested at 
the same time. The total RNA was isolated RNAEasy Mini Kit (Qiagen) according to the 
manufacturers protocol. The RNA was reversely transcribed using QuantiTect Reverse 
Transcription Kit (Qiagen) following the manufacturers protocol using 1 µg of RNA as starting 
material. Obtained cDNA was used as a template for PCR reaction. Reaction mix was prepared 
as follow: 1  µL of cDNA template, 1.25 µL of 10 µM forward primer, 1.25 µL of 10 µM 
reverse primer, 6.25 µL of 2x Phusion High-Fidelity PCR Master Mix with GC buffer (Thermo 
Fisher) and 3.25 µL of H2O. Primers used for the PCR are listed in the Table 5. The following 
PCR program was used: 30 s of initial denaturation at 98°C, 30 cycles of denaturation (98°C, 10 
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s), annealing (58°C, 20 s) and extension (72°C, 15 s), final extension (72°C, 1 min). PCR 
products were separated on 2.5% agarose gel. 
 
Table	  5.	  Primers	  used	  for	  the	  XBP1	  splicing	  assay	  
Primer Sequence 
XBP1_splicing_assay_forward TTACGAGAGAAAACTCATGGCC 
XBP1_splicing_assay_reverse GGGTCCAAGTTGTCCAGAATGC 
 
4.2.11.	  Design	  of	  gRNA	  sequences	  for	  the	  CRISPR-­‐Cas9	  genome	  editing	  experiment	  
 
The DESKGEN Cloud (Desktop Genetics) was used to design a target sequence for the 
CRISPR-Cas9 genome editing experiment. The following target sequence was selected based on 
the efficiency and specificity scores: ACCGCGGATGAGGAATGTGA (exon 22). For each 
target primers allowing for the assembly of the gRNA DNA template were designed as shown in 
the Table 6: 
 
Table	  6.	  Primers	  used	  to	  generate	  DNA	  template	  for	  gRNA	  in-­‐vitro	  transcription	  
Primer Sequence 
Target_gRNA_Forward TAATACGACTCACTATAGACCGCGGATGAGGAATGTGA 
Target_gRNA:Reverse TTCTAGCTCTAAAACTCACATTCCTCATCCGCGGT 
 
4.2.12.	  Synthesis	  of	  gRNA	  
 
Synthesis and purification of gRNA was performed using the GeneArtTM Precision gRNA 
Synthesis Kit (Thermo Fisher Scientific). First, the gRNA template was assembled by PCR 
reaction. The reaction mix was prepared by mixing 1 µL of 0.3 uM target oligos, 1 µL of Tracr 
Fragment containing T7 Primer Mix and 12.5 µL Phusion High-Fidelity PCR Master mix (2X). 
Nuclease-free water was added to 25 µL. The following two-step PCR program was used for the 
reaction: 10 seconds of initial denaturation at 98°C, 32 cycles of denaturation (98°C, 5 seconds) 
and annealing and extension (55°C, 15 seconds), final extension (72°C, 1 min). 6 µL of PCR 
reaction product was mixed with 8 µL of 100 mM NTP mix, 4 µL of 5X TranscriptAidTM 
Reaction buffer and 2 µL of TranscriptAidTM Enzyme mix. In vitro transcription was allowed to 
proceed for 2 h at 37°C. After this time 1 µL of DNase I was added into the reaction and 
incubated for 15 min at 37°C. In vitro transcribed gRNA was purified using GeneJET RNA 
Purification Micro Column (Thermo Fisher Scientific).  
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4.2.13.	  Transfection	  of	  Hek293	  cell	  line	  with	  gRNA-­‐Cas9	  complex	  
 
First 2x106 HEK Flp-InTM T-RexTM 293 cells were seeded in a 10cm tissue culture dish. Cells 
were allowed to attach for 24 h hours. To assemble the Cas9-gRNA RNP complex, 500 µL of 
Opti-MEM (Invitrogen) was mixed with 15 µg of TrueCut Cas9 Protein v2 (Invitrogen) and 3.5 
µg of previously purified gRNA. In a second tube 500 µL of Opti-MEM (Invitrogen) was mixed 
with 43.5 µL of Lipofectamine RNAiMAX transfection reagent (Invitrogen). Reaction tubes 
were incubated for 5 minutes at RT. Then assembled RNP complexes and diluted transfection 
reagent were mixed by gentle pipetting. Reaction was incubated for 10 min at RT. 1 mL of 
Cas9/gRNA/transfection reagent mix was added dropwise to the cell culture dish.  To allow 
genome editing cells were incubated for 48h at 37°C.  
 
4.2.14.	  Single	  cell	  sorting	  
 
48h after transfection cells were detached using 1 mL of TrypLETM Express Enzyme (Gibco) 
without phenol red. Cells were incubated for 1 min at 37°C and the reaction was terminated by 
diluting the enzyme in 10 mL of PBS. Cells were washed twice with PBS and resuspended in 
sorting buffer (0.5 mM EDTA, 0.1% FBS in PBS). Single cell sorting was performed in the Flow 
Cytometry Core Facility at EMBL using the BD FACSMelody cell sorter (BD Biosciences). In 
total 960 single cells were isolated (each into a separate well on 96-well plates) and expanded for 
the following 2 weeks. 
4.2.15.	  Screening	  for	  the	  successful	  mutation	  
 
After clonal expansion cells were trypsinized and transferred to new 96-well plates. To isolate 
genomic DNA 10% of cells from each clone were transferred to QuickExtractTM buffer 
(Lucigen) and vortexed for 15 s. Reactions were incubated for 6 min at 65°C, mixed by 
vortexing for 15 s and incubated 2 min at 98°C. The 435bp long fragment of gp210 gene 
containing the target sequence was amplified by PCR using purified DNA as template. Reaction 
mix was prepared as follow: 1 µL of genomic DNA template, 1.25 µL of 10 µM forward primer, 
1.25 µL of 10 µM reverse primer, 12.5 µL of 2x Phusion High-Fidelity PCR Master Mix with 
GC buffer (Thermo Fisher) and 9 µL of H2O. The following PCR program was used: 30 seconds 
of initial denaturation at 98°C, 30 cycles of denaturation (98°C, 10 s), annealing (68°C, 20 s) and 
extension (72°C, 15 s), final extension (72°C, 1 min). PCR products were purified using 
 107 
QIAquick PCR Purification Kit (Qiagen) and analyzed by sequencing. Primers used for the PCR 
reaction are listed in the Table 7. 
 
Table	  7.	  Primers	  used	  for	  the	  CRISPR	  mutation	  screening	  
Primer Sequence 
CRISPR_screen_forward TACTTCCCCTTTATGGACCTGAAGC 
CRISPR_screen_reverse ATGAGAGGACATTGTGGGACACAG 
 
4.2.16.	  Proteomic	  characterization	  of	  the	  gp210	  knockout	  cell	  line	  
 
For each replicate 1x106 cells in 100 µL PBS were collected. Solubilization, digestion and 
purification were performed according to the protocol described in section 4.1.13. Purified 
peptides were labeled with 6-plex TMT reagent according to the protocol described in section 
4.1.6. with the following exceptions: (i) 10 µg of peptides were first dried and then reconstituted 
in 10 µL of 100 mM Hepes (pH 8.5), (ii) after quenching peptides were pooled together and 
purified using C18 macro spin column (for details see section 4.1.13). Data were acquired as 
described before in the section 4.1.8. 
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5.	  Appendices	  
 
5.1.	  Supplementary	  figures	  
 
 
Supplementary	  Figure	  1.	  Proteome	  profiles	  of	  HCC	  (TMT	  dataset)	  
(A) Heatmap representing the Pearson correlation coefficient of the analyzed sectors. (B) Soft clustering 
analysis of HCC spatial proteome using the fuzzy c-means algorithm (Kumar and E Futschik, 2007). The 
optimal number of clusters was estimated using the “elbow” algorithm (Schwämmle and Jensen, 2010).  
The upper panel includes all measured sectors (including tumor capsule and peri-tumoral tissue). The 
lower panel shows clusters calculated only for the three tumor sectors. The TMT dataset was used to 
create this figure. The DIA data are shown in the Figure 13.  Modified from (Buczak et al., 2018) 
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Supplementary	  Figure	  2.	  Statistical	  models	  for	  tumor	  vs.	  peritumor	  comparison	  
Histograms and the densities of the fitted two-component models (null component = proteins with no 
differential expression; alternative component = proteins with differential expression) are shown. Models 
were fitted on median centered log2- transformed fold-changes (z). Proteins with the q-values < 0.2 were 
considered as differentially expressed..  (A) T1 tumor vs peritumor, (B) T2 tumor vs peritumor, (C) T3 
tumor vs peritumor, (D) T4 tumor vs peritumor, (E) T5 tumor vs peritumor. (F) averaged fold changes 
(averages were calculated without T1). Modified from (Buczak et al., 2018) 
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Supplementary	  Figure	  3.	  Statistical	  models	  for	  periphery	  vs.	  center	  comparisons	  
Histograms and the densities of the fitted two-component models (null component = proteins with no 
differential expression; alternative component = proteins with differential expression) are shown. Models 
were fitted on median centered log2- transformed fold-changes (z). Proteins with the q-values < 0.2 were 
considered as differentially expressed. (A) T1 intratumoral heterogeneity, (B) T2 intratumoral 
heterogeneity, (C) T3 intratumoral heterogeneity, (D) T4 intratumoral heterogeneity, (E) T5 intratumoral 
heterogeneity Modified from (Buczak et al., 2018) 
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5.2.	  Supplementary	  tables	  
 
 
Supplementary	  Table	  1.	  Targeted	  NGS	  data	  
Overview of identified variants in each sector. Provided by dr. Volker Endris. Genes in which mutation 
were found are colored in red. Gene highlighted in yellow indicate the only non homogenous mutation. 
 Allelic frequency (%) 
Aminoacid change peritumor Sector1 Sector2 Sector3 
ABL2:p.Lys909Arg(NM_001168236) 47.91	   43.01	   50.87	   42.69	  
ADGRA2:p.Glu111Lys(NM_032777) 	   	   	   12.99	  
ADGRA2:p.Pro76fs*16(NM_032777) 78.00	   79.60	   79.80	   79.20	  
ADGRB3:p.Asn503Ser(NM_001704) 100.00	   100.00	   100.00	   98.07	  
AFF3:p.Asn519Ser(NM_001025108) 51.87	   48.48	   53.71	   48.02	  
AFF3:p.Ser383Asn(NM_001025108) 100.00	   100.00	   99.38	   100.00	  
AKAP9:p.Asn2792Ser(NM_005751) 56.00	   66.36	   30.00	   54.00	  
ALK:p.Asp1529Glu(NM_004304) 97.60	   98.43	   98.36	   98.65	  
ALK:p.Ile1461Val(NM_004304) 100.00	   100.00	   100.00	   100.00	  
ALK:p.Lys1491Arg(NM_004304) 98.68	   98.86	   100.00	   98.40	  
ARID1A:p.Gln321Glu(NM_006015) 35.00	   51.88	   45.00	   38.00	  
ASXL1:p.Leu815Pro(NM_015338) 98.95	   99.16	   100.00	   100.00	  
ATM:p.Asn1983Ser(NM_000051) 98.96	   98.18	   96.30	   94.87	  
ATR:p.Met211Thr(NM_001184) 92.99	   98.52	   100.00	   98.48	  
AURKA:p.Ile57Val(NM_003600) 100.00	   100.00	   100.00	   100.00	  
AURKA:p.Phe31Ile(NM_003600) 47.33	   55.29	   52.61	   51.29	  
AURKB:p.Met257Thr(NM_001256834) 100.00	   100.00	   100.00	   100.00	  
AXL:p.Asn266Asp(NM_001699) 98.75	   99.06	   98.86	   100.00	  
BCL2L2:p.Gln133Arg(NM_001199839) 100.00	   100.00	   100.00	   100.00	  
BCL9:p.Pro671Ser(NM_004326) 74.11	   72.47	   84.80	   84.76	  
BCR:p.Asn796Ser(NM_004327) 100.00	   100.00	   100.00	   100.00	  
BIRC5:p.Glu129Lys(NM_001168) 100.00	   98.86	   99.05	   100.00	  
BUB1B:p.Arg349Gln(NM_001211) 42.56	   44.92	   46.39	   44.19	  
CASC5:p.Ala460Ser(NM_144508) 94.73	   98.80	   98.50	   98.23	  
CASC5:p.Arg43Thr(NM_144508) 88.13	   100.00	   98.75	   95.41	  
CASC5:p.Arg910Gly(NM_144508) 95.43	   100.00	   100.00	   98.16	  
CASC5:p.Lys1259Glu(NM_144508) 46.45	   47.20	   47.62	   43.74	  
CASC5:p.Met572Thr(NM_144508) 39.67	   50.00	   57.00	   56.00	  
CDH11:p.Ser373Ala(NM_001797) 50.64	   50.51	   52.75	   51.34	  
CDH11:p.Thr255Met(NM_001797) 42.56	   51.60	   46.97	   52.14	  
CDH2:p.Ala118Thr(NM_001792) 48.16	   51.33	   52.14	   50.21	  
CDH5:p.Ile503Thr(NM_001795) 47.25	   47.39	   44.03	   49.14	  
CDK12:p.His369Arg(NM_015083) 	   24.89	   6.79	   	  
CHEK1:p.Ile437Val(NM_001244846) 98.95	   100.00	   100.00	   100.00	  
CMPK1:p.Gly8Arg(NM_001136140) 60.00	   57.00	   64.00	   64.00	  
COL1A1:p.Thr1075Ala(NM_000088) 100.00	   100.00	   100.00	   100.00	  
CREBBP:p.Met2183fs*120(NM_001079846) 14.41	   9.55	   10.04	   12.54	  
CSMD3:p.Ile219Met(NM_052900) 48.06	   57.59	   48.36	   48.04	  
CTNNB1:p.Asn287Ser(NM_001098209) 50.59	   44.00	   50.00	   48.41	  
CYP2D6:p.Cys245Arg(NM_001025161) 100.00	   100.00	   98.66	   100.00	  
CYP2D6:p.Pro34Ser(NM_000106) 10.71	   2.00	   2.00	   6.63	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CYP2D6:p.Thr435Ser(NM_001025161) 98.79	   100.00	   100.00	   100.00	  
DCC:p.Arg201Gly(NM_005215) 52.30	   53.65	   52.35	   49.70	  
DCC:p.Gly1031Arg(NM_005215) 7.09	   7.79	   11.11	   3.19	  
DCC:p.Phe23Leu(NM_005215) 97.99	   100.00	   98.76	   100.00	  
DICER1:p.1420_1421del: (NM_001195573) 59.25	   59.03	   53.80	   52.66	  
DNMT3A:p.Tyr247Phe(NM_153759) 	   29.53	   31.45	   26.83	  
DPYD:p.Arg29Cys(NM_000110) 99.06	   100.00	   100.00	   98.53	  
DST:p.Gln1308Arg(NM_015548) 52.64	   50.28	   52.32	   48.82	  
DST:p.Lys4066Arg(NM_015548) 3.00	   3.93	   5.15	   3.46	  
DST:p.Met2813Ile(NM_015548) 100.00	   100.00	   100.00	   100.00	  
DST:p.Thr2726Ala(NM_015548) 97.64	   99.00	   99.32	   100.00	  
EGFR:p.Arg521Lys(NM_005228) 50.59	   49.61	   50.42	   45.54	  
EML4:p.Ile324Val(NM_001145076) 99.17	   100.00	   100.00	   100.00	  
EML4:p.Lys225Glu(NM_001145076) 98.85	   98.33	   100.00	   100.00	  
ERBB2:p.Ile655Val(NM_001289937) 98.43	   98.57	   100.00	   100.00	  
ERBB2:p.Pro1170Ala(NM_004448) 52.53	   48.20	   57.69	   50.44	  
ERBB3:p.Ser1119Cys(NM_001982) 47.62	   50.56	   51.30	   51.89	  
ERBB3:p.Thr1024Asn(NM_001982) 6.75	   11.38	   12.86	   3.49	  
ERCC2:p.Lys751Gln(NM_000400) 44.79	   52.10	   55.41	   49.57	  
ERCC5:p.Gly1053Arg(NM_000123) 100.00	   100.00	   100.00	   100.00	  
ERCC5:p.Gly1080Arg(NM_000123) 100.00	   94.69	   100.00	   100.00	  
ESR1:p.Gln238fs*12(NM_000125) 93.86	   94.63	   93.67	   94.84	  
ESR1:p.Gln238Leu(NM_000125) 93.86	   94.63	   93.67	   94.84	  
FANCA:p.Gly501Ser(NM_000135) 43.49	   51.44	   53.67	   48.47	  
FANCA:p.Gly809Asp(NM_000135) 48.98	   51.55	   52.22	   52.31	  
FANCA:p.Leu1143Val(NM_000135) 43.99	   45.13	   47.51	   45.59	  
FANCA:p.Ser1088Phe(NM_000135) 7.24	   0.10	   1.00	   2.00	  
FANCA:p.Thr266Ala(NM_000135) 55.75	   48.40	   48.34	   54.75	  
FGFR3:p.Pro473Thr(NM_022965) 4.48	   4.01	   8.44	   14.42	  
FGFR3:p.Val570Ile(NM_022965) 93.86	   90.57	   90.46	   88.12	  
FGFR4:p.Gly388Arg(NM_002011) 95.95	   97.54	   99.83	   100.00	  
FGFR4:p.Pro136Leu(NM_022963) 97.63	   100.00	   100.00	   98.80	  
FLT3:p.Thr227Met(NM_004119) 78.00	   100.00	   90.00	   100.00	  
FLT4:p.His890Gln(NM_002020) 96.62	   100.00	   100.00	   99.34	  
FN1:p.Gln15Leu(NM_002026) 55.65	   45.39	   54.02	   48.57	  
FN1:p.Thr817Pro(NM_002026) 100.00	   100.00	   100.00	   100.00	  
FN1:p.Val1960Ile(NM_212474) 100.00	   100.00	   100.00	   100.00	  
GATA2:p.His323Tyr(NM_001145662) 65.38	   62.83	   39.06	   34.62	  
GNAS:p.Gly35fs*654(NM_080425) 100.00	   100.00	   100.00	   100.00	  
GNAS:p.Ser565fs*63(NM_001077490) 18.10	   18.60	   18.50	   18.70	  
HNF1A:p.Ser574Gly(NM_000545) 100.00	   100.00	   100.00	   98.68	  
HSP90AA1:p.Met71Leu(NM_001017963) 100.00	   100.00	   100.00	   100.00	  
IGF1R:p.Gly596Val(NM_000875) 5.14	   5.14	   4.69	   3.20	  
IGF2R:p.Arg1619Gly(NM_000876) 100.00	   100.00	   100.00	   100.00	  
IL6ST:p.Gly148Arg(NM_001190981) 44.84	   48.18	   51.32	   48.37	  
IL6ST:p.Leu397Val(NM_001190981) 46.69	   49.78	   68.18	   43.48	  
IL7R:p.Ile356Val(NM_002185) 93.64	   98.87	   100.00	   98.49	  
IL7R:p.Ile66Thr(NM_002185) 100.00	   100.00	   100.00	   100.00	  
IL7R:p.Val138Ile(NM_002185) 95.50	   100.00	   95.04	   100.00	  
ITGA9:p.Gly507Glu(NM_002207) 92.99	   100.00	   100.00	   97.68	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ITGB2:p.Gln354His(NM_000211) 100.00	   100.00	   100.00	   100.00	  
KAT6B:p.Glu787_790del(NM_001256469) 9.18	   9.52	   23.00	   9.24	  
KDM6A:p.Thr647Lys(NM_001291418) 95.50	   100.00	   100.00	   89.63	  
KDR:p.Gln472His(NM_002253) 51.95	   62.96	   50.00	   57.06	  
KMT2C:p.Asp348Asn(NM_170606) 15.50	   14.99	   15.77	   15.72	  
KMT2C:p.Leu291Phe(NM_170606) 39.00	   51.00	   38.00	   40.00	  
KMT2C:p.Tyr816_Ile817delins*(NM_170606) 39.79	   45.04	   40.02	   40.08	  
LIFR:p.Val785Ile(NM_001127671) 41.82	   47.76	   45.00	   42.39	  
LRP1B:p.Arg3783Gln(NM_018557) 50.00	   45.81	   46.15	   51.85	  
LRP1B:p.Gln48Arg(NM_018557) 45.83	   45.16	   48.73	   45.41	  
LRP1B:p.Pro1896Ser(NM_018557) 50.18	   43.81	   45.45	   45.83	  
LTF:p.Ala29Thr(NM_002343) 13.42	   11.88	   9.68	   9.08	  
LTF:p.Arg23delinsArgArg(NM_002343) 100.00	   100.00	   100.00	   100.00	  
LTF:p.Lys3Arg(NM_001199149) 50.24	   42.39	   50.85	   52.94	  
LTK:p.Pro62Leu(NM_001135685) 48.22	   46.51	   48.07	   42.33	  
MALT1:p.Arg217Gly(NM_006785) 47.30	   52.20	   51.23	   51.83	  
MEN1:p.Thr546Ala(NM_000244) 100.00	   100.00	   100.00	   100.00	  
MLH1:(NM_001167619) 49.90	   53.45	   56.25	   52.89	  
MLH1:p.Ile219Val(NM_000249) 63.25	   62.83	   59.51	   64.63	  
MTOR:p.Pro201fs*5(NM_004958) 14.40	   12.00	   12.70	   12.60	  
MTR:p.Arg52Gln(NM_000254) 52.50	   53.36	   54.55	   48.85	  
MTRR:p.Ile22Met(NM_002454) 46.20	   49.41	   49.66	   49.50	  
MTRR:p.Ser175Leu(NM_002454) 44.06	   35.76	   54.70	   48.25	  
MUC1:p.Ser227Thr(NM_001204285) 47.39	   40.08	   46.94	   39.30	  
MUTYH:p.Gln324His(NM_001048171) 50.00	   54.00	   51.00	   42.00	  
MUTYH:p.Ser501Phe(NM_001048171) 55.00	   52.00	   54.00	   50.00	  
MYCL:p.Thr362Ser(NM_001033081) 50.86	   55.78	   68.27	   55.39	  
MYH11:p.Leu1563Pro(NM_002474) 3.00	   32.81	   31.58	   27.23	  
NCOA4:p.Phe8Val(NM_001145260) 43.50	   49.80	   45.58	   37.65	  
NIN:p.Gln1125Pro(NM_020921) 98.20	   100.00	   92.53	   100.00	  
NIN:p.Gly1320Glu(NM_020921) 96.80	   98.22	   98.60	   96.73	  
NIN:p.Pro1111Ala(NM_020921) 46.55	   51.98	   49.91	   51.31	  
NLRP1:p.Met1154Val(NM_033006) 10.23	   2.00	   5.00	   	  
NOTCH4:(NM_004557) 41.92	   49.95	   40.06	   49.11	  
NOTCH4:p.Gly348fs*49(NM_004557) 14.80	   16.20	   20.40	   22.80	  
NOTCH4:p.Lys117Gln(NM_004557) 47.04	   53.52	   55.85	   50.60	  
NOTCH4:p.Thr320Ala(NM_004557) 37.64	   44.33	   47.58	   41.31	  
NUP214:p.Pro574Ser(NM_005085) 48.22	   50.04	   44.70	   51.21	  
NUP98:p.Asn297Asp(NM_005387) 3.99	   4.33	   4.03	   3.74	  
NUP98:p.Gln1142Glu(NM_016320) 43.00	   50.00	   51.00	   44.77	  
PARP1:p.Gln353fs(NM_001618) 62.19	   61.05	   62.80	   61.85	  
PARP1:p.Val762Ala(NM_001618) 38.36	   51.14	   40.28	   37.18	  
PAX5:p.Thr264Ile(NM_001280550) 96.28	   98.61	   100.00	   97.09	  
PBX1:p.Gly21Ser(NM_001204961) 40.00	   43.11	   39.22	   40.31	  
PDE4DIP:p.Ala1066Thr(NM_001198834) 50.47	   45.54	   50.65	   49.63	  
PDE4DIP:p.Ala106Val(NM_001002811) 49.86	   49.90	   49.62	   52.24	  
PDE4DIP:p.Ala127Thr(NM_001002811) 53.77	   52.59	   53.13	   54.48	  
PDE4DIP:p.Ala1742Ser(NM_001198834) 11.13	   10.64	   5.51	   7.69	  
PDE4DIP:p.Arg1867Cys(NM_001198834) 22.85	   27.10	   18.11	   29.03	  
PDE4DIP:p.Arg25Leu(NM_001002810) 47.55	   46.68	   49.35	   46.35	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PDE4DIP:p.Arg458His(NM_001002811) 19.90	   23.55	   25.52	   25.89	  
PDE4DIP:p.Arg844His(NM_001002811) 46.30	   49.53	   43.36	   45.08	  
PDE4DIP:p.Asp1910Glu(NM_001198834) 45.23	   48.00	   41.81	   45.17	  
PDE4DIP:p.Glu573Val(NM_001002811) 49.05	   48.88	   47.38	   48.42	  
PDE4DIP:p.His1598Arg(NM_001198834) 24.93	   25.32	   23.35	   29.71	  
PDE4DIP:p.Leu1727Pro(NM_001198834) 13.63	   14.55	   11.91	   11.46	  
PDE4DIP:p.Leu71Ile(NM_001198832) 12.71	   13.06	   11.85	   12.09	  
PDE4DIP:p.Lys1359Glu(NM_001198834) 100.00	   98.08	   100.00	   98.48	  
PDE4DIP:p.Lys257Glu(NM_001002811) 47.30	   51.45	   52.65	   55.35	  
PDE4DIP:p.Phe1013Ile(NM_001198834) 45.22	   42.67	   42.66	   48.16	  
PDE4DIP:p.Ser1097Gly(NM_001198834) 24.29	   23.49	   26.70	   27.77	  
PDE4DIP:p.Ser438Leu(NM_001002811) 49.15	   56.95	   43.65	   45.56	  
PDE4DIP:p.Ser699Thr(NM_001002811) 49.37	   41.63	   38.84	   50.45	  
PDE4DIP:p.Thr2297Ala(NM_001198834) 25.56	   22.79	   25.23	   25.17	  
PDE4DIP:p.Thr6Ala(NM_001198832) 9.44	   9.71	   7.49	   9.19	  
PDE4DIP:p.Trp1396Arg(NM_001198834) 81.63	   77.59	   75.47	   76.96	  
PDE4DIP:p.Trp60*(NM_022359) 57.06	   58.27	   56.22	   55.50	  
PDE4DIP:p.Trp723*(NM_001002811) 25.40	   20.71	   16.06	   26.29	  
PDE4DIP:p.Val1736Glu(NM_001198834) 8.35	   8.72	   4.85	   6.27	  
PER1:p.Ala962Pro(NM_002616) 100.00	   99.20	   100.00	   99.16	  
PIK3CA:p.Ile391Met(NM_006218) 64.15	   48.57	   60.00	   69.00	  
PIK3R1:p.Met56Ile(NM_181504) 41.67	   43.02	   43.23	   37.73	  
PIK3R2:p.Ser313Pro(NM_005027) 100.00	   100.00	   100.00	   100.00	  
PKHD1:p.Ala1262Val(NM_138694) 52.23	   49.64	   54.99	   51.34	  
PKHD1:p.Arg760Cys(NM_138694) 58.80	   48.49	   50.77	   52.27	  
PKHD1:p.Asn830Ser(NM_138694) 53.15	   47.54	   39.68	   50.31	  
PKHD1:p.Gln3899Arg(NM_138694) 40.08	   54.37	   	   44.12	  
PKHD1:p.Leu1870Val(NM_138694) 98.88	   98.72	   98.46	   98.16	  
PML:p.Gly732Val(NM_033250) 44.64	   49.12	   48.68	   43.68	  
PML:p.Phe645Leu(NM_033238) 44.20	   45.45	   56.21	   55.46	  
PML:p.Ser724Gly(NM_033250) 41.73	   47.57	   48.00	   41.39	  
PMS2:p.Lys541Glu(NM_000535) 96.31	   96.49	   95.45	   95.55	  
PMS2:p.Pro470Ser(NM_000535) 52.84	   48.97	   49.52	   50.74	  
RECQL4:p.Ser92Pro(NM_004260) 100.00	   100.00	   100.00	   100.00	  
RET:p.Gly691Ser(NM_020630) 7.49	   1.00	   	   2.00	  
RNASEL:p.Arg462Gln(NM_021133) 57.66	   51.74	   55.19	   51.98	  
RNASEL:p.Asp541Glu(NM_021133) 53.88	   58.33	   48.92	   55.87	  
RNF213:p.Asn1045Asp(NM_001256071) 100.00	   100.00	   100.00	   100.00	  
RNF213:p.Asp1331Gly(NM_001256071) 52.26	   50.00	   49.29	   56.71	  
RNF213:p.Gln1133Lys(NM_001256071) 49.00	   44.96	   50.77	   45.59	  
RNF213:p.Glu1272Gln(NM_001256071) 50.15	   44.30	   54.73	   46.09	  
RNF213:p.Gly1828Ala(NM_001256071) 9.06	   11.34	   4.39	   5.41	  
RNF213:p.Lys1034Met(NM_020954) 8.24	   	   	   2.00	  
RNF213:p.Met270Thr(NM_001256071) 29.74	   32.61	   33.74	   35.33	  
RNF213:p.Ser2334Asn(NM_001256071) 51.91	   52.33	   54.28	   48.66	  
RNF213:p.Val1195Met(NM_001256071) 52.04	   49.68	   51.51	   49.91	  
RPS6KA2:p.Glu32Gly(NM_001006932) 100.00	   100.00	   100.00	   100.00	  
RPS6KA2:p.Thr34Ala(NM_001006932) 99.95	   99.95	   100.00	   100.00	  
SEPT9:p.Met464Val(NM_001113495) 99.95	   99.95	   100.00	   100.00	  
SEPT9:p.Pro138Leu(NM_001113493) 45.17	   46.15	   52.41	   44.79	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SETD2:p.Pro1962Leu(NM_014159) 53.12	   41.01	   50.11	   51.42	  
SMARCA4:p.Pro169Ser(NM_001128845) 41.89	   49.18	   45.52	   36.90	  
SMO:p.Pro698Arg(NM_005631) 49.18	   53.21	   50.41	   48.00	  
SYNE1:p.Ala2802Val(NM_033071) 52.98	   50.99	   47.16	   50.87	  
SYNE1:p.Phe7231Val(NM_033071) 92.46	   95.74	   94.78	   95.37	  
TBX22:p.Glu67Lys(NM_001303475) 92.77	   97.49	   95.19	   97.52	  
TET1:p.Asp162Gly(NM_030625) 49.91	   43.41	   53.99	   51.29	  
TET1:p.Ile1123Met(NM_030625) 100.00	   98.22	   	   83.00	  
TET2:p.Gln729Glu(NM_001127208) 6.90	   3.64	   11.59	   11.24	  
TET2:p.His1778Arg(NM_001127208) 49.52	   56.95	   54.32	   56.36	  
TET2:p.Ile1762Val(NM_001127208) 49.23	   42.29	   44.89	   42.85	  
TET2:p.Leu34Phe(NM_001127208) 45.75	   47.19	   38.27	   45.56	  
TET2:p.Val218Met(NM_001127208) 43.85	   40.87	   40.73	   38.40	  
TGM7:p.Arg552Gln(NM_052955) 60.49	   44.44	   52.00	   53.93	  
TGM7:p.Pro564Leu(NM_052955) 48.26	   41.69	   54.94	   55.35	  
THBS1:p.Gln882His(NM_003246) 22.57	   22.12	   3.91	   8.30	  
THBS1:p.Thr523Ala(NM_003246) 39.95	   47.35	   48.33	   45.03	  
TLR4:p.Asp99Gly(NM_138557) 51.34	   50.66	   46.93	   44.35	  
TLR4:p.Thr199Ile(NM_138557) 42.35	   49.06	   48.40	   42.57	  
TNK2:p.Pro725Leu(NM_005781) 48.58	   58.06	   61.56	   58.24	  
TP53:p.Pro33Arg(NM_001126118) 95.45	   84.81	   85.89	   97.18	  
TPR:p.Ser960Asn(NM_003292) 30.95	   45.65	   53.68	   35.11	  
TRIM33:p.Ile840Thr(NM_015906) 96.60	   100.00	   100.00	   96.84	  
TRIP11:p.Gly1827Ser(NM_004239) 11.79	   11.24	   11.37	   9.95	  
TSHR:p.Arg248Ser(NM_001018036) 100.00	   100.00	   98.84	   100.00	  
TSHR:p.Glu727Asp(NM_000369) 100.00	   100.00	   100.00	   100.00	  
WRN:p.Leu1074Phe(NM_000553) 98.30	   98.27	   100.00	   97.76	  
XPC:p.Gln939Lys(NM_004628) 48.21	   51.00	   53.13	   45.44	  
 
 
Supplementary	  Table	  2.	  Patients	  characteristics	  
Provided by dr. Stephan Singer 
 
Tumor Etiology Grading T-stage Sex Age 
T0 (first 
analysis) 
Steatohepatitis 
and chemicals 
G2 pT2 male 53 
T1 HCV G3 ypT2 male 52 
T2 HBV G2 pT2 male 51 
T3 Steatohepatitis G2 pT1 male 76 
T4 Steatohepatitis G1 pT3 male 81 
T5 Unknown G1 pT2 female 40 
y = pre-operative treatment 
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